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 ABSTRACT 
Economic and Humanistic Impact of Medication Nonadherence in Patients with 
Asthma and Chronic Obstructive Pulmonary Disease 
 
Ashish V. Joshi 
 
 
Asthma and chronic obstructive pulmonary disease (COPD) significantly impact 
morbidity and mortality.  In spite of the well-known benefits of prophylactic medication 
use, especially in asthma, the rate of medication nonadherence is more than 50%.  In 
Phase I, this study examined the relationship between refill-based medication 
nonadherence and healthcare utilization/costs in patients with asthma, COPD, and those 
with both asthma and COPD from the West Virginia (WV) Public Employees Insurance 
Agency (PEIA) program.  In Phase II, the study measured the relationship between refill-
based and self-reported medication nonadherence, health-related quality of life (HRQL), 
and losses in workplace productivity, all of which were determined via a mailed 
questionnaire to patients identified from Phase I. Phase I Results: The prevalence of 
asthma in the study population was similar to national estimates (203/10,000), whereas 
the prevalence of COPD was higher (598/10,000).  Among asthma-only and those with 
both asthma and COPD, more than half the patients received medications according to 
NHLBI guidelines.  Refill-based medication adherence was highest in patients having 
both asthma and COPD, as compared to asthma-only or COPD-only enrollees.  The 
number of adverse outcomes such as hospitalizations and ED visits increased with 
increasing refill-based adherence for the COPD-only patients.  Total healthcare costs 
increased with increasing medication adherence for all three groups.  Thus, increasing 
medication adherence was possibly a reflection of increasing disease severity.  Phase II 
Results: The overall response rate was almost 23% (N=918), and was highest for the 
asthma-only group (25%), followed by the ‘both’ group (24%), and the COPD-only 
group (15%).  The perception of HRQL among WV PEIA enrollees was similar to those 
found in other studies.  Only 40% of all Phase II respondents reported themselves as high 
adherent; the prevalence of self-reported adherence being similar in all three sub-groups.  
The correlations between self-reported and refill-based adherence in the three groups 
were not clinically significant.  Medication adherence was a significant predictor of 
HRQL for the COPD-only group, with HRQL worsening with increasing adherence.  
Self-reported health status was a significant predictor of HRQL for each of the three 
disease groups; and HRQL worsened with deteriorating health status.  In all three groups, 
medication adherence was not significantly associated with losses in workplace 
productivity dollars. 
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 CHAPTER ONE 
 
INTRODUCTION 
 
Asthma is a chronic inflammatory disorder, which consists of excessive airway 
narrowing, in response to a wide range of naturally occurring stimuli (Barbee and 
Murphy, 1998).  More specifically, asthma is characterized by reversibility of airflow 
obstruction characterized by an inflammatory response of the lungs, either spontaneously 
or as a result of pharmacotherapy, in addition to bronchial hyperresponsiveness (Bush, 
1992).  
Chronic Obstructive Pulmonary Disease (COPD) is a disease state characterized 
by airflow limitation that is not fully reversible (Rennard, 1998).  The airflow limitation 
is usually both progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles and gases (Puchelle and Vargaftig, 2001).  Individuals 
diagnosed with any of the following conditions during the course of a lifetime are 
categorized as suffering from COPD: asthmatic bronchitis, chronic bronchitis, chronic 
obstructive bronchitis, and emphysema (Pauwels et al, 2001).  The clinical definition of 
each of these is different, although all of the above except simple bronchitis are 
characterized by airflow limitation. 
 
Epidemiology and Burden 
Respiratory illnesses such as asthma and COPD exert a significant burden on 
payers, providers, patients, and society.  In the United States, asthma was responsible for 
500,000 hospitalizations, 1.8 million emergency room visits, 6,500 deaths, 9 million lost 
work-days, and 10 million lost school days in 1998 (NHLBI, 1999).   Asthma was also 
 1
 responsible for total cost of 11.3 billion dollars, of which 3.6 billion dollars were due to 
hospitalizations (NHLBI, 1999).  The prevalence of asthma has increased over time, with 
more than 17.3 million Americans suffering from asthma in 2002, which is a 75 percent 
increase since 1987 (Mannino et al, 1998).  More than 10 percent of children in the 
United States are affected by asthma, which is one of the most common chronic 
childhood illnesses (Mannino et al, 1998).   Morbidity and mortality due to asthma has 
increased over the past 2-3 decades, making asthma a major public health concern 
(Mannino et al, 1998, Evans et al, 1987, Gergen and Weiss, 1990, Weiss et al 1992).   
COPD is the fourth leading cause of death in the United States (Hurd 2000, 
Sullivan et al, 2000).  The prevalence of COPD in the United States was estimated to be 
61.9/1,000 in 1993 (NHIS, 1993).  It is characterized by rising hospitalization rates, along 
with a concurrent increase in mortality (Sullivan et al, 2000).  Annual COPD costs were 
14 billion dollars in 2000 (Hurd, 2000).  COPD is responsible for 16 million outpatient 
visits annually (NHLBI, 1998).  The age-adjusted death rate for COPD increased by 71% 
between 1966 and 1995 (NHLBI, 1998).  By the year 2020, COPD is expected to be fifth 
highest in overall disease burden to society worldwide (Murray and Lopez, 1996). 
 
Pharmacotherapy for Asthma and Chronic Obstructive Pulmonary Disease 
Treatment for asthma and COPD consist of pharmacological therapy, acute 
care/hospitalization, lifestyle modifications, as well as the use of invasive procedures 
(NHLBI, 1997 and Pauwels et al, 2001).  Pharmacologic therapy for asthma consists of 
long-term-control medications used to achieve and maintain control of persistent asthma, 
and short-term medications used to manage acute episodes of asthma exacerbation 
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 (NHLBI, 1997).  Long-term-control medications include: inhaled corticosteroids (ICS), 
cromolyn sodium and nedocromil, long-acting β2-agonists, methylxanthines, and 
leucotrine modifiers.  Short-acting β2-agonists, anticholinergics and systemic 
corticosteroids are used to manage acute exacerbations.  It has been shown that mean 
forced expiratory volume in one second (FEV1) improved by 25% among patients who 
started ICS within six months of the onset of asthma symptoms, as compared to 8% for 
patients who were symptomatic 2-5 years before initiating ICS treatment (Selroos et al, 
1995).  Pharmacologic treatment for COPD consists of bronchodilators (long-acting and 
short-acting β2-agonists, anticholinergics, methylxanthines), and glucocorticosteroids 
(inhaled as well as oral) (Pauwels et al, 2001).   
 
Role of Medication Adherence 
Medication adherence is defined as the “extent to which a person’s medication-
taking behavior coincides with medical advice.” (Haynes et al, 1979)   Full medication 
adherence occurs when all the instructions of the prescriber are followed.  Fish and Lung 
(2001) have defined nonadherence as consisting of any of the following behaviors: failure 
to fill a prescription, consuming the medication at an incorrect dosing interval, 
consuming incorrect / suboptimal doses of the medication, premature discontinuation of 
medication, use of an incorrect administration technique, taking the medication for the 
wrong disease condition, and substitution of one drug for another.  
Lack of compliance with prescribed drug regimens costs the United States $100 
million annually (National Pharmaceutical Council, 1992).  Plus, there exists a circuitous 
relationship between adherence and outcomes, where nonadherence to medications 
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 impacts clinical severity, which in turn results in adverse outcomes (Fish and Lung, 
2001).  It has been shown that emergency visits due to asthma exacerbations costs more 
than $1.6 billion annually, and a part of these expenditures can be attributed to 
nonadherence (Weiss et al, 1992).  
Generally, adherence rates for asthma medications range between 3 to 46%, with 
the mean being less than 50% (Fish and Lung, 2001, Kelloway et al, 1994, Barr et al, 
2002, Bauman et al, 2002, Bender, 2002).  This accounts for a significant proportion of 
high costs, both to the person as well as the society.  Among children too, the adherence 
rates have been found to be lower than 50% (Bender, 2002).  Various investigators have 
tried to assess the prevalence of nonadherence among patients with asthma.  Watts and 
colleagues (1997) matched asthma prescriptions written by the physician with those 
actually dispensed over a 3-month period in a rural setting in Australia.  They observed 
that only 70% of the prescriptions were dispensed by the pharmacies, which results in a 
primary noncompliance rate of 30%.  The actual nonadherence rate may be even higher 
considering that the actual adherence rate after receiving the prescription is less than 
50%.  Some studies have tried to assess the extent of nonadherence with inhaler therapy, 
since ICS form the mainstay of asthma treatment.  Apter and colleagues (1998) found 
that mean adherence to twice daily ICS was 63%, with only 54% of their patients 
recording at least 70% of the prescribed number of doses. 
Nonadherence to asthma medications significantly impacts economic as well as 
clinical outcomes, although there is relatively less evidence of its impact on humanistic 
outcomes such as health-related quality of life (HRQL).  Nonadherence significantly 
increases the rate of acute exacerbations, which consequently increase emergency 
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 department (ED) use and hospitalizations, contributing to spiraling healthcare costs.  
Bradley and colleagues (1999) have estimated that noncompliance to asthma medications 
contributes to treatment failure in 50% of the patients with asthma.  Braunstein et al 
(1996) have shown that noncompliance with asthma therapy increased severity and 
frequency of asthma exacerbations, combined with hospitalizations, resulting in increased 
morbidity.       
 
Factors Affecting Adherence with Asthma Therapy 
The factors that impact adherence / nonadherence can be grouped into three broad 
categories such as: (1) treatment-related factors, (2) patient-related factors, and (3) 
healthcare professional-related factors.  Treatment-related factors consist of regimen 
complexity (Tashkin 1995, Greenberg 1984), mode of administration (Ringdal et al, 
1998, Osman, 1996, Fish and Lung, 2001), cost, and prolonged therapy.  Patient-related 
factors consist of knowledge of the disease, disease severity (Leidy, 1995), and self-
efficacy. Healthcare professional-related factors consist of good communication with the 
physician, and regular access to care.      
         Various studies have examined the factors that affect nonadherence to asthma 
therapy.  Leickly and colleagues (1998) examined the relationship between self-reported 
adherence, asthma management behavior, and barriers to care among inner city children 
visiting an ED.  The study measured adherence in terms of four aspects: medicine use, 
appointment-keeping, emergency actions and asthma attack prevention.  Side-effects 
were significantly higher among nonadherent patients, as were doubts regarding the 
usefulness of medications.  Overall, the study showed that barriers to adherence may 
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 exist in any of these four areas, which may adversely impact asthma control.  A study by 
Barr and colleagues (2002) examined adherence to asthma therapy among older women 
and identified predictors of adherence.  The researchers found that adherence with 
guidelines decreased as severity increased.  Severity, increasing age, lower 
socioeconomic status (SES), smoking, and a number of medical conditions were 
significantly associated with asthma, whereas measures of social isolation, emotional 
well-being, and caregiving were not.   
 
Health-Related Quality of Life in Asthma and COPD 
HRQL has been defined as “the functional effects of illness and its consequent 
therapy upon a patient, as perceived by the patient.” (Schipper et al, 1996).  Overall, 
research in asthma and COPD has focused on the economic impact of asthma and COPD, 
with relatively little research measuring the humanistic impact of these diseases.  This 
gap needs to be addressed since both asthma and COPD have a considerable impact on 
physical, psychological and social domains of HRQL.  Some studies have found small 
relationships between HRQL and pulmonary function in patients with asthma.  Bousquet 
and colleagues (1994) found correlations ranging from 0.35 to 0.47 for various domains 
of the SF-36 such as physical functioning, physical role functioning, general health 
perception, and pain, with FEV1 levels.  Disease-specific HRQL measures have also 
been shown to correlate poorly with clinical endpoints in asthma and COPD  (van 
Molken et al, 1997, Juniper et al, 1995, Leidy and Coughlin, 1997, van Molken et al, 
1995).  Strong correlations have been shown between pulmonary function and HRQL in 
the symptoms domain of Juniper’s Asthma Quality of Life Questionnaire (J-AQLQ) 
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 (Juniper et al, 1995, Leidy and Coughlin, 1997).  Among instruments that can be used in 
both asthma as well as COPD, the St George’s Respiratory Questionnaire (SGRQ) (Jones 
et al, 1992) is the most stable instrument.   
 
Nonadherence and Health-Related Quality of Life 
An important aspect of asthma therapy is to improve humanistic outcomes such as 
HRQL, in addition to the more tangible clinical and economic outcomes.  Although the 
bulk of the health outcomes research in asthma has focused on the impact of medication 
use and economic outcomes such as healthcare use and costs, or the impact of medication 
nonadherence on economic outcomes, surprisingly, very little research has examined the 
relationship between nonadherence and HRQL.  Berzon and colleagues (1995) have 
suggested that adherence can be impacted by a medication’s side-effect profile, which 
can subsequently impact HRQL.  Thus, any direct evidence of nonadherence on HRQL in 
chronic pulmonary disease is still lacking.  
Creators of various asthma-specific HRQL instruments have always included 
factors related to medication use in order to explain changes in HRQL.  These include 
bothersome aspects of symptoms, side-effects, and inconvenience due to medication 
regimen.  For instance, the J-AQLQ includes questions pertaining to symptoms, 
medication costs, and medication availability.  Similarly, the Living with Asthma 
Questionnaire (LWAQ) (Hyland, 1991), and the SGRQ (Jones et al, 1992) ask questions 
pertaining to medication side-effects, nuisance, access, and effectiveness.  These are all 
factors that impact adherence but do not directly quantify adherence.  Overall, there is a 
dearth of evidence pertaining to the relationship between nonadherence and HRQL. Since 
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 HRQL is a subjective outcome, it may not be very easy to examine this relationship.  For 
instance, a patient who is worried about the disease, may adhere to the complex treatment 
regimen, but may still experience lower HRQL, due to a feeling of poor well-being.  The 
vice-versa can also be true, where patients who are suffering from depression either as a 
function of asthma, or other factors, may be nonadherent to the regimen, thereby 
aggravating symptoms and exacerbations (Bosley et al, 1995).  These patients are more 
likely to report poorer HRQL.   
 
Workplace Productivity and Chronic Respiratory Disease 
  There has been a growing interest in measuring the impact of chronic diseases on 
workplace productivity in the more recent past (Kessler et al, 2001).  However, there is 
not enough evidence regarding the impact of asthma and COPD on workplace 
productivity.  This is in spite of the fact that tremendous productivity losses have been 
attributed to asthma (Wiess et al, 1992).  Chronic disease like asthma and COPD would 
not only result in lost workdays (absenteeism), but also reduce productivity while at work 
(presenteeism).  Only few studies have examined the impact of specific anti-asthma drugs 
on workplace productivity either.   One study examined the impact of inhaled terbutaline, 
an inhaled beta-agonist, on productivity in school children and adults (Northfield et al, 
1991).  Adults and children who used diaries to record either lost workdays or school-
days, respectively, experienced a decrease in the lost workdays or school-days by 57% in 
an open label, single group trial of patients with asthma in primary care.  Another study 
reported losses in workdays due to asthma (Kessler et al, 2001).  The study showed that 
on average, patients with asthma experienced a loss of 3 workdays in a calender year.  It 
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 has been reported that patients with emphysema (COPD) experienced around 19 mean 
absenteeism days, and losses in presenteeism equivalent to almost 28 days per year 
(Wang et al, 2003).  The same study also reported significant losses in absenteeism (11 
days per year) and presenteeism (18 days per year) in patients with asthma.         
 
STATEMENT OF PROBLEM 
In spite of the well-known benefits of asthma medications (NHLBI Guidelines, 
1997, Selroos et al, 1995, Olivieri et al, 1997, Balkrishnan and Christensen, 2000), 
adherence to the medication regimen continues to be a major problem among patients 
with asthma.   The adherence rates among patients with asthma range from 3-46% (Fish 
and Lung, 2001, Bender, 2002, Bauman et al, 2002).  On average, more than half of the 
adult patients with asthma continue to remain non-adherent (Fish and Lung, 2001).  The 
rate of nonadherence among children is also similar (Fish and Lung, 2001).  
Conceptually, one would expect nonadherence to impact both economic as well as 
humanistic outcomes in patients with chronic pulmonary disease.  First, patient, 
physician, as well as disease-related factors would impact nonadherence.  Nonadherence 
would subsequently impact healthcare utilization and costs, as well as HRQL.  HRQL 
can independently impact healthcare utilization, albeit HRQL itself would also be a 
function of perceived control and to a certain extent, disease severity.     
The relationship between nonadherence, healthcare utilization and costs, and 
HRQL has not been examined in a single study, although studies have assessed the 
relationship between nonadherence and its impact on healthcare utilization (Olivieri et al 
1997, Balkrishnan and Christensen, 2000), and HRQL and its impact on future healthcare 
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 use and costs (Eisner et al, 2002).  Appropriate use of ICS has been associated with a 
significant decrease in acute exacerbations, hospital and emergency room use, and 
mortality in asthma patients (Olivieri et al, 1997, Balkrishnan and Christensen, 2000).  
Eisner and colleagues (2002) have also shown that better baseline HRQL scores were 
associated with significantly lower odds of future hospitalization, and significantly lower 
total healthcare costs in asthma patients, after controlling for sociodemographic as well as 
clinical factors. Another study has shown that a composite measure of patients’ self-
reported health status (encompassing presence of comorbidities, quality of life and 
functioning, prior health service use, and medication use) to be highly correlated with 
healthcare utilization and costs (Balkrishnan et al, 2000).   Vollmer and colleagues have 
also shown that patients’ perception of asthma control significantly impact healthcare 
utilization, as well as HRQL (Vollmer et al, 1999).  They found that outpatient visits, 
hospital use, and emergency room use increased, as the problems with asthma control 
increased.  Thus, not only nonadherence, but also patients’ perception of control, which 
encompasses patient management, medication adherence, as well as disease severity 
significantly impact asthma outcomes.  
Adherence to maintenance therapy has been shown to improve outcomes in 
patients with chronic asthma.  The regular use of ICS has also been recommended as the 
mainstay of asthma therapy by the National Heart, Lung, and Blood Institute (NHLBI) 
Expert Panel 2 guidelines.  In COPD, maintenance therapy has not contained the 
progression of the disease, but it has reduced the rate of acute exacerbations and 
mortality, and improved self-perceived health status and HRQL.  However, the 
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 effectiveness of these medications is a function of adherence, which continues to be a 
chronic problem, especially among patients with asthma.    
The primary objective of this study is to address this gap by examining the impact 
of nonadherence to pharmacotherapy on healthcare utilization and costs, and HRQL in 
the West Virginia (WV) Public Employees Insurance Agency (PEIA) population.  PEIA 
provides healthcare insurance coverage to state employees.  These benefits are provided 
to PEIA employees in terms of reimbursement for the use of prescription drug services, 
outpatient use, hospital use, emergency room use as well as prescription use.  This study 
will measure medication refill adherence from pharmacy claims data, using indices 
previously developed and validated.  Nonadherence and economic outcomes such as 
healthcare utilization and costs would be measured using PEIA administrative claims 
data.  HRQL would be measured using a previously validated instrument.  The secondary 
analysis would constitute Phase 1 of the study, and the primary component would 
constitute Phase 2.        
 
Conceptual Framework 
The purpose of this research is to examine the relationship between medication 
nonadherence, healthcare utilization and costs, and HRQL in asthma and COPD patients.  
This study consists of two phases.  Phase I consists of examining the relationship 
between medication nonadherence, and healthcare utilization and costs in patients with 
asthma and COPD.  Phase II consists of examining the relationship between 
nonadherence to medication regimen and its impact on HRQL in patients with asthma 
and COPD.                      
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Phase I 
The following sections will describe the rationale for the selection of WV PEIA 
population for this study, cohort definition, selection of independent variables, 
medication adherence, and evaluation of patient outcomes in this study.  
 
Selection of PEIA Population 
 This study will examine the impact of medication adherence on economic 
outcomes such as healthcare utilization and costs in Phase I in WV PEIA covered 
members with asthma and COPD.  PEIA provides healthcare insurance coverage to its 
state employees for inpatient and outpatient services, prescription drugs, laboratory tests, 
home healthcare, nursing home care, family planning, and supplies.  Thus, a retrospective 
analysis of PEIA claims data can provide all the required data in one place.  Also, the 
impact of medication adherence on outcomes has not been examined previously in the 
PEIA population.  In asthma, there are specific guidelines recommending the use of 
maintenance medications, such as ICS (NHLBI, 1997).   
 
Cohort Definition    
 The WV PEIA program maintains pharmacy and medical claims data for its 
recipients from providers of healthcare services.  This data includes the date when the 
service was provided, type of service, amount paid, type of provider, and recipient 
number.  Information about utilization and expenditures for services can be extracted for 
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 various time periods from the claims data.  For this study, all PEIA recipients with a 
primary  
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 Figure 1:  Conceptual Model Explaining the Relationship between Medication Adherence and Study Outcomes 
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 diagnosis code for asthma or COPD between July 2001 and June 2003 in their medical 
claims will be used.  Pharmacy claims for these recipients will be extracted for this time 
period.  In addition, medical and pharmacy claims data for these recipients from July 
2003 to December 2003 will also be extracted.   From these patients, all members less 
than 18 years of age and greater than 64 years will be removed.  Enrollees more than 64 
years of age will not be included since they have Medicare as the primary insurer and 
data would be incomplete in PEIA files.  For the same reason, managed care enrollees 
will also be excluded.  Also, since the study includes sending a mail survey in Phase II, 
members less than 18 years of age were excluded in order to address informed consent 
and confidentiality issues.   
 
Classification of Patients  
 Based on their International Classification of Diseases, 9th Edition, Clinical 
Modification (ICD9) codes, the patients will be classified into 3 groups – asthma-only, 
COPD-only, and recipients having both asthma and COPD.  This classification will also 
be used as a proxy for chronic respiratory disease severity.  The assumption is that 
patients with both asthma and COPD are most severe, followed by COPD-only, and 
asthma-only patients, in that order.  In addition, for the asthma-only group, patients will 
be categorized into 5 disease severity levels based on a pharmaceutically determined 
asthma-specific disease severity index (Grana et al, 1997).  This index categorizes 
patients from Level I through Level V – Level I being least severe, and Level V being 
most severe.  Since claims data do not have information on clinical measures of disease 
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 severity, this classification will serve as a proxy for disease severity for the purpose of 
this study.   
 
Definition of Medication Adherence    
 Medication adherence has been defined as the “extent to which a person’s 
medication-taking behavior coincides with medical advice.” (Haynes et al, 1997)  
Medications for asthma and COPD have been categorized into two main classes – long-
term control medications or maintenance medications to be used prophylactically, and 
medications for the treatment of acute exacerbations.  The first category includes 
medications such as ICS, long-acting beta agonists, and leucotrine modifiers, whereas the 
second category includes anticholinergics, short-acting beta agonists, and oral 
corticosteroids.  For Phase I, refill frequency for the maintenance medications will be 
used to measure adherence.  Refill-based indices have been shown to be valid measures 
of medication adherence (Steiner et al, 1988).  Two indices – the medication possession 
ratio (MPR), and median gap will be used to measure adherence.  Although both indices 
use refill frequency to measure adherence, MPR is defined as the sum of days supply for 
all claims during a defined period of time divided by the number of days elapsed during 
the time period.  For this study, the MPR will be based on a 365-day time period 
(Motheral and Fairman, 2000).  The second index – median gap – is defined as the 
number of days between the assumed date of depletion of one claim, and the fill date of 
the next refill (Motheral and Fairman, 2000).  Refill-based adherence will be used as a 
primary independent variable in Phase I.  
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 Prescription refill rates provide valuable information regarding the frequency and 
timeliness of refills of prescribed medications (Farris et al, 1994, Christensen et al, 1997).  
In the presence of an integrated pharmacy system, monitoring refill patterns can be an 
effective way of assessing adherence.  The other advantage of using refill patterns is that 
patients are not aware that adherence is being measured, which tends to eliminate any 
potential biases arising out of a testing effect (Motheral and Fairman, 2000).  There are 
however, certain limitations to this approach as well.  It can be hard to measure 
adherence in patients having access to multiple pharmacies, and to assess unusual refill 
patterns and multiple conflicting drugs.  The biggest limitation is the assumption that “a 
prescription filled is a prescription taken.” (Motheral and Fairman, 2000)     
 
Other Independent Variables 
 The other independent variables used in Phase I include the total number of 
medications (TMS) used, as well as the total number of chronic medications (CMS) used.  
TMS is defined as the total number of medications for which the patient has had claims 
throughout the year, and CMS is defined as the total number of medications for which the 
patient has 4 or more refills per year (Balkrishnan and Christensen, 2001).  The use of 
these measures serves two purposes.  First, both TMS and CMS would impact the 
patients’ adherence behavior.  Conceptually, patients having a high TMS and/or CMS 
would indicate a complicated disease regimen thereby potentially impacting adherence to 
asthma and COPD-related medications.  Second, TMS and CMS also serve as proxies for 
overall patient health status, a high TMS/CMS would indicate deteriorating overall health 
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 status, which could potentially impact adherence to asthma and COPD medications as 
well.        
 
Evaluation of Outcomes 
 Maintenance medications for asthma when taken regularly show significant 
benefits in terms of the reduction of adverse outcomes such as hospitalizations and ED 
visits, as well as mortality.  Some benefits have been shown in COPD as well (Rowe et 
al, 1992 and Hatoum et al, 1994), however, the evidence in the literature has not been 
convincing enough to recommend maintenance medications in formal guidelines.  The 
cohort of patients selected in this study will be followed to detect changes in healthcare 
utilization and costs, as well as the risk of adverse outcomes.  The study will first 
examine whether physician prescribing is in accordance with guidelines – NHLBI 
guidelines for asthma, and GOLD guidelines for COPD (Pauwels et al, 2001).  The 
proportion of patients with asthma receiving ICS would indicate the extent to which 
prescribing is in accordance with guidelines.  At the same time, a high percentage of 
respondents receiving short-acting beta agonists would indicate the lack of prophylactic 
medication use among these patients, leading to acute exacerbations, which have to be 
treated with short-acting beta-agonists.  For COPD, since guidelines do not explicitly 
recommend the use of any particular agent, the proportion of COPD patients receiving 
different classes of medications will be examined.  The prevalence of chronic respiratory 
illness in WV PEIA members will also be measured.  Prevalence rates will be compared 
between age groups, and gender.      
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  Since medication nonadherence would result in adverse outcomes such as 
hospitalizations and ED visits, as well as result in outpatient visits, the impact of 
medication adherence on the utilization variables will be measured using regression 
analyses.  Regression analyses will be conducted for each of the utilization variables with 
medication adherence as the primary predictor variable.  The use of regression will allow 
us to measure the impact of adherence after adjusting for various covariates such as age, 
gender, TMS, CMS, as well as proxies for disease severity.  Regression analyses will also 
be used to examine the impact of medication adherence on total asthma and COPD –
related healthcare costs.  Since a small number of patients are responsible for the major 
proportion of total costs (skewed data), logarithmic transformations will be used to 
achieve normality.   
 The relationship between medication adherence and outcomes should be 
measured prospectively as well.  The impact of medication adherence in a temporal 
manner will enable the measurement of adverse outcomes such as hospitalizations and 
ED episodes as a consequence of adherence.  A case-control study design will be 
employed, where patients having adverse outcomes (cases) will be compared with those 
that do not (controls).  For cases, the refill patterns prior to the adverse outcomes will be 
examined and for controls the refill patterns will be examined for a predefined period.  
Results from this analysis will allow the estimation of a relative risk estimate – the 
probability of experiencing an adverse outcome among patients who are adherent versus 
those who are not.      
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 Phase II    
 The main objective of Phase II of the study is to determine the impact of 
medication adherence on HRQL in PEIA enrollees with asthma and COPD.  The other 
objectives of Phase II includes the measurement of self-reported medication adherence, 
and the estimation of losses in workplace productivity in terms of work-days lost due to 
days absent from work (and corresponding absenteeism dollars), and number of hours 
unproductive while at work (and corresponding presenteeism dollars) due to asthma and 
COPD.  This phase will involve sending a survey to PEIA members suffering from 
asthma and COPD who were identified in Phase I.  
 PEIA members with asthma and COPD will be sent a survey consisting of the 
following components: a disease-specific HRQL instrument, a self-report adherence 
scale, and the Work Productivity Short Inventory (WPSI) – a scale used to measure 
losses in workdays and unproductive hours while at work due to asthma and COPD.  In 
addition, questions about age, gender, education and self-reported health status will also 
be included.  Unfortunately, although there is considerable evidence of the impact of 
medication adherence and economic outcomes, there is very scant literature examining 
the relationship between medication nonadherence and HRQL.  Conceptually, HRQL 
should improve with increasing adherence to maintenance medications, however, since 
HRQL is patients’ perception of health, it can be very subjective and does not always 
correlate well with clinical measures of disease severity.  The relationship between 
medication adherence is very complex.  On one hand, improved medication adherence 
should result in fewer adverse outcomes and consequently improve HRQL.  However, it 
is also possible that increase in disease severity would result in poor HRQL, consequently 
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 impacting medication adherence.  Thus, the study explores the relationship between 
HRQL in conjunction with medication adherence, and healthcare utilization and costs.   
 The survey used to measure HRQL is the SGRQ (Jones et al, 1992).  This 
questionnaire has been created and validated for use in patients suffering from both 
asthma as well as COPD.  This questionnaire consists of three domains – symptoms, 
activity, and impacts.  In addition, a total HRQL score is also available.  The instrument 
also defines a clinically significant change in HRQL as 4 units, which is particularly 
useful since differences between groups may not be statistically significant but clinically 
meaningful.  HRQL scores can thus be compared between asthma and COPD members, 
and members suffering from both asthma and COPD.  The impact of medication 
adherence on HRQL will be measured using regression analyses, which will allow for the 
adjustment for various covariates such as age, gender, TMS, CMS, and disease severity.   
 Medication adherence was measured in phase I using refill-based measures.  
Since refill-based measures have their limitations, a self-report measure of medication 
adherence was also incorporated into the survey.  This measure, known as the Morisky 
scale is a generic, 4-item measure of medication adherence, which classified patients as 
high, medium or low adherent (Morisky et al, 1996).  Scores from the Morisky scale will 
be correlated with the refill-based compliance measures such as the MPR and median gap 
to examine congruence between the measures.                 
 In order to obtain the complete impact of asthma and COPD in conjunction with 
medication adherence, another outcome, self-reported losses in workplace productivity, 
was added.  This component of the survey consisted of questions from the WPSI, also 
known as the Wellness Inventory (Goetsel et al, 2003).  The WPSI consisted of questions 
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 that ask about the number of days with asthma or COPD symptoms in the past year, the 
number of workdays missed due to asthma/COPD, and the numbers of unproductive 
hours while at work due to the disease.  In order to translate the lost workdays and 
unproductive work-hours into dollar metrics, a previously developed algorithm was used 
which incorporated average hourly wage rates for various professions in WV, obtained 
from the US Department of Labor (2003).      
 The response rate to the survey will be calculated after subtracting from the 
denominator the total number of respondents who requested to be removed from the 
study, as well as surveys that were returned due to incorrect addresses.  Response rates 
will be calculated for each disease group (asthma or COPD) as well as for the overall 
Phase II sample.  Difference in response rates can thus be compared between respondents 
with asthma and COPD.  Thus, this phase of the study will give a better understanding of 
the impact of asthma and COPD by measuring HRQL, and workplace productivity.  
Phase II will also help validate the measurement of adherence, by examining the 
congruence between self-reported medication adherence and refill-based adherence.                   
         
STUDY OBJECTIVES AND RESEARCH QUESTIONS 
Phase I 
The overall goal of Phase I is to examine the relationship between medication 
nonadherence and healthcare utilization and costs in patients with asthma and COPD.  
Specific research questions that will be used to achieve this objective for asthma and 
COPD are stated separately.  
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 For Asthma:  
 Research Question 1:  Is medication prescribing for patients with asthma in accordance 
with NHLBI guidelines?  More specifically, among PEIA recipients with asthma, how 
many patients received drug therapy in either of the following four classes: 
I. Short-acting beta-agonist only; 
II. Combination therapy without inhaled anti-inflammatory medications; 
III. At least one prescription claim for inhaled anti-inflammatory therapy 
(ICS, inhaled cromolyn, or inhaled nedocromil) 
IV. No prescription claims for chronic pulmonary disease-related medications.   
Rationale:  This is an exploratory question that assesses the appropriate/inappropriate 
prescribing of drugs in patients with asthma.  Since NHLBI guidelines recommend the 
use of ICS as the most potent and cost-effective treatment for asthma, all patients with 
asthma should ideally use ICS prophylactically.  Thus, the study should find that most 
patients with asthma use ICS as a maintenance medication on a regular basis.  At the 
same time, since regular use of ICS reduce acute exacerbations, regular use of ICS should 
result in reduced utilization of short-acting beta-agonists.  Ideally, patients receiving 
short-acting beta-agonists only, should be at a minimum.    
 
Research Question 2:  Describe patterns of distribution of select demographic factors 
such as age, and gender in patients with asthma.   
Rationale:  This is an exploratory question that assesses the overall prevalence of asthma 
and rates of prevalence by age group and gender among PEIA covered members.  
Null Hypothesis A:  There is no difference in asthma prevalence by age group and gender.   
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Research Question 3:  What is the prevalence of nonadherence to maintenance 
medications among PEIA patients with asthma?  
Rationale:  This exploratory question assesses the extent of nonadherence to maintenance 
medications in the WV PEIA population, as measured from refill behavior.  This research 
question will examine the refill patterns among PEIA patients with asthma for all 
maintenance medications for asthma.   
 
Research Question 4:  Is there a difference in the number of adverse outcomes 
(hospitalizations and/or ED visits), outpatient visits, and hospital length-of-stay (LOS) 
between patients with asthma who are adherent to medications and those who are not? 
Null Hypothesis B:  There is no difference in the number of adverse outcomes between 
patients with asthma who are adherent to maintenance medications and those who are 
not.   
Null Hypothesis C:  There is no difference in the number of outpatient visits between 
patients with asthma who are adherent to maintenance medications and those who are 
not.  
Null Hypothesis D:  There is no difference in LOS between patients with asthma who are 
adherent to maintenance medications and those who are not.  
 
Research Question 5:  Is there a difference in total asthma-related healthcare costs 
(hospitalization, ED, outpatient, and prescription costs) between patients with asthma 
who are adherent to maintenance medications and those who are not? 
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 Null Hypothesis E:  There is no difference in total asthma-related healthcare costs 
between patients with asthma who are adherent to maintenance medications and those 
who are not. 
 
Research Question 6:  Is there a difference in the relative risk of adverse health outcomes 
such as a hospitalizations and/or and ED visits between patients with asthma who are 
adherent to medications and those who are not? 
Null Hypothesis F:   There is no difference in the risk of adverse outcomes such as 
hospitalizations and ED visits between patients with asthma who are adherent to 
maintenance medications and those who are not.   
 
For COPD:  
Research Question 1:  To examine whether medication use in COPD patients is in 
accordance with GOLD guidelines.  More specifically, among PEIA recipients with 
COPD, how many patients received drug therapy in either of the following two 
categories: 
I. Bronchodilators (which consist of short-acting and long-acting beta-
agonists, anticholinergics, methylxanthines); 
II. Corticosteroid therapy (ICS and oral corticosteroids) 
III. No prescription claims for chronic pulmonary disease-related medications.   
Rationale: This is an exploratory question that assesses the appropriate/inappropriate 
prescribing of drugs in COPD patients.  Unlike asthma, GOLD guidelines in COPD do 
not specifically recommend the use of ICS as a prophylactic/maintenance medication.  
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 Thus, this research question will examine the proportion of COPD patients who received 
either bronchodilators or corticosteroids (either inhaled or oral).   
 
Research Question 2:  Describe patterns of distribution of select demographic factors 
such as age and gender in patients with COPD.     
Rationale:  This is also an exploratory question that assesses the overall prevalence of 
COPD, and rates of prevalence of COPD by age group and gender among PEIA covered 
members.  
Null Hypothesis A:  There is no difference in COPD prevalence by age group and gender.  
    
Research Question 3: What is the prevalence of nonadherence to maintenance 
medications among COPD patients in PEIA?  
Rationale: This exploratory question assesses the extent of nonadherence to medications 
in the WV PEIA COPD patients, as measured by refill behavior.   
 
Research Question 4:  Is there a difference in the number of adverse outcomes 
(hospitalizations and/or ED visits), outpatient visits, and hospital length-of-stay (LOS) 
between COPD patients who are adherent to maintenance medications and those who are 
not? 
Null Hypothesis B:  There is no difference in the number of adverse outcomes between 
COPD patients who are adherent to maintenance medications and those who are not.   
Null Hypothesis C:  There is no difference in the number of outpatient visits between 
COPD patients who are adherent to maintenance medications and those who are not.  
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 Null Hypothesis D:  There is no difference in LOS between COPD patients who are 
adherent to maintenance medications and those who are not.  
 
Research Question 5:  Is there a difference in total COPD-related healthcare costs 
(hospitalization, ED, outpatient, and prescription costs) between COPD patients who are 
adherent to maintenance medications and those who are not? 
Null Hypothesis E:  There is no difference in total COPD-related healthcare costs 
between COPD patients who are adherent to maintenance medications and those who are 
not. 
 
Research Question 6:  Is there a difference in the relative risk of adverse health outcomes 
such as a hospitalizations and/or and ED visits between COPD patients who are adherent 
to maintenance medications and those who are not? 
Null Hypothesis F:  There is no difference in the risk of adverse outcomes such as 
hospitalizations and ED visits between COPD patients who are adherent to maintenance 
medications and those who are not.  
 
Phase II 
The main objective of Phase II is to examine the association between 
nonadherence to ICS pharmacotherapy and HRQL.  The other objectives of Phase II 
include measuring patients’ self-reported nonadherence and losses in workplace 
productivity due to asthma and COPD.  Specific research questions are:  
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 For Asthma:  
Research Question 7:  What is the overall HRQL of patients with asthma? 
Rationale:  This exploratory research question will assess the domain-specific as well as 
overall HRQL scores for asthma patients.  Absolute values for HRQL scores obtained for 
the WV PEIA patients with asthma will be compared with HRQL scores from other 
studies using the SGRQ.     
  
Research Question 8:  What is the self-reported nonadherence of PEIA recipients with 
asthma? 
Rationale:  In Phase I, adherence was measured based on prescription refill patterns from 
claims data.  Here, patients’ self-reported adherence will be measured from the 
questionnaire, which will include Morisky scale. 
 
Research Question 9:  Is there high correlation between asthma patients’ self-reported 
adherence and adherence calculated from prescription refills in claims data? 
Rationale: A high congruence between self-reported adherence and adherence obtained 
from prescription refills would validate the measurement of adherence.  
Null Hypothesis G:  There is no significant correlation between self-reported adherence 
and adherence measured from prescription refills.   
 
Research Question 10:  Is there a difference in HRQL between patients with asthma who 
are adherent to maintenance medications and those who are not?   
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 Null Hypothesis H:  There is no difference in HRQL between patients with asthma who 
are adherent to maintenance medications and those who are not.  
 
Research Question 11:  Is there a difference in workplace productivity dollars between 
patients with asthma who are adherent to maintenance medications and those who are 
not?   
Null Hypothesis I:  There is no difference in workplace productivity dollars between 
patients with asthma who are adherent to maintenance medications and those who are 
not.  
  
For COPD:  
Research Question 7: What is the overall HRQL of patients with COPD? 
Rationale:  This exploratory research question will assess the domain-specific as well as 
overall HRQL scores for COPD patients.  Absolute values for HRQL scores obtained for 
the WV PEIA COPD patients will be compared with HRQL scores from other studies 
using the SGRQ.     
 
Research Question 8: What is the self-reported adherence of PEIA recipients with 
COPD?  
Rationale:  In Phase I, adherence was measured based on prescription refill patterns from 
claims data.  Here, patients’ self-reported adherence will be measured from the 
questionnaire, which will include the Morisky scale. 
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 Research Question 9:  Is there high correlation between COPD patients’ self-reported 
adherence and adherence calculated from prescription refills in claims data? 
Rationale: A high congruence between self-reported adherence and adherence obtained 
from prescription refills would validate the measurement of adherence.  
Null Hypothesis G:  There is no significant correlation between self-reported adherence 
and adherence measured from prescription refills.   
 
Research Question 10:  Is there a difference in HRQL between COPD patients who are 
adherent to maintenance medications and those who are not?   
Null Hypothesis H:  There is no difference in HRQL between COPD patients who are 
adherent to maintenance medications and those who are not.  
 
Research Question 11:  Is there a difference in workplace productivity dollars between 
COPD patients who are adherent to maintenance medications and those who are not?   
Null Hypothesis I:  There is no difference in workplace productivity dollars between 
COPD patients who are adherent to maintenance and those who are not.  
 
ASSUMPTIONS 
Phase I Assumptions 
 Phase I requires several assumptions.  The first assumption concerns the validity 
of the paid claims data.  Claims data are primarily collected for reimbursement purposes, 
and not research.  Thus, any billing or coding errors will result in inaccuracies, which will 
affect the study.  The important assumption with respect to claims data is the diagnosis.  
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 Since ICD9 codes will be used to classify patients as having asthma or COPD, any data 
entry errors will affect the study validity.  WV PEIA claims data has not been used for 
research purposes before this project, and this study will be a test of its validity.  As it is 
not possible to test the validity of this data, this assumption must be made.  The next 
assumption is with respect to the measurement of medication adherence.  Since 
adherence will be measured based on refill claims, the biggest assumption is that a refill 
obtained is a refill consumed.  It is not possible to ascertain whether a patient used 
inhaled corticosteroid or any other maintenance drug appropriately.  Hence, the 
assumption has to be made that a patient understood the correct use of inhalers, and 
patients who received a prescription actually consumed the medication as prescribed.    
Phase II Assumptions  
Phase II requires certain assumptions too.  First, the accuracy of the diagnosis as 
determined from the ICD9 code will impact who receives the survey.  If the survey 
recipient has been inaccurately classified as having asthma or COPD, their inclusion will 
result in an inaccurate study group, and will also affect the survey response rate.  Hence, 
the assumption is that PEIA members who have the ICD9 code for asthma or COPD 
actually have the disease.  The next assumption is with respect to self-reported adherence 
and productivity data.  Respondents are more likely to report themselves as adherent in 
order to provide socially desirable responses.  It is however, within the scope of the study 
to examine the congruence between self-reported adherence, and adherence obtained 
from claims data.  The assumption that the respondents accurately report their adherence 
has to be made.  Similarly, some respondents are likely to underreport the number of 
workdays missed, or underreport the number of unproductive hours while at work due to 
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 the fear of being reprimanded by the employer (state).  Thus, the assumption that the 
respondents are not underreporting the lost workdays, and unproductive work-hours has 
to be made.        
 
LIMITATIONS 
 The limitations of this study arise from the fact that the study design is a non-
randomized, observational design, which could potentially induce selection bias.  The 
second limitation of his study is its cross-sectional nature.  Thus, the study cannot 
determine what outcomes resulted from poor adherence, as compared to studies where 
poor adherence was a marker for unmeasured causal factors.  There is also endogeneity 
between the predictor variable – medication adherence and the outcome variables, such 
as HRQL and healthcare utilization and costs.  Thus, it is difficult to conclude whether 
poor HRQL is a consequence of adherence, or poor HRQL resulting from the disease 
affected medication adherence.  Also, medication adherence was measured using proxy 
indices.  The use of these indices have limitations, the biggest assumption being that a 
prescription dispensed is a prescription taken, although these indices have been used and 
validated previously (Farris et al, 1994 and Christensen et al, 1997).  This study is also 
subject to general limitations of claims data, such as the use of ICD9 codes, which are 
subject to misclassification bias.  Another limitation of this study is that the exact disease 
severity of the patient is not known, and ICD-9 diagnosis and CPT-4 procedure codes 
were used as proxy.  Other variables such as socioeconomic status, and physician-patient 
interaction, which affect medication adherence, as well as outcomes resulting from 
adherence were not available, and the study could suffer from potential omitted variable 
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 bias.  Finally, the study has limited generalizability, as the results are representative of 
WV state employees diagnosed with asthma and COPD.  This patient population is likely 
to be more educated, and of a higher socioeconomic status than the rest of the state 
residents.      
 
STUDY SIGNIFICANCE 
Phase I Significance 
This study is the first study conducted in WV state employees examining the 
impact of medication adherence on economic outcomes such as healthcare utilization and 
costs in asthma and COPD.  This is also the first study, which provides some estimates 
regarding the epidemiology and burden of asthma and COPD in state employees in WV.  
Finding from this study will help the state health insurance agency in designing programs 
to educate asthma and COPD patients about the disease.  This study will provide the state 
data regarding the prescription use behavior among asthma and COPD patients, and help 
design interventions to improve physician prescribing as well as patient medication-
taking behavior.  Results from this study could also act as a yardstick for guiding future 
health policy decisions with respect to asthma and COPD for not only the state of WV, 
but also other states.   
Phase II Significance 
 This study not only examines economic outcomes, but also humanistic outcomes 
such as HRQL.  This study will help us fathom the impact of asthma and COPD from the 
patient perspective, and examine changes in HRQL as a consequence of medication 
adherence.  Literature examining the relationship between HRQL and nonadherence is 
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 scarce in any chronic disease, let alone asthma or COPD, and findings from this study 
will add substantially to the scant body of literature.  A unique achievement of this study 
is the measurement of losses in workplace productivity due to asthma and COPD, with 
respect to workdays lost, as well as estimating unproductive hours while at work.  These 
lost workdays and lost work-hours will be translated into dollar values, and will provide 
the true impact of the disease from the employer perspective, which in this case is the 
state of West Virginia.  Measuring losses in productivity from an employer perspective 
have assumed tremendous significance in the more recent past, since patients with 
chronic diseases are living longer, and costly therapies are becoming more common 
(Kessler et al, 2001).  Incorporation of this perspective takes this study closer towards 
capturing the complete impact of asthma and COPD.   
 
This chapter gave a brief introduction to the problem, explained the conceptual 
framework, study objectives and research questions, as well as study assumptions, 
limitations, and its significance.  The next chapter will examine the literature in detail as 
it pertains to medication nonadherence, and its impact on economic and humanistic 
outcomes.  
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 CHAPTER TWO 
LITERATURE REVIEW 
 
The review of the literature provides a background of the various aspects of the 
study involving medication nonadherence, health-related quality of life assessment, and 
the impact of medication use on economic and humanistic outcomes.  The first section of 
the chapter discusses the clinical definitions, epidemiology and burden of disease, and 
national guidelines for the pharmacotherapeutic management of asthma and COPD.  The 
following section examines evidence from the literature regarding the impact of 
prophylactic medication use on outcomes.  This is followed by a discussion of the various 
factors that affect medication nonadherence, the prevalence of medication nonadherence, 
and ways of measuring adherence. The final section examines health-related quality of 
life in respiratory disease, with a discussion of the various instruments used for its 
assessment.  
 
Clinical Definitions 
Asthma is a chronic pulmonary condition, which consists of excessive airway 
narrowing, in response to a wide range of naturally occurring stimuli (Barbee, 1998).  
More specifically, asthma is characterized by reversibility of airflow obstruction, either 
spontaneously or as a result of therapy, in addition to bronchial hyperresponsiveness 
(Kamp, 1992, and Lemaneske, 1992).  There is excessive mucous production, bronchial 
edema, and eosinophilic and lymphocytic inflammation, which is at least partially 
reversible.  The airway inflammatory response may be divided into three phases: acute, 
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 late (chronic), and remodeling (Lemaneske, 1992, and Bush, 1992).  The acute phase is a 
reaction to various stimuli – both immunologic and nonimmunologic such as allergens, 
exercise, irritants, and medications.  The acute phase is characterized by a release of 
chemical mediators such as histamine, leukotrines, prostaglandins, platelet activating 
factor, and thromboxanes by the activated airway mast cells.  These chemical mediators 
cause smooth muscle contraction, bronchial hyperresponsiveness, and airway wall 
edema.  They also lead to the recruitment of other inflammatory cells and mediators 
(Kamp, 1992, Lemaneske 1992, Bush 1992, Oettgen and Geha, 2001).   
The late phase of the asthmatic response is characterized by airway infiltration of 
the mast cells, eosinophils, lymphocytes, and macrophages.  Subsequently, cytokines, 
chemokines, cationic proteins, and enzymes are released by these cells, which cause the 
marked inflammatory response that is typical in asthmatic airways.  Airflow is 
compromised by bronchial hyperresponsiveness, airway wall edema, and mucous 
production, by the primary and secondary mediators (Kamp, 1992, and Lemaneske, 
1992).  
The remodeling phase is an aberrant restorative process, which results in airway 
modeling.  Histologically, this phase is marked by basement membrane thickening and 
fibrosis, mucous gland hypertrophy and hypersecretion, smooth muscle hypertrophy, 
inflammatory cell infiltration, angiogenesis, and epithelial damage.  If the inflammatory 
component of asthma is not adequately treated, it can be followed by this phase, which 
eventually results in total, irreversible loss of lung function (Kamp, 1992, Lemaneske, 
1992, Bush, 1992, Oettgen and Geha, 2001).       
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 Based on the days/nights with symptoms, FEV1 (% predicted), and peak flow 
variability, asthma has been categorized into 4 disease severity levels: Step 1 – Mild 
Intermittent, Step 2 – Mild Persistent, Step 3 – Moderate Persistent, and Step 4 – Severe 
Persistent (NHLBI Guidelines, 1997).    
COPD, on the other hand, is characterized by airflow limitation that is not fully 
reversible (Rennard, 1998 and Pauwels et al, 2001).  The airflow limitation is not only 
progressive, but also associated with an abnormal inflammatory response of the lungs to 
noxious particles and gases (Puchelle and Vargaftig, 2001).  Individuals diagnosed with 
any of the following conditions during the course of a lifetime are categorized as 
suffering from COPD: asthmatic bronchitis, chronic bronchitis, chronic obstructive 
bronchitis, and emphysema (Pauwels et al, 2001).  The clinical definition of each of these 
is different, although all of the above except simple bronchitis are characterized by 
airway flow limitation.  Symptoms of COPD include dyspnea, fatigue, sputum 
production, or chronic cough.  Unlike asthma, the airway obstruction in COPD is 
irreversible.  It is indicated by a postbronchodilator FEV1 < 80% of predicted value, in 
combination with FEV1/FVC < 70%, confirms the presence of COPD (GOLD guidelines 
1998).  Based on spirometry results, FEV1/FVC values, presence/nature of symptoms, 
respiratory failure/signs of right heart failure, COPD patients are characterized into 4 
groups: Stage 0 – At Risk, Stage 1 – Mild COPD, Stage 2 – Moderate COPD, and Stage 
3 – Severe COPD (Rennard, 1998).    
 The differences between asthma and COPD are summarized in Table 1.  
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 Table 1:  Clinical Differences between Asthma and COPD  
 
Characteristics Asthma COPD 
 
Age of onset 
 
Usually early, variable 
 
 
 
 
Average age is 30 years 
 
 
Usually in the 5th or 6th 
decade, some patients may 
be diagnosed as early as 40 
years of age 
 
Average COPD patient is 
65 years of age 
 
Atopy 
 
Usually present 
 
Usually non-atopic 
 
Symptoms 
 
Dyspnea, chest tightening, 
wheeze and cough 
 
When present, symptoms are 
usually intermittent, 
occasionally chronic and can 
be mild, moderate or severe 
 
Increased cough, sputum 
and/or dyspnea 
 
When present, symptoms 
are chronic 
 
Diurnal variation 
 
Waking at night with cough / 
wheeze  
 
Nocturnal attacks rare 
 
Evolution 
 
Episodic 
 
Slow, cumulative disabling 
pattern 
 
Reversibility of airflow 
obstruction 
 
Airflow obstruction is episodic 
and usually reversible with 
therapy 
 
FEV1 usually normal between 
attacks and quickly improves 
with bronchodilators 
 
Reduction in FEV1 may be 
partially irreversible with long-
standing asthma 
 
Airflow obstruction is 
chronic and persistent 
 
 
FEV1 is persistently 
reduced if disease 
significant 
 
With bronchodilators, 
FEV1 usually unchanged, 
but may improve in some 
patients 
 
Chest exam 
 
Normal, wheezing, prolonged 
expiratory phase 
 
Wheezing, hyperresonance, 
barrel chest deformity, 
subxiphoid apical impulse 
 
Role of smoking 
 
Not directly related may 
 
Directly related 
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 Characteristics Asthma COPD 
aggravate the condition 
 
Airway hyperreactivity 
 
20% fall in FEV1 usually 
occurs at </= 16 mg/mL 
methylcholine 
 
20% fall in FEV1 does not 
usually occur at <25 mg/mL 
methacholine  
 
CO diffusion (DLCO) 
 
CO diffusion not decreased 
 
CO diffusion is decreased, 
suggests impaired gas 
exchange commonly due to 
emphysema, should be 
confirmed with a high-
resolution CT scan  
 
Sputum induction for 
cytology 
 
Eosinophils predominate in the 
sputum of asthma patients 
 
Neutrophils predominate in 
the sputum of most COPD 
patients 
 
Radiographic findings 
 
Often normal, may show 
pulmonary hyperinflation 
 
 
Elevated lung lucency 
 
Pulmonary hyperinflation, 
Decreased vessels, focal 
hyperaeration (emphysema) 
 
Increased interstitial 
markings (chronic 
bronchitis)  
Sources: NHLBI Guidelines, 1997, GOLD Guidelines, 1998, Jeffrey, 1999, D’Urzo, 
2001. 
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 Epidemiology and Burden 
 
Asthma exerts a significant burden on society, both in terms of direct as well as 
indirect costs.  More than 15 million people in the United States are affected by asthma 
(Weiss and Sullivan, 2001), which is prevalent in 5-10% of the US population (Mannino 
et al, 1998, and Weiss and Sullivan, 2001).  The prevalence rate for asthma in 2001 was 
73/1,000 (CDC, 2001).  Rates were higher in children (87/1,000) than adults (69/1,000).  
Among adults, females showed a 30% higher prevalence than males, however, this trend 
was the opposite in children, with boys having 30% higher prevalence than girls (CDC, 
2001).  Prevalence rates were 10% higher in non-Hispanic blacks as compared to non-
Hispanic whites, and around 40% higher than Hispanics.  The outpatient visit rates were 
37.9/1,000, and ED episode rates were 67/10,000 (CDC, 2001).  The overall 
hospitalization rate among patients with asthma was 17/10,000, with children and non-
Hispanic blacks having the highest rates for both ED episodes and hospitalizations (CDC, 
2001).  The overall mortality rate in asthma was 1.6 deaths per 100,000 in 2000 (CDC, 
2001).   
Asthma was responsible for 500,000 hospitalizations, 1.8 million emergency 
room visits, 6,500 deaths, 9 million lost workdays, and 10 million lost school days in 
1998 (Data Fact Sheet, NIH, NHLBI, 1999). The costs of asthma to the United States 
range from 11.3 billion dollars (Data Fact Sheet, NIH, NHLBI, 1999) to 12.7 billion 
dollars (Weiss et al, 1992) per year.  Hospitalizations and ED visits account for the most 
dollars.  The average cost for an ED episode due to asthma ranges from $234 (Stanford et 
al, 1999) to $457 (Segal et al, 1995).  The average hospitalization costs for asthma were 
$3,103 with a mean LOS of 3.8 days (Stanford et al, 1999).  There costs ranged from 
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 $2,000 for patients hospitalized with mild asthma to $15,000 for patients with more 
severe disease (Stanford et al, 1999).  Asthma costs are highly skewed, as indicated by a 
population-based cost-of-illness study, which showed that less than 20% of the people 
with asthma were responsible for more than 80% of total costs (Malone et al, 2000). 
Patients with asthma having lower income and minority status experience more adverse 
outcomes, thereby leading to higher utilization and costs, primarily as a result of poor 
access to care (Druss et al, 2001).   
COPD is one of the leading causes of mortality and morbidity in the United States 
(Hurd, 2000 and Sullivan et al, 2000).  Various studies have reported the economic 
burden of COPD thus far (Sullivan et al, 1993, Ward et al 1994, Wilson et al, 1996, Hurd, 
2000).  These range from 33.2 billion (Wilson et al, 1996), to 23.9 Billion (Sullivan et al, 
1993).  These costs include direct as well as indirect costs.  Another study showed that 
direct costs due to COPD were 14 billion US dollars (Hurd, 2000).  Hospital use, 
medications, and oxygen therapy were the major cost drivers for COPD.  Per capita 
Medicare expenditures for COPD patients were 2.4 times higher than those of other 
Medicare beneficiaries ($11,841 vs. $4901, 2000 values) (Grasso et al, 1998).  The study 
also showed that hospital expenditures, which constituted 64% of total expenditures, 
were 2.7 times higher, while outpatient use was 2.2 times higher for patients with COPD.  
Among indirect costs, COPD was responsible for losses in employment translating into 
$9.9 billion in the United States (Sin et al, 2002).  Another study showed that the annual 
cost of health services utilization in the United States was $4,119 per patient with COPD, 
with indirect costs accounting for $1,527 per COPD patient (Halpern et al, 2003).  After 
adjusting for age and gender, COPD patients in a managed care population were 2.3 
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 times more likely to have been hospitalized than patients with other conditions, and those 
admitted had significantly longer lengths of stay (4.7 vs. 3.9 days, P<0.001) (Mapel et al, 
2000).  Disease burden was also correlated with disease severity.  Stage 1 patients 
experienced the lowest costs ($1,681), followed by Stage 2 ($5,037), and Stage 3 
($10,812) (Hilleman et al, 2000).  Healthcare utilization in COPD patients is highly 
skewed, with the top 10% accounting for more than 50% of total expenditures (Ruchlin 
and Dasbach, 2001).  
The prevalence of emphysema was 7.8/1,000 in 1994 (Wilson et al, 1994).  The 
prevalence was higher in men (9.34/1,000) than women (7.33/1,000) (Murray and Lopez, 
1996).  The prevalence of chronic bronchitis was 54/1,000 in 1994 (Wilson et al, 2000).  
Another study reported the overall prevalence of COPD to be 61.9/1,000 in 1993 (NHIS, 
1993).  In 1996, the overall hospitalization rate was 8.9 hospitalizations/10,000, the 
outpatient utilization rate was 732 visits/1,000, and the emergency department use rate 
was 9 ED episodes/10,000 (NIH, 1995 and Wilson et al, 2000).  Patients with 
emphysema had higher hospitalization rates compared to chronic bronchitis patients, 
however, chronic bronchitis patients had higher outpatient use rates.  The rate of ED use 
was similar in both groups (NIH, 1995 and Wilson et al, 2000).  Predictors of costs and 
utilization in COPD patients include age, health status, disease severity, physician 
specialty, geographic location, and type of insurance coverage (Ruchlin and Dasbach, 
2001).  
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 Prophylactic Therapy in Asthma and Chronic Obstructive Pulmonary Disease 
In 1997, the National Asthma Education and Prevention Program Expert Panel 
Report 2 was released by the National Heart, Lung and Blood Institute, which consisted 
of published guidelines for the management of asthma (NHLBI Guidelines, 1997).  This 
report stated that ICS were the most potent and effective long-term control medications 
for asthma.  The stepwise guidelines for the treatment of asthma are as follows:  
Stepwise approach to pharmacologic therapy for asthma 
Step 1: Occasional use of relief bronchodilators 
Step 2: Regular inhaled anti-inflammatory medications 
*Initial trial of sodium cromoglycate or nedocromil sodium 
*If unsuccessful, budesonide or beclomethasone dipropionate, 200-800 µg/day 
Step 3: High-dose inhaled glucocorticosteroid (e.g., budesonide 1200-1600 µg/day) 
Step 4: High-dose inhaled glucocorticosteroid and regular bronchodilators 
*Oral slow-release theophylline 
*Possible addition of inhaled ipratropium bromide or long-acting β2-agonist (salmeterol) 
Step 5: Long-term alternate day or daily oral prednisone 
Step 6: When stepping down, review treatment every 3 to 6 weeks 
These guidelines state that the most cost-effective way to reduce acute symptoms 
with anti-inflammatory therapy is a short course (<= one week) of a systemic 
corticosteroid, followed by chronic use of an ICS.  The guidelines recommend that ICS 
should be used in conjunction with a long-acting beta-agonist.  In patients with COPD, 
the use of ICS has been underscored in many studies, although consensus guidelines have 
not been developed (van Schyak et al, 1996, Rowe et al, 1992, Hatoum et al, 1994).  
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 Overall, pharmacotherapy in COPD is used to improve symptoms and/or disease 
complications.  None of the existing medications for COPD have been shown to modify 
the long-term decline in lung function, which is a characteristic of COPD.  An important 
component of COPD treatment is smoking cessation (Pauwels et al, 2001).  
The 1997 NHLBI asthma guidelines recommend the use of ICS for control of 
bronchial asthma in patients already receiving systemic corticosteroids, and those patients 
who are unresponsive to nonsteroid regimen.  They are not recommended for the acute 
relief of asthma, which can be controlled by bronchodilators, and other nonsteroid 
medications and in patients who require systemic corticosteroid treatment infrequently, or 
in the treatment of non-asthmatic bronchitis.  It is also contraindicated in primary 
treatment of status asthmaticus when intensive measures are required, when there is 
hypersensitivity to any ingredient, or when there are systemic fungal infections and 
persistently positive sputum cultures in patients for candida albicans.  Localized fungal 
infections have occurred in patients who are on corticosteroid inhaler pharmacotherapy.  
Clinical responsiveness to ICS is highly dependent on proper administration.  Bai 
(1995) reviewed ICS from a clinical and economic standpoint, and suggested that the 
choice of inhaled glucocorticosteroid for therapy depends upon a number of factors such 
as systemic bioavailability, delivery device, patient acceptance, and most importantly, 
cost.  High cost of ICS makes them cost-prohibitive.  The use of these medications, 
however, results in cost savings to the overall healthcare system due to reduced work 
absences, losses in productivity, reduced ED and hospitalizations, and bronchodilator use.  
Also, as shown in the Sasketchewan study, premature death is lower in patients taking 
ICS.  Thus the use of ICS is clearly justified, according to Bai (1995). 
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Clinical Efficacy of Inhaled Corticosteroids: A Review of Meta-Analyses 
Rowe and colleagues (1992) conducted a meta-analysis to examine the effect of 
steroid therapy on pulmonary function, admission rates and relapse rates in patients 
presenting with acute exacerbations of asthma.  The study, which used results from 30 
randomized clinical trials, found that the use of steroids, early in the treatment of 
asthmatic exacerbations significantly reduced admission in adults (OR 0.47, 95% CI 
0.27-0.79) and children (OR 0.47, 95% CI 0.06-0.42).  They also found that 
corticosteroids were effective in preventing the rates of relapse in outpatient treatment of 
asthmatic exacerbations (OR=0.15, 95% CI 0.05-0.44) (Rowe, 1992).  
Another meta-analysis conducted by Hatoum and colleagues (1994) to determine 
the role of ICS in the treatment of mild chronic asthma used peak expiratory flow rates 
(PEFR) as the outcome measure.  Using PEFR as the objective endpoint for effect size, 
the authors found that effect sizes ranged between 0.41 to 0.89, and the overall weighted 
average effect size for PEFR was 0.59.  The statistical significance of the results enabled 
the authors to conclude that ICS were beneficial in the treatment of mild chronic asthma.  
In patients with COPD, recent evidence shows that although ICS do not slow the 
progression of the disease, they do reduce exacerbations, mortality, as well as self-
perceived health status and HRQL.  In a retrospective analysis of managed care claims 
data, it was shown that COPD patients receiving ICS and/or salmeterol experienced 14 
percent lower mortality rates than patients who did not receive the drugs (Mapel et al, 
2002).  Van der Valk and colleagues (2002) showed that COPD patients receiving 
fluticasone experienced a significant reduction in acute exacerbations, as well as a 
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 significant improvement in HRQL, as compared to patients not receiving fluticasone.   
Unlike asthma, where bronchial hyperresponsiveness is related to severe inflammation, in 
COPD, bronchial hyperresponsiveness is a function of the degree of existing airway 
obstruction.  The GOLD guidelines released by the NHLBI recommend that inhaled 
glucocorticosteroids should only be prescribed for symptomatic COPD patients with a 
documented spirometric response to glucocorticosteroids, or for those with an FEV1 
<50% predicted and repeated exacerbations requiring treatment with antibiotics and/or 
oral glucocorticosteroids (Pauwels et al, 2001).  A review of 14 studies conducted by van 
Schyak and colleagues (1996), indicated that the use of ICS in COPD seems to have 
some beneficial effects on lung function.    
 
Prophylactic Pharmacotherapy and Economic Outcomes 
Various studies have documented the beneficial effects of prophylactic 
pharmacotherapy in chronic pulmonary disease.  Huse and colleagues (2000) examined 
the impact of choosing ICS versus long-acting bronchodilators on total costs.  They found 
that patients who used inhaled medications only, experienced a statistically significant 
decline in costs in the year following the treatment as compared to patients who used 
bronchodilators only, as maintenance therapy ($93 vs. $76; p<0.0001).  These costs were 
age-adjusted, and both groups had similar costs during the baseline year.  However, the 
study was nonrandomized, and did not explicitly measure adherence.  The use of long-
acting bronchodilators over inhaled medications could be preferential as well.  Stempel 
and colleagues (1997) have indicated that specialists are more likely to prescribe inhaled 
corticosteroids as compared to generalists.  If asthma patients were treated by a specialist, 
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 39% received a prescription for inhaled corticosteroid; whereas if the treating physician 
was a generalist, only 22% were prescribed an inhaled corticosteroid.  These trends 
continued over time.  Another study by Wu and colleagues (2001) showed that asthma 
patients treated by pulmonologists were more likely to be treated with an inhaled 
corticosteroid than those treated by a generalist.  These patients were also more 
knowledgeable about the disease, and experienced fewer ED visits and hospitalizations.  
Thus, physician specialty should be included as a covariate in studies examining asthma 
outcomes.  In a managed care population consisting of Medicare, Medicaid, as well as 
commercial enrollees, only 26% of the enrollees received an inhaled corticosteroid.  
Around 33% of the enrollees utilized only short-acting beta-agonists.  These enrollees 
experienced significantly higher incidence of adverse outcomes such as ED visits and 
hospitalizations, as compared to those receiving inhaled corticosteroids (Nestor et al, 
1998).     
In an analysis of the Saskatchewan Health databases, Suissa and colleagues 
(2000) carried out a population-based cohort study of patients using anti-asthma drugs.  
The relative risk of mortality was calculated after adjustment of various covariates such 
as age, gender, and medication use in the year before the index date, and number of 
hospitalizations two years before the index date.  The cases experienced a 21% lower 
mortality rate with each additional canister of inhaled corticosteroid used (RR=0.79; 95% 
CI 0.65 to 0.97).  Also, the death rate was higher in the first three months after therapy 
discontinuation, as compared with those who continued to take the inhaled medication.  
Thus, the regular use of inhaled corticosteroids was associated with a reduced risk of 
mortality due to asthma.  Ernst and colleagues (1992) conducted a nested case-control 
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 analysis to examine the risk of fatal and near-fatal asthma events in relation to ICS use.  
After adjustment for ‘other’ medication use, and markers of asthma severity such as prior 
hospitalizations and visits to specialists, the study found a 90% reduction in the 
probability of a fatal or a near-fatal event in patients receiving ICS compared to those 
who did not (OR 0.1; 95% CI 0.02 – 0.6).     
 Inhaled steroid dispensing was associated with a 50% decrease in the risk of 
hospitalization, after adjusting for age, race and other asthma medications in a managed 
care population (Donahue, 1997).  Regular use of inhaled corticosteroids has also been 
associated with a significant reduction in the rate of readmission in asthma patients (Blais 
et al, 1998).  The study compared first-time users of ICS with first-time users of 
theophylline.  The study found an 80% reduction in hospital readmission rates in the 
group receiving inhaled corticosteroids; although disease severity, age and gender were 
potential confounders.  Another cohort study by Blais and colleagues (1998) examined 
the impact of inhaled corticosteroid use on the risk of readmission for asthma.  This study 
found that although inhaled corticosteroids reduced the risk of readmission due to asthma 
by 40%, the positive effects of therapy disappeared after 6 months of use. The authors 
attributed this disappearance of the beneficial effect to confounding by disease severity.  
Most studies examining outcomes in asthma focus on short-term effects of 
pharmacotherapy.  A study by Suissa et al (2002) focused on long-term hospitalization 
outcomes in patients receiving ICS therapy.  Regular use of ICS was associated with a 
31% reduction in asthma-related hospitalizations, and a 39% reduction in readmission 
rates.  This reduction during the first four years of follow-up was maintained in the long-
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 term; thereby resulting in a reduction of five asthma hospitalizations per 1,000, and 27 
readmissions/1,000.    
Selroos and colleagues (1995) examined the effects of introducing early versus 
late ICS treatment in patients with mild or moderate asthma.  The use of ICS for more 
than one year resulted in significant improvements in PEFR and FEV1.  However, these 
improvements were the highest among patients experiencing asthma symptoms for less 
than two years.  In patients experiencing symptoms for more than two years, the 
improvement in FEV1 and PEFR was highest after one year of ICS therapy, but 
decreased thereafter.  Thus, early introduction of ICS therapy was associated with 
improved clinical outcomes, which supports the NHLBI guidelines recommending early 
use of ICS therapy following asthma diagnosis.  These findings were further reinforced 
by Selroos and colleagues (2004).  They compared an early treatment group with a 
delayed treatment group with varied symptom durations.  Early treatment with ICS was 
associated with better airway function and asthma control.  
The positive impact of ICS therapy has been seen in children as well.  
Balkrishnan and colleagues (1998) found that the introduction of prophylactic ICS 
pharmacotherapy was associated with significant clinical and economic benefits in 
Medicaid-enrolled children.  Regular inhaler refills were associated with a significant 
reduction on total healthcare costs in asthma patients.  Another study by Balkrishnan et al 
(1998) found a 50% reduction in the rate of hospitalizations, and a 26% reduction in 
outpatient use, after initiation of ICS pharmacotherapy, in a Medicaid population.   The 
study also found a 24% decrease in total healthcare costs per asthmatic per month as a 
result of the introduction of ICS pharmacotherapy.  
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 Rutten van Molken et al (1995) examined the costs and effects of combined 
bronchodilator and ICS pharmacotherapy in asthma and COPD patients.  They found that 
the addition of ICS to β-agonist pharmacotherapy lead to significant improvements in 
respiratory function and restricted activity days.  Although the cost of ICS/bronchodilator 
therapy was almost twice that of bronchodilator/anticholinergic therapy, this resulted in 
savings in other healthcare costs by $175.  Although the ICS/bronchodilator therapy 
increased net costs by $201 per patient per year, this translated into a significant 
reduction in the number of restricted activity days due to improved lung function.  Thus, 
the high costs of therapy were offset by improvement in overall productivity resulting in 
a net societal savings of $42 per day.  Another study by Smith and colleagues (2001) 
supported these findings.  They found that the increase in costs due to ICS was offset by 
the reduction in acute care-related medical visits.   
Balkrishnan and Christensen (2000) examined the impact of medication 
adherence to ICS pharmacotherapy in patients with both asthma as well as COPD, on 
health services utilization and costs.  This study used the Med-Total approach to measure 
adherence, where adherence is defined as the days of prescription supply dispensed 
divided by the days between prescription refills.  This study conducted in elderly patients 
with asthma, found that poor medication adherence was associated with a 5% decrease in 
physician visits (p<0.05), whereas better medication adherence was associated with a 
20% decrease in annual hospitalizations, after adjusting for respiratory disease-specific 
severity using proxy measures based on ICD-9 codes, as well as overall disease severity 
using Charlson’s comorbidity index.  Overall, studies have shown that adherence to 
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 NHLBI guidelines, which recommend the use of ICS as the most potent and cost-
effective prophylactic medication for asthma, resulted in better outcomes.      
 
Conceptual Definition of Medication Adherence 
Medication adherence is defined as the “extent to which a person’s medication-
taking behavior coincides with medical advice.” (Haynes et al 1979)   Adherence is a 
newer term, which suggests a more proactive role on the part of the patient to adhere to 
recommendations of their physicians, vis-à-vis the more traditional term “compliance”, 
which implies that the patient passively submits to the prescriber’s advice towards a 
medication regimen (Fish and Lung, 2001).  Full medication adherence occurs when all 
the instructions of the prescriber are followed.  Possible signs of nonadherence include 
patients’ failure to fill the prescription, loss to follow-up of the patient for further 
evaluation, and zero serum-drug concentrations.  Partially adherent patients take their 
drug more or less often than prescribed and/or take their doses erratically.   
Fincham (1995) has suggested a continuum to be considered when examining the 
use of medication adherence.  The continuum of adherence comprise of four points: 
Initial Adherence.  The patient receives a written prescription, has the prescription 
phoned to a pharmacy or transferred to it, but does not wait or return to pick up the filled 
prescription. This group also includes patients who do not present written prescriptions 
for filling the medication. 
Partial Adherence.  The patient takes the dispensed medication at a level less than the 
prescriber or the dispenser intended.  
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 Adherence.  The process of adhering with a prescribed regimen precisely as the prescriber 
or dispenser has intended.        
Hyperadherence.  The case where a patient takes a prescribed or dispensed medication at 
a level over and above the recommended or intended dosing level.  
Fincham also indicates that the patient moves from one type of adherence to 
another at varying times and with different dosage regimens.     
There are some concerns with measuring adherence: (1) adherence follows along 
a continuum from total adherence to total nonadherence, (2) lack of consistency in a 
given patient, and (3) measurement of adherence may be dependent on accurate provision 
of information by the patient, depending on the method used to assess adherence (Fish, 
2001).  
The importance of pharmacologic therapy in the overall treatment regimen cannot 
be undermined.  Lack of compliance with prescribed drug regimens costs the United 
States $100 million annually (National Pharmaceutical Council, 1992).  In general, 
nonadherence have at least 3 deleterious effects: (1) reduction of effectiveness, (2) 
increased occurrence of adverse effects due to uncontrolled disease, and (3) in clinical 
trials, it can result in masking of side-effects due to the drug in question. 
 
Factors Affecting Medication Adherence 
The factors that impact adherence / nonadherence can be grouped into three broad 
categories: 
1. Treatment-related factors:  
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 a. Regimen complexity:  Adherence rates are directly correlated with dosing 
frequency.  Adherence rates drop drastically at higher dosing frequencies 
(Greenberg, 1984 and Tashkin, 1995).  Patients are more likely to be 
adherent in a treatment plan that is simple.  
b. Mode of administration:  Studies have shown that adherence varies based 
on methods of administration.  Some patients prefer using oral 
medications as compared to using inhalers, because they feel that inhalers 
are less convenient, and at the same, they feel uncomfortable about using 
inhalers in public (Osman, 1996 and Ringdal et al, 1998).  Overall, 
adherence rates have been higher with oral versus inhaled therapy (Fish 
and Lung, 2001)  
c. Cost:  The nature of prescription drug coverage can significantly impact 
the probability of obtaining prescriptions.  Patients who do not have 
adequate prescription drug coverage should be prescribed economically 
efficient prescriptions.  
d. Prolonged / Prophylactic therapy:  Asthma treatment also consists of long-
term use of controller medication, which acts prophylactically, and 
prevents the occurrence of asthma symptoms and acute exacerbations.  
Patients are required to take these medications daily, even when symptoms 
are absent.  If patients no longer think they need medications since 
symptoms are absent, it can lead to adverse outcomes, which can be 
attributed to nonadherence.    
2. Patient-related factors:  
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 a. Knowledge of disease/treatment:  Patients who do not understand the 
importance of long term controller medication often are likely to have 
poorer adherence and worse outcomes.  Patients should also understand 
the pathophysiology of the disease, and its symptoms.  Patients should 
know that inflammation is the primary mechanism that occurs in asthma, 
and that asthma is a chronic disease.  Patients should also be educated 
about asthma symptoms and what happens during an asthma attack. 
Patients should be able to recognize an exacerbation and take treatment 
accordingly.  
b. Disease severity:  Adherence to medications has been lower in patients 
with mild asthma or severe asthma.  Thus, a curvilinear relationship exists 
between severity and adherence.  A possible explanation could be that 
patients with mild asthma do not feel the need for controller therapy and 
are hence nonadherent.  This could potentially lead to acute exacerbations, 
and more patients in this phase feel that taking medications is hopeless, 
again resulting in poor adherence (Leidy, 1995).  Another explanation is 
that severe patients have worse HRQL, which impacts self-efficacy 
resulting in nonadherence.  
c. Self-efficacy:  Adherence will tend to be lower in patients with low-
efficacy.  It has been shown that patients are more likely to be adherent if 
their perception regarding their own well-being is positive (Peters et al, 
1995, and Leidy, 1995).  Apter and colleagues (1998) examined patient 
characteristics that may influence adherence with twice daily inhaled 
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 steroid regimens.  The study used electronic monitoring to measure 
adherence, and found that the factors associated with poor adherence were 
poor physician-patient communication, lack of education, income, and 
language barriers.  Locus of control, however was not a significant 
predictor of adherence.  Self-efficacy can also be a function of other 
comorbidities.  It has been shown that clinically depressed patients are 
three times as likely to be nonadherent with pharmacological therapy than 
patients without depression (Dimatteo et al, 2000).  
3. Healthcare professional-related factors: 
a. Communication:  Good communication between the physician and the 
caregiver improves adherence, as it makes the patient a part of the 
decision-making process.  If the physician is disinterested, adherence rates 
will drop.  
b. Regular access to care:  If the patient is seeing a different physician with 
each visit (rotating caregivers), adherence rates will drop. Patient 
confidence in both treatment as well as the physician, has been shown to 
drop when patients are seen by more than one primary care physician 
(Bender, 2002).  
 
Measurement of Adherence 
 The measurement of adherence has always been a challenge to researchers as well 
as practitioners.  There is no gold standard to measure adherence or the lack of it, and 
there is controversy with regards to which measure provides the best estimate of a 
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 patient’s medication-taking behavior.  Some reviews have suggested that biologic assays 
are the most accurate measure of patient nonadherence, followed by pill counts, and that 
self-reports are the most inaccurate (O’Hanrahan and O’Malley, 1981, Evans and 
Spelman, 1983, Eraker et al, 1984, Rudd, 1991).  Other researchers have suggested that 
self-reported adherence is the most valid measurement, but only when the interview is 
conducted in person (Fletcher et al, 1979, Stewart, 1987, Landry et al 1988).   
Pharmacy claims databases have also been extensively used to measure adherence 
as defined by the frequency of refills (Farris et al, 1994, Christensen et al, 1997, Steiner 
and Prochazka, 1997, Grymonpre et al, 1998).  Steiner and Porchazka (1997) conducted a 
literature review of studies measuring refill compliance.   They concluded that refill 
compliance is a useful indicator of patient adherence when direct measurement is not 
practical.  Another study by Steiner and colleagues (1988) concluded that refill-based 
measures correlated well with disease-specific drug effects, and were therefore valid 
measures of compliance.  Farris et al (1994) concluded that while refill compliance 
measured using ‘days supply’ as indicated in prescription claims data was a good 
measure of compliance, they indicated that refill measures were better indicators of 
population-level adherence, rather than individual patient-level adherence.   
Some studies have compared different methods of assessing adherence.  Choo et 
al (1999) compared adherence from patient self-reports with pill counts, and pharmacy 
records.  They concluded that adherence measured from pharmacy records were a valid 
measure of adherence.  Another study by Erickson and colleagues measured 
nonadherence in asthma patients who used metered dose inhalers (MDIs) with that 
obtained from pharmacy claims data.  The study found a statistically significant 
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 agreement (75.5%; p<0.01) between adherence reported from pharmacy claims and 
adherence obtained from the self-reported questionnaire.   
 
 
Morisky Medication Adherence Scale 
The Morisky Medication Adherence scale (Morisky et al, 1986) has been 
extensively used to measure self-reported adherence in various disease conditions.  This 
scale is a generic, 4-item scale which measures adherence on a continuous scale of 0 to 4, 
where 0 represents most adherent and 4 represents most nonadherent.  Specifically, 
patients responding with a score of 0 are classified as ‘high adherent’, patients having 
scores from 1 to 2 are classified as ‘medium adherent’, and those having scores greater 
than or equal to 3 are classified as ‘low adherent.’  This scale has been shown to be both 
reliable and valid, as indicated by its high internal consistency (Morisky et al, 1988).  The 
scale also demonstrated good concurrent as well as construct validity, and reasonable 
predictive validity (Morisky et al, 1988).  The Morisky scale has been used to measure 
self-reported adherence in patients with various disease conditions such as hypertension, 
HIV, tuberculosis, as well as measure adherence to antibiotic therapy (Morisky et al, 
1990, Huang and Morisky, 1999, Gao and Nau, 2000, Ward et al, 2000, Pratt et al, 2001, 
Busto et al, 2001).   
 
Workplace Productivity Losses in Asthma and COPD 
 Both asthma and COPD being chronic diseases significantly impact workplace 
productivity in terms of days absent from work (absenteeism), as well as reduced 
effectiveness while at work due to the disease (presenteeism).  Asthma is a condition that 
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 affects adults of working age.  Patients with asthma experienced around 11 mean 
absenteeism days, and losses in presenteeism equivalent to almost 18 days per year 
(Wang et al, 2003).  Among indirect costs, asthma resulted in a loss of work-days, which 
translated into $1,550 per asthmatic annually (Cisternas et al, 2003).  The study showed 
that asthma resulted not only in decreased effectiveness while at work, but was also 
responsible for loss of employment (Ungar and Coyte, 2000 and Blanc et al, 2001).  
COPD, although more prevalent in the elderly, can also affect the working age 
population.  As indicated in the 1995 National Ambulatory Medical Care Survey, almost 
three-fourths of COPD patients were under 65 years of age, and were accountable for 
67% of COPD-related office visits, and 43% of all hospitalizations (Strassels et al, 2001).  
COPD was responsible for losses in employment translating into $9.9 billion in the 
United States (Sin et al, 2002).  Another study showed that the annual cost of health 
services utilization in the United States was $4,119 per patient with COPD, with indirect 
costs accounting for $1,527 per COPD patient (Halpern et al, 2003).  Patients with 
emphysema experienced around 19 mean absenteeism days, and losses in presenteeism 
equivalent to almost 28 days per year (Wang et al, 2003). 
    
Measurement of Losses in Workplace Productivity 
 Several instruments have been used to measure losses in productivity due to 
asthma and COPD.  These instruments include national surveys such as the National 
Medical Expenditure Survey (Strassels et al, 2001), the Third National Health and 
Nutrition Examination Survey (NHANES III) (Sin et al, 2002), the World Health 
organization’s Work and Health Performance Questionnaire (Wang et al, 2003), the 
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 American Productivity Audit (APA) (Stewart et al, 2003), the Confronting COPD Survey 
(Halpern et al, 2003), the McArthur Foundation Midlife Development in the United 
States (MIDUS) (Kessler et al, 2001), and the National Comorbidity Survey (Kessler et 
al, 2003).  Also, other instruments such as the Work Productivity and Activity 
Impairment Questionnaire (WPAI) (Reilly et al, 1996), the Worker Productivity Index 
(WPI) (Burton et al, 1999), the Work Limitations Questionnaire (WLQ) (Lerner et al, 
2001), the Endicott Work Productivity Scale (Endicott and Neel, 1997), and the Work 
Productivity Short Inventory (WPSI) (Goetsel et al, 2003) have also been used.     
   
Work Productivity Short Inventory (WPSI) 
 For the measurement of losses in productivity due to asthma and COPD in this 
study, the WPSI, also known as the Wellness Inventory will be used (Goetsel et al, 2003).  
This instrument was originally created to measure absenteeism and productivity losses at 
work due to eleven chronic diseases including respiratory illnesses.  The instrument was 
chosen since it has shown good evidence of reliability, and has low respondent burden 
(Goetsel et al, 2003).  The instrument asks three questions to measure the impact of 
disease on lost productivity.  These include the number of days with disease, days missed 
from work due to disease, and number of unproductive hours while at work due to the 
disease.  The creators have also developed an algorithm to convert the losses in workdays 
and work-hours into dollar metrics.  Since the instrument included only three questions to 
measure productivity losses, the low respondent burden was especially appealing with 
regards to choice of the instrument, since productivity was just one component of the 
survey, in addition to measuring HRQL, and self-reported adherence.            
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 Health-Related Quality of Life in Asthma and Chronic Obstructive Pulmonary 
Disease 
 HRQL has been defined as “the functional effects of illness and its consequent 
therapy upon a patient, as perceived by the patient.” (Schipper et al, 1996).  Although 
there is a considerable amount of economic and epidemiologic evidence of the impact of 
asthma and COPD, relatively little is known regarding its impact on HRQL.  This gap 
needs to be addressed since both asthma and COPD have a considerable impact on 
physical, psychological and social domains of HRQL.  The chronic nature of asthma and 
the unpredictability and uncertainty of acute episodes can substantially lower patients’ 
HRQL.  The presence and fear of symptoms may cause patients with asthma to avoid 
physical activities and social situations, which they might otherwise enjoy.  More 
specifically, patients with asthma are more concerned about restrictions in daily activities 
such as performing household chores, gardening and participating in sports (Nocon and 
Booth, 1991).  Nocturnal symptoms in asthma can disturb sleep and rest patterns, which 
can have a detrimental impact of overall vitality and energy levels.  Managing this 
chronic condition can drain an asthmatic physically, mentally as well as financially. 
 
Correlation between HRQL and Disease Severity 
Although one would expect a high correlation between disease severity and 
HRQL, this is not always true. HRQL is subjective and varies from individual to 
individual.  Thus, although conventional measures such as spirometry, medication use, 
symptom severity, airway hyperresponsiveness and sputum analysis provide valuable 
clinical information, they tell us very little about functional impairments that are 
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 important to asthma patients in their daily lives.  In fact studies have shown that there is a 
very poor correlation between clinical outcomes such as FEV1 and PEFR, and HRQL.  
The correlation between spirometry and HRQL is also weak (Jones et al, 1989, and Jones 
et al, 1992).  Both generic instruments such as the SF-36 (Bousquet et al, 1994), as well 
as disease-specific instruments have found poor to moderate relationships with clinical 
indicators in chronic respiratory disease (Juniper et al, 1995, , van Molken et al, 1995, 
van der Molen et al, 1997, Leidy and Coughlin 1997).  There could be several possible 
explanations for this weak correlation.  First, HRQL assesses patient perceptions of the 
condition and life experience over time, whereas pulmonary function is a static indicator; 
hence the low correlation with HRQL in a condition like asthma characterized by 
variability.  Second, the nature of the relationship between HRQL and pulmonary 
function may be nonlinear, both cross-sectionally and longitudinally (Jones, 1995).              
In COPD, unlike asthma, there may be no sudden episodes of acute chest 
tightness, dyspnea, or wheezing, that might catch the patients’ attention.  Breathlessness 
may be noticed by the patients during recreational activities or exercise.  This disturbance 
of physical activity causes the patients to be handicapped since their impairment 
constrains the activities they wish to perform.  Not only breathlessness, but cough and 
sputum production can have physical, social and emotional effects on patients.  Anxiety 
and depression levels are usually higher in COPD patients.  A significant correlation has 
been found between loss of vital capacity and depression in patients with COPD (Jones, 
1995).  In order to capture the overall effect of COPD, disturbances in a range of different 
aspects of disease activity, disability and distress should be examined.         
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 HRQL Measurement: Asthma versus COPD 
An instrument that measures HRQL in patients with asthma will differ from a 
COPD instrument since both diseases impact different domains (Jones, 1995, and 
Janssens, 2001).  For example, the domains that are most likely to be affected in asthma 
include symptoms, activity limitations, and emotional disturbances (Mahler, 2000, and 
Jones, 1995).  In COPD patients, dyspnea (Mahler and Mackowiak, 1995, Breslin et al 
1998, Hajiro et al, 1999) and days/nights disturbed by respiratory complaints are the 
domains that are more likely to be affected (Breslin et al, 1998).  In fact, the impact of 
dyspnea in HRQL in COPD is so significant that some researchers have recommended 
using extent of dyspnea by itself to categorize COPD patients based on disease severity 
(Hajiro et al, 1999).  Also, chronic cough and sputum production in COPD patients are 
likely to have physical, social and emotional effects on patients (Jones, 1995).  Anxiety 
and depression levels will tend to be higher in COPD patients as well (Jones, 1995).  Due 
to the chronic nature of COPD, the impact of reduced vital capacity on social and 
emotional dimensions are likely to be significantly higher in COPD; as compared to 
asthma, where due to the episodic nature of the disease, temporary loss in activity 
limitations, and impact of symptoms will be greater (Jones, 1995 and Janssens, 2001).  
Also, when the impact of disability is captured, it can mean differently to a patient with 
asthma versus a patient with COPD.  An asthmatic is likely to be younger, whereas a 
COPD patients is likely to be much older, retired, and disability would be a function of 
the inability to perform leisurely activities, as compared to a patient with asthma, where 
the disability would be a function of the inability to perform daily activities or loss in 
productivity at work (Jones, 1995 and Wijnhoven et al 2001).  Thus a comprehensive 
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 picture of HRQL in COPD would consist of measuring the following dimensions: disease 
activity, disability and distress, as compared to asthma where the focus is on symptoms 
and activity limitations.  Some domains recommended for measuring COPD HRQL are: 
cough, wheeze, walking distance, disability and anxiety level.  Domains recommended 
for asthma include: symptoms (shortness of breath, chest tightness, wheeze, cough), 
emotions, activities (sports, social activities, pets, housework), environment (dust, 
cigarettes, air pollution, pollen).  Cigarette smoking is another factor that can affect 
asthma and COPD patients differently.  These are some of the considerations that would 
go in choosing domains and specific items for measuring HRQL in asthma/COPD 
patients.  In order to distinguish between asthma and COPD patients, questions related to 
the following factors should be included: age at diagnosis, onset, nature of symptoms 
(such as cough, symptoms, nocturnal occurrences), prevalence of smoking, type of 
medications used, and frequency of medications.  Explicit questions such as: Have you 
ever been told by your doctor that you have asthma, will be used with a dichotomous 
Yes/No response.  These questions would help us determine which patients have asthma 
and / or COPD if diagnosis is not already known. 
 
HRQL Measurement: Choice of Scales 
The nature of the scales used in the instrument would depend on the intended use: 
whether the instrument is designed to be used for discriminative (or cross-sectional), 
evaluative (or longitudinal) or predictive purposes.  A discriminative instrument would 
consist of mainly yes/no type of responses (Juniper, 1995 and Sen et al, 1999).  For 
evaluative instruments, individual items have to be sensitive to change.  Scores should 
 63
 change when clinically or humanistically important changes occur.  Items with 5, 7, or 9 
response options or visual analog scale (VAS) can be used in an evaluative instrument 
(Juniper, 1995).  For a predictive instrument, a response set that maximizes correlation 
between scores and a criterion measure should be used (Juniper, 1995).  
 
HRQL Measurement: Psychometric Stability 
Reliability and validity testing can also change based on the intended purpose.  
An instrument that is used for discriminative purposes should have established reliability, 
cross-sectional validity (Guyatt et al, 1992), whereas an evaluative instrument should 
have reliability and longitudinal validity (Juniper, 1995 and Sen et al, 1999).  Reliability 
between patients would be measured by assessing the signal to noise ratio where signal 
represents between group differences, and noise represents within group differences 
(Streiner et al, 1989 and Juniper, 1995).  An indicator of this would be the ICC, or the 
intra class coefficient, which related the between patient variance to the total variance 
(Juniper, 1995).  Cronbach’s alpha on the other hand, measures the internal consistency, 
where it measures the correlation between an individual item and how it correlates with 
the overall domain (Juniper, 1995).   Cross sectional construct validity would be 
measured by looking at the correlations between the HRQL scores, and indicators of 
asthma / COPD severity, such as FEV1, or the walk-test, or dyspnea, or correlations with 
the Sickness Impact Profile (SIP) (Juniper, 1995).  For evaluative instruments, 
longitudinal construct validity and responsiveness have to be established in addition to 
reliability.  In order to measure longitudinal construct validity, one would measure the 
changes in HRQL scores with corresponding changes in relevant outcome measures, such 
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 as severity or symptom measures in a predicted manner (Juniper, 1995).  In order to 
assess responsiveness, one would measure changes in HRQL scores with corresponding 
changes in disease over time.  Thus the instrument can be readministered in the same 
sample after a certain time period (say 1 week), and changes in HRQL should correspond 
with changes in disease severity over time, for the instrument to satisfy the criteria of 
responsiveness (Guyatt et al, 1987 and Juniper, 1995).  The magnitude of the 
responsiveness can be measured by looking at the effect size: magnitude of change to the 
random variability in scores.  On the other hand, if the severity has not changed over 
time, and the instruments is readministered, and HRQL scores do not change, this does 
not indicate presence or absence of responsiveness, it does however, indicate that the 
instrument is reproducible (test-retest reliability).        
 
HRQL Measurement: Clinical versus Statistical Significance 
Even if the difference in HRQL scores between groups is statistically significant, 
it may not necessarily be clinically significant (Juniper, 1994 and Juniper, 1998).  To 
interpret HRQL scores, two approaches can be used: the distribution-based approach, and 
the anchor-based approach (Lydick and Epstein, 1993, and Juniper 1999).  The 
distribution-based approach would use the statistical significance, based on the effect 
size, which is derived from the magnitude of change and variability in stable patients.  
This approach does not indicate whether the change is clinically relevant to the patient 
(Juniper, 1998 and Juniper, 1999).  Clinical relevance can be captured by the anchor-
based approach, which defines the minimally important difference (MID) as ‘the smallest 
difference in score in the domain of interest which patients perceive as beneficial and 
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 would mandate, in the absence of troublesome side-effects and excess costs, a change in 
the patients management’ (Juniper, 1999).  In addition the number needed to treat (NNT) 
can be calculated if the MID is known.  The NNT is the number of patients who need to 
be treated with the new intervention for one patient to have a clinically important change 
over and above which he/she would have experienced with the control intervention 
(Juniper, 1998 and Guyatt et al, 1998).   
 
HRQL Instruments Used in Asthma and COPD 
A range of instruments have been used to measure HRQL in both adults and 
children with asthma.  Some instruments have better psychometric properties than others, 
although not a single instrument can be psychometrically perfect.  There are two types of 
HRQL instruments used in asthma and COPD: generic and disease-specific.  Generic 
questionnaires have been designed for use in patients with various diseases.  Among 
them, the most commonly used and validated in adults are the Sickness Impact Profile 
(SIP) (Bergner et al, 1981), the Medical Outcomes Study Short-Form – 36 (SF-36) 
(Stewart et al, 1988), the Nottingham Health Profile (Hunt et al, 1980), the McMaster 
Health Index questionnaire (Sackett et al, 1977), and the Dartmouth COOP Charts 
(Nelson et al, 1987).  Each instrument attempts to measure HRQL in different ways.  The 
SF-36 has 3 major attributes: (functional status, well-being and overall evaluation of 
health).  These 3 attributes or domains are not combined into one overall score.  On the 
other hand, the SIP has 2 subscales: physical and psychosocial, which can be combined 
into one overall score.  
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 The major limitation of generic instruments is that they may not capture areas of 
impairment that may be relevant to the particular disease.  For example, the SIP tends to 
focus on more severe impairments such as feeding and dressing. that may not be relevant 
to a disease like asthma.  Also, the responsiveness of generic instruments to small but 
clinically important changes tends to be very poor, thereby potentially restricting their 
use in clinical trials.  
Utility-based instruments measure the value or utility the individual or society 
places on various health states.  These scales provide a number representing HRQL from 
zero to one, and they meet the assumptions for utility theory.  These instruments are 
widely used by economists to conduct cost-effectiveness analyses, which generally 
measure HRQL in quality adjusted life-years (QALYs).  The most commonly used 
utility-based scales include the Standard Gamble (Torrance, 1986), the Time Trade Off 
(Torrance, 1986), and the Feeling Thermometer (Torrance, 1986).  Instruments that 
measure the value that society places on various health states include the Quality of Well-
Being (QWB) scale (Kaplan et al, 1989), the Multiattribute Health Utilities Index (Feeny 
et al, 1992), and the EuroQol (The EuroQol Group, 1990).  Most of the above 
instruments have been used in their generic form for a long time, however recently, the 
Standard Gamble and the Feeling Thermometer have been modified for use in children 
with asthma, and appear to show better measurement properties.  
Evidence suggests that thus far both the SF-36 and the SIP have satisfactory 
properties for measuring HRQL as discriminative instruments in asthma.  The SIP has 
shown good reliability (ICC=0.81) (Rutten van Molken, 1994), and acceptable cross-
sectional correlations with clinical indices of asthma and disease specific HRQL (Juniper 
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 et al, 1993, Rowe and Oxman, 1993, Rutten van Molken, 1994).  The SF-36 has shown 
moderate cross-sectional correlations with clinical asthma severity in 5 of 9 domains, and 
with FEV1% predicted in 3 of 9 domains (Bousquet et al, 1994).  Two asthma clinical 
trials failed to show differences in treatment groups using the SIP (Rutten van Molken et 
al, 1994 and Jones, 1994).  Also, the SIP was shown to have poor responsiveness in 
validation studies of disease-specific instruments (Juniper et al, 1993 and Marks et al, 
1993). 
The most commonly used disease-specific instruments in chronic pulmonary 
disease include Juniper’s Asthma Quality of Life Questionnaire (J-AQLQ) (Juniper et al, 
1993 and Juniper et al, 1992), Marks’ Asthma Quality of Life Questionnaire (M-AQLQ) 
(Marks et al, 1992, and Marks et al, 1993), the Living with Asthma Questionnaire 
(LWAQ) (Hyland, 1991), Life Activities Questionnaire for Asthma (LAQ) (Creer et al, 
1992), Asthma Bother Profile (Hylan et al, 1995), St. George’s Respiratory Questionnaire 
(SGRQ) (Jones et al, 1992), Respiratory Illness Quality of Life Questionnaire (QOL-
RIQ) (Maille et al, 1994 and Ferrer et al, 2002), the Chronic Respiratory Questionnaire 
(CRQ) (Guyatt et al, 1987), and the Functional Performance Inventory (FPI) (Leidy, 
1994).  Other less commonly used instruments include the How Are You (HAY) 
Questionnaire (le Coq et al, 2000), the Airways Questionnaire (AQ20/AQ30) 
(Alemayehu et al, 2002), and the ITG Asthma Short Form (Eisner et al, 2002).  The first 
5 instruments are asthma-specific, the SGRQ, the CRQ and the QOL-RIQ have been 
created for HRQL measurement in both asthma as well as COPD.  The FPI has been 
created for measuring the functional performance component of HRQL in COPD only.  
Following is a review of the more commonly used instruments.  These are grouped into 
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 two categories: 1) Instruments used in both asthma as well as COPD, and 2) Instruments 
used in either asthma only or in COPD only.     
 
Instruments Used in Both Asthma and COPD 
SGRQ:  The SGRQ is a disease-specific questionnaire designed to measure the impact of 
COPD on overall health, daily life, and perceived well-being (Jones et al, 1992).  This 
questionnaire contains 76 items covering the 3 domains of symptoms, activity and 
impact.  The symptoms domain measures the frequency and severity of symptoms; the 
activities domain measures activities that cause or are limited by breathlessness; and the 
impacts domain measures the impact of COPD in terms of social functioning or 
psychological disturbances arising from chronic airways disease.  The questionnaire takes 
around 10 minutes to complete, and can be self-administered or interviewer-administered 
(face-to-face or telephone).  In Section I (symptoms domain), scaling of responses is on a 
5-point Likert scale, whereas Sections II and III, which measure activity and impact 
respectively, are scored on a dichotomous Yes/No scale.  There is a score for each section 
and a total summary score, each ranging from 0 to 100, where 0 indicates best HRQL, 
and 100 indicates the worst HRQL. 
 The SGRQ has exhibited good psychometric properties.  There is evidence of 
both test-retest reliability as well as internal consistency (Jones et al, 1991, and Jones et 
al, 1992).  The instrument has also shown good evidence of validity.  There was a high 
correlation between total scores and the presence of cough sputum and wheeze (Jones et 
al, 1992).  Significant correlations have also been found between the symptoms, activity, 
and impact domains and other measures of disease activity such as FEV1, 6-minute 
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 walking distance (6-MWD), the Medical Research Council (MRC) respiratory symptoms 
questionnaire, MRC dyspnea grade, anxiety score, SIP total score, SIP symptoms 
domain, and the SIP psychosocial domain (Jones et al, 1992).   The instrument has also 
been shown to be responsive (Jones et al, 1994).  Based on empirical data and interviews 
with patients, a mean change in total score of 4 units is associated with slightly 
efficacious treatment, 8 units for moderately efficacious, and 12 units was associated with 
highly efficacious treatment (Jones et al, 1992 and Jones et al, 1994).  This instrument 
has also been validated for its use in bronchiectasis (Wilson et al, 1997).   This instrument 
has been used in clinical trials (Jones et al, 1994, and Lahdensuo et al, 1996).  The MID 
for this instrument is 4 units on the total summary score (Jones et al, 1992).  
 Although the instrument was originally created and validated in the UK English 
language, it has also been translated into American English and has been found to be 
psychometrically stable (Barr et al, 2000).  In addition to American English, this 
instrument has been translated into Finnish, Dutch, Italian, Spanish, French, Portuguese, 
Danish, Swedish, Polish and Chinese.  Overall, the SGRQ has been widely recognized as 
having very good reliability and responsiveness in both COPD as well as asthma 
(Janssens, 2001).  
 
CRQ:  This instrument is a 20-item questionnaire covering the 4 domains of dyspnea, 
fatigue, emotional function, and mastery (Guyatt et al, 1987).  The questionnaire takes 
around 25-30 minutes to complete (which indicates high respondent burden), and each 
question has to be answered on a 7-point scale. The instrument has been shown to be 
reliable and responsive (Janssens, 2001).  However, the biggest shortcoming of this 
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 instrument is that the questions are individualized.  Therefore CRQ scores have to be 
compared pre- and post- intervention in the same patient.  Hence, comparisons between 
groups of patients are theoretically invalid.   
 
QOL-RIQ:  This instrument consists of 55 questions covering the 7 domains of: breathing 
problems, physical problems, emotions, daily or domestic activities, social activities, 
relationships and sexuality, and general activities (Maille et al, 1994).  The QOL-RIQ did 
show good correlations with clinical indices as well as measures of workplace 
productivity.  However, the reliability (in terms of the intra-class coefficient) has not 
been established.  The measurement properties for use of this instrument in clinical trials 
have not been established either.  Like the St. Georges Respiratory Questionnaire, this 
instrument has been created to measure HRQL in asthma as well as COPD.  
 
Instruments Used in Either Asthma / COPD 
J-AQLQ:  The J-AQLQ is a 32-item questionnaire, where items were chosen exclusively 
based on their importance to patients with asthma.  Responses to each item were rated on 
a 7-point scale.  The items are grouped into four domains such as symptoms, emotions, 
exposure to environmental stimuli, and activity limitations.  The instrument is available 
in both self- as well as interviewer-administered format, and takes approximately 5 to 10 
minutes to complete.  The J-AQLQ has been validated by the creators (Juniper et al, 
1993), validated in a clinical trial in an emergency room setting (Rowe and Oxman, 
1993), and also validated in a study comparing salbutamol versus salmeterol clinical trial 
(von Molken et al, 1994), where measurement properties of various HRQL instruments 
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 were compared.  The J-AQLQ demonstrated good reliability (ICCs ranging between 0.89 
to 0.94), and very good responsiveness.  The instrument showed cross-sectional and 
longitudinal correlations with clinical asthma measures as well as generic HRQL 
instruments as hypothesized.   
 
M-AQLQ: The M-AQLQ is a 20-item, self-administered questionnaire consisting of the 
following 4 domains: breathlessness and physical restrictions, mood disturbance, social 
disruption and concerns for public health.  Each item is rated on a 5-point scale.  The 
instrument shows good reliability (ICC=0.80) (Marks et al, 1992).  The instrument 
exhibits good discriminative properties (Sen et al, 1993).  Sen and colleagues (1993) have 
also stated that although the M-AQLQ was primarily designed as an evaluative 
instrument, its psychometric characteristics make it appropriate for use as a 
discriminative instrument.  
 
LWAQ: The LWAQ is a 68-item questionnaire covering 11 domains (social/leisure, 
sport, holidays, sleep, work, colds, morbidity, effects on others, medication use, sex and 
dysphoric states and attitudes).  Patients rate their responses on a 3-point scale, thereby 
implying that the instrument may have poor responsiveness.  This instrument shows very 
good discriminative properties, but poor evaluative properties (Hyland, 1991 and Juniper, 
1995). 
 
FPI:  This instrument is a self-reported scale used to assess functional performance in 
COPD patients (Leidy, 1994).  Performance is assessed in terms of day-to-day activities 
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 COPD patients need to do in order to meet basic needs.  The instrument consists of 65 
items over 6 domains (body care, household maintenance, physical exercise, recreation, 
spiritual activities and social activities).  Responses are measured on a 4-point scale (from 
activity can be performed easily to activity could no longer be performed due to health 
reasons).  The instrument has shown good evidence of reliability (Leidy, 1999) and 
validity (Leidy and Haase, 1996, Larson et al, 1998, Leidy, 1999).     
For HRQL measurement in asthma, only the J-AQLQ and the M-AQLQ possess 
discriminative as well as evaluative properties.  There is consistent evidence of 
responsiveness and longitudinal construct validity.  In addition, the J-AQLQ quantifies 
the interpretation of the data in terms of clinical significance (a difference in 0.5 units per 
question can be termed as clinically significant).  The QOL-RIQ has shown evidence of 
reliability but the evidence regarding its validity is ambiguous.  The FPI has shown good 
reliability and validity, however, it can only be used to assess HRQL in COPD.  The 
SGRQ is the only instrument that has demonstrated good evidence of psychometric 
stability in both asthma as well as COPD.    
This chapter presented a review of the literature with respect to the clinical 
definition of asthma and COPD, their epidemiology and burden, pharmacotherapy and its 
effectiveness.  The chapter also examined factors affecting nonadherence, the prevalence 
of nonadherence, and the different ways of assessing adherence.  Finally, the chapter 
examined HRQL in asthma and COPD, in terms of its need and measurement issues 
followed by a discussion of various instruments used for HRQL measurement.  The next 
chapter will discuss the methodology employed to achieve the goals of this study.     
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 CHAPTER THREE 
METHODOLOGY 
 
 The purpose of this study was to examine the consequences of nonadherence to 
prophylactic pharmacotherapy in recipients with asthma and COPD.  More specifically, 
this study has two goals.  The first goal is to assess the impact of nonadherence on 
healthcare utilization and costs.  The second goal is to assess the impact of nonadherence 
on HRQL.  Phase II will also examine the impact of medication nonadherence on 
workplace productivity.  This chapter will discuss in detail the methodologies used to 
achieve both goals.   
 
Phase I  
The study design, data source, study population and perspective, cohort definition, 
and patient inclusion and exclusion criteria are as follows.  
 
Data Source 
The data source for this study consisted of the West Virginia Public Employees 
Insurance Agency (PEIA) data.  The state of West Virginia provides healthcare benefits 
to its employees through the PEIA system.  PEIA contracts with the pharmacy benefit 
management company Express Scripts Inc. to manage its pharmacy benefits.  The state 
also contracts with Acordia Inc. to manage its medical claims.  The PEIA administrative 
claims database consists of information on all aspects of member healthcare utilization, 
including pharmacy and medical claims.  This database enables researchers to view a 
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 specific diagnosis, monitor the consequences of specific treatments or diseases, or even 
evaluate patterns of drug use across patients over time, as well as cross-sectionally.  One 
can also examine the charges associated with a disease and its treatments.  Specific fields 
included in the pharmacy and medical files are listed in Appendix A.     
 The recipient information includes patient name, social security number, birth-
date, as well as demographic information such as address, ethnicity, marital status, and 
gender.  The provider files consist of provider name and complete address, as well as 
provider specialty.  For each claim, the data includes benefit year, the first and last date 
of service, date the claim was entered, date of admission, date of discharge, date the 
claim was received, claim adjustment date and the date of final processing.  The billing 
information consists of amount that was charged, the paid amount, and deductibles or 
coinsurance, any out-of-pockets costs, as well as any amounts paid by Medicare.  
Medical claims also include a place of service field, which indicates whether the service 
took place in an inpatient or outpatient setting, physician office, urgent care center, 
surgical center, extended care facility, dental office or a birthing center.  Medical claims 
also include Current Procedure Terminology – 4 (CPT) procedure codes, as well as 
International Classification of Diseases – 9th Edition, Clinical Modification (ICD-9-CM) 
diagnosis codes.  There is one primary diagnosis code and up to nine secondary diagnosis 
codes.  Thus, each claim can have up to ten ICD-9-CM codes listed.  The pharmacy 
records include information regarding the date the prescription was written, the service 
date, days supply, quantity, whether the prescription was new or a refill, NDC drug code, 
drug name, drug category code, as well as dosage description.  The billing information 
includes ingredient cost, dispensing fee, tax, copayment if any, and billed amount.  In 
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 general, the amount paid by PEIA is the billed amount minus the copayment.  This 
amount was used to assess pharmacy costs to PEIA. The pharmacy data also includes 
pharmacy related information such as pharmacy name, pharmacy number, and location.  
 
Study Population 
The study population consisted of all PEIA recipients between 18 and 64 years of 
age, who had a diagnosis for chronic pulmonary ailments such as asthma, chronic 
obstructive pulmonary disease, chronic bronchitis, chronic airway obstruction or 
emphysema, and who were continuously enrolled for a 2-year period from July 1st, 2001 
to June 30th, 2003.  All patients with a primary diagnosis (ICD9) code for asthma 
(493.xx), or COPD (466.xx, 490.xx, 491.xx, 492.xx, 496.xx) in their medical claims were 
selected for this study.   
  
Data Extraction 
 The West Virginia PEIA medical and pharmacy claims data obtained from 
Accordia and Express Scripts, respectively, is loaded on the server maintained by West 
Virginia University’s Accessible Intelligent Medication Strategies (AIMS) program, a 
grant funded academic detailing initiative.  After obtaining approval from West Virginia 
PEIA and subsequently, West Virginia University Institutional Review Board (IRB) for 
conducting this study, the data needed for this study was extracted using the software 
BRIO-Intelligence.  These data files were extracted as text files, and then converted into 
either Statistical Package for Social Sciences (SPSS) or MS Access datasets.   Study 
subjects were identified using the specific inclusion and exclusion criteria, and the 
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 variables/fields that were relevant to this study were downloaded for the defined study 
period.   
 
Data Cleaning and Modification 
The data obtained after initial extraction from the AIMS server was divided into 
two files – medical and pharmacy.  The medical claims files included claims for 
hospitalization, ED claims, and outpatient claims (physician visits).  Elaborate criteria 
were used to separate the three types of claims – hospitalizations, ED visits and 
outpatient visits.  In addition to the coding used in the datasets, strict criteria were used to 
verify that a particular episode was actually what it was supposed to be, as explained 
below.  
In order to separate the hospitalization claims from the ED claims, diagnosis related 
groups (DRG) and Current Procedure Terminology (CPT) codes were used along with 
the LOS.  The specific algorithm used to separate these claims is outlined as follows:  
• First, a LOS variable was created based on the first date of service and the last 
date of service (number of days between the first date and the last date)  
• All claims having a LOS greater than or equal to 1 were separated from those 
having a LOS = 0 days.   
• All claims having a LOS >= 2 days, and having a DRG code greater than zero 
were separated and classified as hospitalization claims.   
• Among claims with LOS = 0 days, and having a CPT code between 99281 – 
99285 or revenue codes between 450 – 459 were separated and classified as ED 
claims.  
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 • The remaining claims having LOS = 0 days were separated and classified as 
outpatient claims.  Among outpatient claims, claims related to lab tests and 
transportation claims were removed from the outpatient files.   
• In addition, claims that were rejected by PEIA were omitted in order to prevent 
duplication.  A rejected claim was followed up with a negative claim.  Both the 
negative and positive claims were rejected from the database.   
 
Study Perspective 
The selection of the appropriate study perspective was vital since it determines the 
methodology used to estimate the costs and benefits associated with the outcomes in 
question.  In this study, the perspective used was that of PEIA, and costs to PEIA were 
used to estimate the economic outcomes.  If it can be shown that substantial dollars can 
be saved as a consequence of maximum adherence, it will provide beneficial information 
to PEIA in designing recipient-directed interventions to promote adherence, as well as in 
making coverage-related policy decisions.  
 
Patient Exclusion, Treatment Arms and Time Frame   
The study design will be a retrospective, longitudinal cohort study.  The time 
frame of the study will be two years, and six months.  Since the study objective was to 
follow patients taking prophylactic pharmacotherapy, and examine the impact of using 
prophylactic medications on healthcare utilization and costs, it was imperative to use at 
least 2 years of data.  This is an optimal time period since it allows enough time to 
examine the effects of nonadherence to pharmacotherapy to result in specific outcomes.  
 78
 Demographic (age, gender), clinical (diagnoses), resource utilization (outpatient, 
inpatient, prescription and emergency room use) and economic variables (amount billed 
to PEIA for any type of medical service rendered) were used for achieving the first study 
objective.  Various study indices were calculated for the above variables retrieved from 
the PEIA dataset.  
The following steps were followed in selecting the patients eligible for this study.  
First, the patients had to be continuously enrolled for the duration of the study period.  
All recipients having medical claims with a primary ICD-9-CM code for asthma 
(493.xx), patients with additional bronchitis/bronchiolitis (ICD-9-CM 466.xx), 
unspecified bronchitis (ICD-9-CM 490.xx), chronic bronchitis (ICD-9-CM 491.xx), 
emphysema (ICD-9-CM 492.xx), and chronic airway obstruction (ICD-9-CM 496.xx) 
were included in the cohort.  Claims not reimbursed by PEIA were excluded from the 
analyses.  PEIA recipients with asthma (ICD9 493.xx), and PEIA recipients with COPD 
(chronic bronchitis ICD9 491.xx, emphysema ICD9 492.xx, and chronic airway 
obstruction ICD9 496.xx, additional bronchitis ICD9 466.xx, unspecified bronchitis 
ICD9 490.xx) were analyzed separately.  Also, recipients having medical claims with a 
primary diagnosis of both asthma as well as COPD were analyzed separately.  Since 
misclassification of diagnosis could potentially be a major concern, patients having no 
prescriptions for asthma or COPD- related medications will be compared with those 
having prescriptions in terms of their mean outpatient visits and asthma or COPD-related 
total costs.  If total asthma or COPD-related costs, and mean number of outpatient visits 
are lower for patients without prescriptions, it could have three implications.  First, the 
patients are less severe disease, and do not require medications. Second, they require 
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 medications but are not being prescribed according to guidelines. The third possibility is 
that they do not have asthma or COPD, and have been falsely classified as having the 
disease, most likely due to data coding errors.       
 
Working Definition of Medication Adherence 
In order to assess adherence, only the use of maintenance medications as 
prophylactic therapy were included.  These medications included inhaled corticosteroids, 
nedocromil, and cromolyn, long-acting β-agonists, and leukotrine modifiers.  Using refill 
patterns from claims data, adherence indices were calculated to measure adherence.  
Although the supplement to the 1997 NHLBI Expert Panel 2 guidelines for asthma 
therapy recommend ICS as the preferred long-term control medication for asthma, many 
patients preferentially use nonsteroidal medications as prophylactic therapy, mainly due 
to the long-term adverse effects of taking steroids.  Therefore, in the context of this study, 
medication adherence referred to obtaining regular refills of any medications in the 
therapeutic classes mentioned earlier.  A comprehensive list of medications along with 
their therapeutic class is mentioned in Appendix C.   
 
Measurement Indices for Adherence 
 The indices used to measure medication adherence are the medication possession 
ratio (MPR) and gaps in therapy.  Both indices are described as follows.   
Medication Possession Ratio   
The MPR is defined as the sum of the days supply for all claims during a defined 
period of time divided by the number of days elapsed during the time period (Motheral 
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 and Fairman, 2000).  The MPR yields a value between 0 and 1.  The MPR is affected by 
gaps in treatment, or terminations of treatment.  Thus, the MPR does not take into 
account number of days the patient may have been hospitalized, in which medication use 
is not recorded.  Recipients having no prescription claims were assigned a value of ‘0’ for 
MPR.  MPR was used as a continuous variable in the models, where 0 indicates 0% 
adherence, and 1 indicates 100% adherence.  
Gap Estimation 
A gap was defined as the number of days between the assumed depletion date of 
one claim (claims fill date plus days supply) and the fill date of the next refill (Motheral 
and Fairman, 2000).  Median gaps were calculated for each recipient.  Recipients having 
no prescriptions in the study period were assigned a value of 910 days for their median 
gap, since the total duration of their study period was 2.5 years (910 days).    
 
Demographic Variables 
 The demographic variables used in the analyses were age and gender.  Age was 
calculated by subtracting the birth-date from the index date of the study, which was July 
1st, 2001.  The field “recipient gender” was used to identify the patients’ gender.   
 
Measurement of Medication-Related Variables 
 Since the availability of drugs being used is limited, summary indices were 
calculated for medication-related variables.  The Chronic Med Score (CMS) and Total 
Med Score (TMS) were calculated, which measured the total number of chronic 
medications and the total number of medications throughout the year, respectively 
(Balkrishnan and Christensen, 2001).  CMS was defined as the number of medications 
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 for which a patient has four or more refills each year.  The TMS was defined as the total 
number of medications for which the patient has had claims throughout the year.   The 
Other Med Score would be = TMS-CMS.  Both TMS and CMS were used as continuous 
variables in the models.   
 
Index for Measuring Asthma Disease Severity 
 Since the dataset did not provide information on disease severity, PEIA recipients 
with asthma were stratified into five severity levels based on their prescription drug use.  
This criterion has been successfully used to predict adverse outcomes such as 
hospitalizations (Grana et al, 1997) in asthma.  The recipients will be classified into five 
severity levels (level I being least severe, and level 5 being most severe).  Those PEIA 
recipients with asthma having three or less ß-agonist claims in one year were classified as 
Level I. Those with four or more ß-agonist claims without other asthma medications in 
one year were classified as Level II.  Recipients in Level III consisted of individuals 
having a ß-agonist claim, and at least one other asthma medication during one year.  
Level IV recipients consisted of individuals who had a claim for an oral steroid, and 
either a ß-agonist or at least one other asthma medication, if they did not qualify for level 
V.  Recipients classified as severity level V consisted of those with at least four or more 
ß-agonists and at least one other asthma medication, as well as oral steroids dispensed 
more than two times in one year.  This criteria has been successfully used as a proxy for 
asthma severity to risk-stratify asthma patients (Grana et al, 1997).  Asthma disease 
severity was used as a continuous variable in the ordinary least squares (OLS) and 
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 Poisson regression models, and was included as a categorical variable in the logistic 
regression models.    
 
Research Design 
 The research design used for this part of the study was a quasi-experimental, 
cross-sectional, longitudinal design.  The study involved examining the outcomes among 
patients with asthma and COPD in conjunction with medication adherence cross-
sectionally.  The patients were followed for a period of two years and six months.  
Additionally, since the study involved following a cohort of patients longitudinally to 
examine the presence of adverse outcomes, and then classifying them as cases and 
controls, it can be called a cohort study.       
 
Data Analysis 
 The data analysis for this phase is presented by the research questions proposed.  
The statistical packages SPSS® and SAS® were used to conduct the data analyses.  The 
data analysis plan for patients with asthma and those with COPD are described 
separately.     
For Asthma: (For all asthma analyses, only recipients with a primary diagnosis for 
asthma were used)  
Research Question 1: Estimating whether medication prescribing was according to 
NHLBI guidelines 
In order to address the first research objective, which was to examine whether 
medication prescribing was in accordance with NHLBI guidelines, all prescription claims 
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 for the sample population selected (recipients with a primary diagnosis code for asthma 
only) after applying the selection criteria were used.  The NDC codes and the drug names 
were used to assign recipients into one of the four groups (as described in objective 1).  
This enabled us to assess how many patients received β-agonist only, how many patients 
received combination therapy without inhaled anti-inflammatory medications, how many 
patients received a prescription for inhaled anti-inflammatory therapy, and how many 
patients received no prescriptions for asthma. Frequencies were calculated to identify 
proportions of patients in each group, and subanalyses by age group and gender will also 
be carried out.  
 
Research Question 2: Estimating the overall prevalence of asthma, and examining the 
prevalence by select demographic factors 
The second objective of the study was to measure the prevalence of asthma, and 
to describe patterns of distribution of select demographic factors such as age group and 
gender in patients with asthma.  All PEIA recipients having medical claims for asthma 
were used to measure prevalence.  Rates of prevalence of asthma by age group and 
gender were calculated.  Descriptive statistics such as chi-squares, t-tests, and ANOVA 
were used to examine differences in prevalence by each factor. 
Prevalence per 10,000 = 10,000 * (Number of PEIA members with asthma / total # PEIA              
members) 
Similarly, prevalence was calculated by age group, and gender with the 
denominator including the total number of PEIA members in each age group and gender, 
respectively.   
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 Research Question 3: Estimating the prevalence of medication nonadherence 
The third study objective was to measure the prevalence of nonadherence to 
pharmacotherapy.  Recipients having at least one claim for any medication listed as a 
prophylactic medication in the two-year study period were selected.  A list of the 
medications included along with the therapeutic class is included in Appendix C.  Based 
on the refill patterns for maintenance medications for these recipients, the adherence 
indices of MPR and median gap were calculated.  Since the indices defined adherence 
differently, the use of both indices will enable us to validate the measurement of 
adherence and accurately assess its prevalence.   Recipients who did not receive any 
prophylactic medication were categorized as nonadherent, and were assigned a value of 
‘0’ for their MPR, and 910 days for their median gap.   
 
Research Question 4: Estimating the impact of medication adherence on the number of 
hospitalizations, ED visits, outpatient visits, and LOS 
The fourth objective was to assess the association between medication 
nonadherence and healthcare utilization as indicated by the number of hospitalizations, 
ED visits, outpatient visits, and inpatient LOS.  For the dependent variables of adverse 
outcomes (hospitalizations and/or ED visits), and number of outpatient visits, the use of 
OLS regression would be inappropriate.  This is because when the dependent variable is 
count data, very few patients have a value greater than 0, thereby violating the 
assumption of normal distribution.  However, OLS regression has been used when the 
dependent variable is count data in health services research (Buzcko, 1989, and 
Balkrishnan and Christensen, 2000).  The use of OLS can be justified if the number of 
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 zeroes in the dependent variable are at a minimum.  However, since a majority of asthma 
and COPD patients in this study had no hospitalizations or ED visits, a Poisson 
distribution was assumed.  Thus, for the dependent variables of number of adverse 
outcomes, and number of outpatient visits, Poisson regression was used (Wang, 2003).  
This regression assumed that the dependent variable (count data) has a Poisson 
distribution.  If the variance was greater than the mean, the Poisson regression procedure 
was replaced by the negative binomial regression procedure.  OLS regression was used 
for the model having LOS as the dependent variable.  For the OLS regression model, the 
assumptions of normality, multicollinearity, autocorrelation, and heteroskedasticity were 
checked.  The Variation Inflation Factor (VIF) was used to check for multicollinearity 
(VIF > 10 indicates multicollinearity).  The Durbin-Watson Statistic was used to check 
for autocorrelation.  For 5 or more independent variables, and more than 100 cases, a 
Durbin-Watson statistic between 1.57 and 2.22 indicates no autocorrelation.  The model 
was also checked for heteroskedasticity by examining the graph of predicted values vs. 
residual values.  Three different regression models were run, with the dependent variables 
being number of adverse outcomes (either hospitalizations or number of ED visits), 
number of outpatient visits, and LOS.  In addition to nonadherence, all the independent 
variables used are shown in the model below.  Separate regression models were run with 
MPR and median gap as primary predictor variables.     
The model is represented as: 
 Utilization = β0   
           + β1 (Adherence)  
          + β2 (demographics – age, gender) 
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                       + β3 (disease severity – based on prescription drug use) 
             + β4 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as indicated by MPR or median gap.  
β2 represented demographic characteristics of age and gender.  Age was included as a 
continuous variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
β3 indicated asthma disease severity, as indicated by the pharmaceutically determined 
index (Grana et al, 1997). 
β4 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
 
Research Question 5: Estimating the impact of medication adherence on total costs 
 The fifth objective was to assess the association between medication 
nonadherence and total healthcare costs (hospitalizations, ED, outpatient, and 
prescription costs).  OLS regression analysis was used to achieve this objective.  The 
dependent variable was log-transformed total costs.  Costs were log-transformed in order 
to achieve normality.  In addition, the VIF was used to examine multicollinearity, and the 
Durbin-Watson statistic was used to examine autocorrelation.  The model was checked 
for heteroskedasticity by examining the graph of predicted values versus residual values.  
Separate regression models were run with MPR and median gap as primary predictor 
variables.     
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 The model is represented as: 
Total Costs = β0   
           + β1 (Adherence)  
          + β2 (demographics – age, gender) 
                      + β3 (disease severity – based on prescription drug use) 
             + β4 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as indicated by MPR or median gap. 
β2 represented demographic characteristics of age and gender.  Age was included as a 
continuous variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
β3 indicated asthma disease severity, as indicated by the pharmaceutically determined 
index (Grana et al, 1997). 
β4 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
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 Research Question 6: Estimating the relative risk of adverse outcomes 
The sixth objective was to examine the relative risk of adverse health outcomes 
such as a hospitalization or an ED visit as a consequence of medication nonadherence.  In 
research question 4, the association between nonadherence and the number of 
hospitalizations and ED visits was examined.  Although this helped us to assess how 
utilization changed with nonadherence, the presence of a temporal relationship is 
necessary to attribute any causal effects.  In research question 4, adherent behavior was 
measured as an average for the study period.  It was necessary to measure nonadherence 
in the time period preceding the event of interest.  Through this research question, how 
nonadherence impacted the probability of an adverse outcome such as an ED visit or a 
hospitalization was assessed.  The methodology used to achieve this objective was a case-
control study, and is described as follows. 
Case-Control Study Methodology:  This objective measured the impact of nonadherence 
on the probability of an adverse outcome, comparing patients who experienced the event 
(cases), with those who did not (controls).  All PEIA recipients with asthma (identified 
from medical claims) were followed from the 1st to the 24th month of the study period.  
Any recipient with an adverse outcome between the 7th to the 24th month in this time 
period was a case.  The number of refills for any maintenance drug in the 6 months prior 
to the adverse outcome were determined to assess nonadherence.  An MPR for these six 
months was calculated based on the number of refills.  The controls consisted of 
recipients who had no adverse outcomes between the 7th and 24th months.  For the 
controls, adherence was measured by the MPR during the first six months of the study 
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 period.  A logistic regression model was used with a dichotomous dependent variable 
(indicating presence/absence of an adverse outcome).    
The model is represented as: 
Adverse outcome  = β0   
           + β1 (Adherence – MPR for 6 months)  
          + β2 (demographics – age, gender) 
                      + β3 (disease severity – based on prescription drug use) 
             + β4 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as measured by the MPR for 6 months. 
β2 represented demographic characteristics of age and gender.  Age was included as a 
categorical variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
β3 indicated asthma disease severity, as indicated by the pharmaceutically determined 
index (Grana et al, 1997).  This index was entered as a categorical variable, with Level I 
asthma patients as the reference group.   
β4 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
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 For COPD: (For all COPD analyses, only recipients with a primary diagnosis for COPD 
only were used)  
  
Research Question 1: Estimating whether medication prescribing was according to 
GOLD guidelines 
In order to address the first research objective, which was to examine whether 
medication prescribing was in accordance with GOLD guidelines, all prescription claims 
for the sample population selected (recipients with a primary diagnosis code for COPD 
only) after applying the selection criteria were used.  The NDC codes and the drug names 
were used to assign recipients into one of the three groups (as described in objective 1).  
This enabled the assessment of the number of patients who received bronchodilators 
(long and short-acting beta-agonists, anticholinergics, and methylxanthines), 
corticosteroids (oral as well as inhaled), or no pharmacotherapy.  Frequencies were 
calculated to identify proportions of patients in each group, and subanalyses by age group 
and gender were carried out.  
 
Research Question 2: Estimating the overall prevalence of COPD, and examining the 
prevalence by select demographic factors 
The second objective of the study was to measure the prevalence of COPD, and to 
describe patterns of distribution of select demographic factors such as age group and 
gender in patients with COPD.  All PEIA recipients having medical claims for COPD 
were used to measure prevalence.  Rates of prevalence of COPD by age group, and 
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 gender were calculated.  Descriptive statistics such as chi-squares, t-tests, and ANOVA 
were used to examine differences in prevalence by each factor. 
Prevalence per 10,000 = 10,000 * (Number of PEIA members with COPD/Total  # PEIA 
members) 
Similarly, prevalence was calculated by age group, and gender with the 
denominator including the total number of PEIA members in each age group and gender, 
respectively.   
 
Research Question 3: Estimating the prevalence of medication nonadherence 
The third study objective was to measure the prevalence of nonadherence to 
pharmacotherapy.  Recipients having at least one claim for any medication listed as a 
prophylactic medication in the two-year study period were selected.  Based on the refill 
patterns for maintenance medications for these recipients, the adherence indices of MPR 
and median gap were calculated.  Recipients who did not receive any prophylactic 
medication were categorized as nonadherent, and were assigned a value of ‘0’ for their 
MPR and 910 days for their median gap.   
 
Research Question 4: Estimating the impact of medication adherence on the number of 
hospitalizations, ED visits, outpatient visits, and LOS   
The fourth objective was to assess the association between medication 
nonadherence and healthcare utilization as indicated by the number of hospitalizations, 
ED visits, outpatient visits and LOS.  For the dependent variables of numbers of ED 
visits, hospitalizations and number of outpatient visits, Poisson regression was used.  If 
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 the variance was greater than the mean, the Poisson regression procedure was replaced by 
the negative binomial regression procedure.  OLS regression was used for the model 
having LOS as the dependent variable.  For the OLS regression model, the assumptions 
of normality, multicollinearity, autocorrelation, and heteroskedasticity were checked.  
The VIF was used to examine multicollinearity, and the Durbin-Watson statistic was used 
to examine autocorrelation.  The model was checked for heteroskedasticity by examining 
the graph of predicted values versus residual values.  Three different regression models 
were run, with the dependent variables being number of adverse outcomes (either 
hospitalizations and/or number of ED visits), number of outpatient visits, and LOS.  In 
addition to nonadherence, all the independent variables used are shown in the model 
below.  Separate regression models were run with MPR and median gap as predictor 
variables.    
The model is represented as: 
 Utilization = β0   
           + β1 (Adherence)  
          + β2 (demographics – age, gender) 
                      + β3 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as indicated by MPR or median gap. 
β2 represented demographic characteristics of age and gender.  Age was included as a 
continuous variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
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 β3 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
 
Research Question 5: Estimating the impact of medication adherence on total costs 
 The fifth objective was to assess the association between medication 
nonadherence and total healthcare costs (hospitalizations, ED, outpatient, and 
prescription costs).  OLS regression analysis was used to achieve this objective.  The 
dependent variable was log-transformed total costs.  Costs were log-transformed in order 
to achieve normality.  In addition, the VIF was used to examine multicollinearity, and the 
Durbin-Watson statistic was used to examine autocorrelation.  The model was checked 
for heteroskedasticity by examining the graph of predicted values versus residual values. 
Separate regression models were run with MPR and median gap as primary predictor 
variables.     
The model is represented as: 
Total Costs = β0   
           + β1 (Adherence)  
          + β2 (demographics – age, gender) 
                      + β3 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as indicated by MPR or median gap. 
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 β2 represented demographic characteristics of age and gender.  Age was included as a 
continuous variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
β3 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
 
Research Question 6: Estimating the relative risk of adverse outcomes  
The sixth objective was to examine the relative risk of adverse health outcomes 
such as a hospitalization or an ED visit as a consequence of medication nonadherence.  In 
research question 4, we examined the association between nonadherence and the number 
of hospitalizations and ED visits.  Although this helped assess how utilization changed 
with nonadherence, the presence of a temporal relationship is necessary to attribute any 
causal effects.  In research question 4, adherent behavior was measured as an average for 
the study period.  Nonadherence was measured in the time period preceding the event of 
interest.  This research question (question 6) assessed how nonadherence impacted the 
probability of an adverse outcome such as an ED visit or a hospitalization.  The 
methodology used to achieve this objective was a case-control study, and is described as 
follows. 
Case-Control Study Methodology:  This objective measured the impact of nonadherence 
on the probability of an adverse outcome, comparing patients who experienced the event 
(cases), with those who did not (controls).  All PEIA recipients with COPD (identified 
from medical claims) were followed from the 1st to the 24th month of the study period.  
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 Any recipient with an adverse outcome between the 7th to the 24th month in this time 
period was a case.  The number of refills for any maintenance drug in the six months 
prior to the adverse outcome was determined to assess nonadherence.  An MPR for these 
six months was calculated based on the number of refills.  The controls consisted of 
recipients who had no adverse outcomes between the 7th and 24th months.  For the 
controls, adherence was measured by the MPR for the first six months of the study 
period.  A logistic regression model was used with a dichotomous dependent variable 
(indicating presence/absence of an adverse outcome).    
The model is represented as: 
Adverse outcome  = β0   
           + β1 (Adherence – MPR for six months)  
          + β2 (demographics – age, gender) 
                      + β3 (medication use – TMS, CMS) 
            + Error 
Where β1 represented medication adherence as indicated by the MPR for six months. 
β2 represented demographic characteristics of age and gender.  Age was included as a 
categorical variable, and gender was dichotomous variable, with females coded as 0, and 
males coded as 1.  
β3 indicated the number of total medications (TMS) or the number of chronic 
medications (CMS) per year.  Both TMS and CMS were included as continuous 
variables.  
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 Phase II 
The primary objective of the second phase was to examine the relationship 
between nonadherence to ICS pharmacotherapy, and HRQL.  In order to achieve this 
objective, primary data was collected.  After obtaining permission from the West Virginia 
University IRB, a questionnaire was mailed to patients with asthma and COPD, which 
contained the SGRQ, the Morisky adherence scale, and questions to measure losses in 
workplace productivity.  Nonadherence was assessed using secondary data from Phase I, 
as well as self-reported nonadherence from the Morisky scale.  The following section 
describes the methodology used to identify the study population, rationale for choosing 
the survey instrument, data collection process and the statistical techniques used in Phase 
II.  
 
Study Population 
 The study population for Phase II consisted of patients with asthma and COPD 
who were selected based on the inclusion/exclusion criteria used for Phase I selection.  
Thus, adult recipients (between 18 and 64 years of age) who had a claim for asthma or 
COPD between the duration of the study period July 1st, 2001 to June 30th, 2003 were 
selected.  The recipients were continuously enrolled in PEIA during this study period.   
 
Sampling Technique 
 Based on the above inclusion criteria, 1,493 recipients had diagnosis codes for 
asthma only, whereas 7,161 recipients had primary diagnoses of COPD only, and 940 
recipients had diagnosis codes for both asthma and COPD, in their medical claims.  The 
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 total number of recipients with asthma and / or COPD was 9,594.  All patients with 
asthma only (n=1,493), and both asthma and COPD (n=940) were mailed the HRQL 
questionnaire.  For recipients with COPD only, a random sample of 2,000 recipients was 
selected from the 7,161 recipients, and were mailed the questionnaire.  Simple Random 
Sampling (SRS) without replacement was used to identify the random sample of COPD 
recipients (Kalton G, 1987).  In this technique, the randomly selected recipients in the 
sample are not replaced to be given a further chance of selection.  SRS without 
replacement yields more precise estimates than sampling with replacement, hence this 
technique was used.  Also, SRS technique allows the use of both means as well as 
proportions along with the associated confidence intervals.      
 
Sample Size Determination for COPD-only Recipients 
 Among recipients with primary diagnosis codes for COPD-only (n=7,161), 2000 
randomly selected recipients were mailed the HRQL questionnaire.  The following 
formula was used for calculating the SRS for this study sample: 
 n = (z/e)2 * π(1- π) 
Where, 
n is the sample size 
z is the number of standard errors for a given confidence interval 
π is the estimated proportion of people who were adherent to their medication 
e is the required estimator 
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  Based on the table of normal distribution, (95 % of normal distribution falls 
within 1.96 standard deviations around the distribution’s means), for confidence interval 
of 95%, z = 1.96.  An estimator that is within 5% of the population percentage with 95% 
probability, was employed in the study (Kalton G, 1987).  
 It has been shown that adherence rates among chronic pulmonary disease patients 
range between 3-48% (Fish and Lung 2001, Bender 2002).  Thus, π could be anywhere 
between 0.05 and 0.48.  However, the most conservative sample size would be obtained 
by taking π = 0.5, hence 0.5 was chosen as the value of π.  
Inputting above values in the equation yielded N= 384.  
Net sample size = (Gross Sample Size) * (Mail Response Rate) * (Usable Response Rate) 
Hence, Gross Sample Size = Net Sample Size / (Mail Response Rate) * (Usable 
Response Rate) 
We assumed a conservative response rate of 20%, and that only 90% of the responses 
would be usable.  Hence,  
  Gross Sample Size = 384 / 0.20 * 0.9 = 2000 
Thus, a total of 2,000 recipients with COPD were surveyed.   
 
Health-Related Quality of Life Assessment 
The St. George’s Respiratory Questionnaire (SGRQ) was used to measure HRQL 
in patients with asthma and COPD (Jones et al, 1992).  This instrument has been shown 
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 to be a valid predictor of HRQL in patients with asthma as well as COPD (Jones et al, 
1992, Barr et al, 2000).  PEIA recipients having medical claims with primary ICD9 codes 
for asthma and COPD were mailed the SGRQ to measure their HRQL.  This 
questionnaire, developed by Jones and colleagues (1992) has also been validated in the 
US population (Barr et al, 2000).  The SGRQ is a 76-item questionnaire, grouped into 
three domains (symptoms, activity, and impacts).  Responses in the symptoms domain 
were rated on a 7-point scale, whereas the activity and impacts domains consisted of 
dichotomous (yes/no) responses.  Each domain score as well as the total HRQL score is 
on a scale of 0 to 100, where 0 indicates best HRQL, and 100 indicates worst HRQL. 
Also, a difference in total HRQL score of 4 units is considered as a clinically significant 
difference.    
For the purpose of this study, the SGRQ will be used as a discriminative 
instrument.  This is because the objective of Phase II is to examine differences between 
two groups of patients: those who were adherent, and those who were nonadherent to ICS 
pharmacotherapy.  Instruments used to distinguish between two or more groups of 
patients are discriminative in nature.  The psychometric properties required of a 
discriminative instrument are reliability and cross-sectional construct validity.  This 
instrument has shown good evidence of reliability as well as validity in a US population 
(Barr et al, 2000).   
 
Self-Reported Nonadherence Assessment  
In addition to the HRQL questionnaire, the Morisky adherence scale (Morisky et 
al, 1986 and Pratt et al, 2001), and the Work Productivity Short Inventory (WPSI) also 
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 known as the Wellness Inventory (Goetsel et al, 2003), were added to the SGRQ.  The 
Morisky Scale, which is a 4-item questionnaire, used to measure self-reported adherence 
has been used in recipients with various disease conditions (Morisky et al, 1986 and Pratt 
et al, 2001).  Scores obtained from this scale range from 0 to 4, where 0 indicates high 
adherence, and 4 indicates nonadherence.  Patients responding with a score of ‘0’ are 
classified as ‘high adherent’, patients having scores from 1-2 were classified as ‘medium 
adherent’, and patients having scores greater than 2 were classified as ‘low adherent.’ 
(Morisky et al, 1988).  
 
Workplace Productivity Assessment 
In addition to the adherence measure, the WPSI or Wellness Inventory was used 
to measure losses in workplace productivity due to both asthma and COPD (Goetsel et al, 
2003).  This instrument consists of 4 questions measuring the number of days the disease 
was experienced, the number of days the patient was absent due to the disease, and the 
number of hours the patient was unproductive while experiencing the disease.  The 
number of days absent, as well as the number of unproductive hours were translated into 
dollar metrics.  The formulae for calculating absenteeism costs (losses in productivity 
when absent from work due to disease), presenteeism costs (losses in productivity when 
present at work due to disease), and total costs are shown below.  The average hourly 
wage rate for West Virginia for 2002 was $14.04 (US Dept. of Labor, 2003).  For 
calculating presenteeism costs, the number of days experienced was multiplied by 
236.5/365 to adjust for the number of workdays in a year (Goetsel et al, 2003).   
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 Absenteeism Costs = Total Days Absent * 8 Hours * $14.04 
Presenteeism Costs = (Days Experienced * 236.5/365) – Days Absent *  
                                    # Unproductive Hours * 14.04 
Total Costs = Absenteeism costs + Presenteeism costs 
 
Data Collection  
 PEIA recipients identified with asthma and COPD from the medical claims were 
mailed the questionnaire (consisting of the SQRQ, the Morisky scale, and the WPSI) 
along with a personalized cover letter and a business reply envelope.  The cover letter 
explained the purpose of the survey, which would be to assess the HRQL among 
recipients with asthma or COPD, and assured confidentiality of the respondents.   
Data from the survey respondents was linked to their adherence scores obtained 
from the claims data.  HRQL scores for each domain, as well as total summary scores 
were compared between respondents with good adherence and those with poor 
adherence.  HRQL scores were also compared with prior healthcare utilization in order to 
examine the overall relationship between nonadherence, utilization of healthcare services, 
and HRQL.  Since the questionnaire was mailed in October 2003, medical and pharmacy 
claims were extracted for 6 additional months for the study population – from July 
through December 2003.  This allowed the examination of utilization behavior at the time 
of measuring HRQL.   
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 Data Entry and Analysis   
 Each questionnaire received was checked for completeness and clinical relevance.  
Respondents who had entered less than 76% of the items in the questionnaire were 
omitted from the analysis, as recommended by Jones and colleagues (1992).  Data from 
all questionnaires considered acceptable was entered into an SPSS dataset.  The analysis 
plan for examining each research question in Phase II is explained as follows.  
 
Research Question 7: To examine the HRQL of PEIA patients with asthma and COPD  
This research question consisted of examining domain-specific as well as total 
summary HRQL scores for the asthma-only, COPD-only, and both groups.  HRQL scores 
among PEIA patients with asthma and COPD were compared with those from other 
studies that used the SGRQ.  T-tests and one-way ANOVAs were used to compare 
HRQL scores among the three groups.   
 
Research Question 8: To examine the self-reported nonadherence of PEIA recipients with 
asthma and COPD 
 Based on the Morisky scale scores, respondents were classified as high, medium, 
or low adherent.  The prevalence of adherence was compared among the three groups 
(asthma-only, COPD-only, and both) by using chi-square statistics. 
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 Research Question 9: To examine the congruence between self-reported and claims-
based medication adherence 
This research question examines the congruence between adherence measured 
using claims data and self-reported adherence from the Morisky scale.  Spearman’s 
correlation was used to measure the correlation between the two adherence scores for the 
survey respondents.  In order to account for the possibility of misclassification, which 
may result in patients not having any prescriptions in their medical claims, only 
respondents having at least one prescription for maintenance medications (MPR > 0) 
were used for the purpose of addressing this research question.  Spearman’s correlation 
between refill-based adherence measures and the Morisky scale score was calculated.       
 
Research Question 10:  To examine differences in HRQL by medication nonadherence  
This question examines differences in HRQL scores between adherent and 
nonadherent respondents.  Bivariate analyses were carried out to examine differences in 
domain-specific as well as total summary HRQL scores among respondents who were 
classified as high adherent, medium adherent, and low adherent based on scores obtained 
from the Morisky scale, and mean MPR and median gap scores were compared for each 
of the three groups – asthma-only, COPD-only, and both.  Chi-square statistics and one-
way ANOVAs were used for this analysis.  In order to measure the impact of claims-data 
based adherence on HRQL, OLS regression analyses were carried out with the total 
summary score as the dependent variable.  Separate models were run for each of the 
asthma-only, COPD-only, and both groups.  Also separate models were run with MPR 
adherence and Morisky scale adherence as predictor variables.  Morisky scale was used 
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 as a categorical variable, with respondents classified as high adherent as the reference 
group.  MPR was used as a continuous variable on a scale from 0 to 1.  Age, TMS, and 
CMS were used as continuous variables, whereas gender was used as a dichotomous 
variable, with females coded as 0, and males coded as 1.      
The model is represented as:  
Total HRQL = β0   
           + β1 (Adherence – MPR or Morisky)  
          + β2 (demographics – age, gender) 
                      + β3 (medication use – TMS, CMS) 
            + Error 
 
Research Question 11: To examine the impact of medication adherence on workplace 
productivity 
This question examines the impact of nonadherence on workplace productivity.  
Absenteeism, presenteeism, as well as total productivity costs were compared between 
the asthma-only, COPD-only, and both groups using t-tests and one-way ANOVAs.  In 
order to assess the impact of medication nonadherence on productivity costs, OLS 
regression analysis was used with total productivity costs as the dependent variable.  
Separate regression models were run for each group – asthma-only, COPD-only, and 
both.  Also separate models were run with MPR adherence and Morisky scale adherence 
as predictor variables.  Morisky scale was used as a categorical variable, with 
respondents classified as high adherent as the reference group.  MPR was used as a 
continuous variable on a scale from 0 to 1.  Age, TMS, and CMS were used as 
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 continuous variables, whereas gender was used as a dichotomous variable, with females 
coded as 0, and males coded as 1.      
The model is represented as:  
Total Productivity Costs = β0   
                                  + β1 (Adherence – MPR or Morisky)  
                      + β2 (demographics – age, gender) 
                                  + β3 (medication use – TMS, CMS) 
                        + Error 
 
 This chapter has discussed in detail the methodology used to achieve both Phase I 
and Phase II objectives.  The next chapter will consist of the results obtained from the 
analyses.   
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 CHAPTER FOUR 
RESULTS AND DISCUSSION 
 
 Chapters I and II have thus far described the need for conducting this study, 
existing evidence regarding medication adherence and its impact on outcomes in 
respiratory illness, and study objectives.  Chapter III described in detail the methodology 
used to achieve these objectives.  The impact of medication adherence was measured 
using a retrospective analysis of WV PEIA claims data in Phase I, and HRQL, self-
reported medication adherence, and losses in productivity were measured in Phase II 
using a mail survey.  This chapter provides the results of the analyses along with a 
discussion of the results.       
 
Phase I Results 
 Phase I of this study consisted of analyzing medical and pharmacy claims data of 
WV PEIA members with asthma and COPD from July 2001 through December 2003.  
The overall goal of this analysis was to determine the impact of medication nonadherence 
(as determined by refill patterns in claims data) on overall healthcare utilization and 
costs, and adverse outcomes such as ED visits and hospitalizations.   
WV PEIA claims data were provided by Accordia (medical claims), and Express 
Scripts (pharmacy claims).  On average, PEIA had around 119,725 adult enrollees per 
year in 2001, 2002, and 2003 in WV.  Of these, around 16,000 enrollees had an ICD-9 
code for asthma and/or COPD in their medical claims.  Of these, only continuously 
eligible enrollees between the ages of 18 and 64 years were selected for the purpose of 
this study, which yielded 9,594 enrollees.  Among these, 1,493 enrollees had primary 
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 ICD-9 codes for asthma only, 7,161 enrollees had ICD-9 codes for COPD-only, and 940 
enrollees had ICD-9 codes for asthma as well as COPD.  These enrollees were also non-
managed care, and not Medicare eligible, since they were less than 65 years of age.  
Pharmacy claims for these enrollees were extracted.  Table 2 shows the overall extraction 
process from claims data.      
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 Table 2: Selection of Study Sample for Phase I 
Inclusion Criteria Number of Recipients 
STEP 1: Pre-extraction  
Total Adult PEIA Recipients in WV 2001 N = 112,150 
2002 N = 121,082 
2003 N = 125,942 
STEP 2: Recipients with Asthma/COPD   
Number of Recipients N =16,000 
STEP 3: Non-Medicare and Continuously Eligible 
Between the Ages of 18 – 64 years 
 
Number of Recipients N = 9,594 
Asthma-only N = 1,493 
COPD-only N = 7,161 
Both Asthma and COPD N = 940 
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 The demographic characteristics of the final Phase 1 study participants are shown 
in Table 3.  For the overall Phase I sample, the average age was around 50 ± 9.6 (SD) 
years.  This can be explained by the fact that the majority of the recipients were COPD 
patients, which is more prevalent in older individuals. Almost 70% of all adults were 
between 46 and 64 years of age.  The sample was predominantly female, with only one-
third of the sample recipients being male. The trend for age and gender distribution was 
similar for the asthma-only, COPD-only, and the both groups.  There was a slightly 
higher percentage of 46 – 64 year olds in the both group.  Also, the proportion of females 
in the both group was higher than the COPD-only group.  Data on race distribution was 
unavailable.     
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 Table 3: Demographic Characteristics of the Phase 1 Final Study Recipients 
Demographic 
Characteristics 
Overall Sample Asthma-only COPD-only Both Asthma 
and COPD 
 N % N % N % N % 
Age*         
18 – 30 435 4.5 86 5.8 322 4.5 27 2.9 
31 – 45 2,475 25.8 417 27.9 1,862 26.0 196 20.9 
46 – 64 6,684 69.7 990 66.3 4,977 69.5 717 76.3 
Mean Age ± SD  49.5 ± 9.6 48.4 ± 9.9 49.6 ± 9.6 50.9 ± 8.9 
Gender*          
Male 3,386 35.3 422 28.3 2,719 38.0 245 26.1 
Female 6,208 64.7 1,071 71.7 4,442 62.0 695 73.9 
*Significantly different (p<=0.05); SD: Standard Deviation  
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  Overall healthcare utilization and costs for the overall sample as well as each of 
the 3 disease groups for the entire duration of the study (2.5 years) are shown in Table 4.  
For the overall Phase I sample, prescription costs were the largest cost driver (50.7%), 
followed by outpatient costs (33.7%).  The same trend was observed for each of the three 
disease groups.  Among the asthma-only group enrollees, hospitalization costs constituted 
7.4% of total costs, outpatient costs constituted 35.5% of total costs, and prescription 
costs constituted more than half (55.7%) of total costs.  Among the COPD-only group 
enrollees, hospitalization costs constituted 14.4% of total costs, outpatient costs 
constituted 38.8% of total costs, and prescription costs constituted slightly less than half 
(47.5%) of total costs.  Among both-group enrollees, hospitalization costs as a percentage 
of total costs were higher than those for the asthma-only and the COPD-only groups 
(15.7%), whereas outpatient costs as a percentage of total costs were lower than those for 
the asthma-only or COPD-only groups (29.4%).  ED costs as a percentage of total costs 
were slightly higher for the COPD-only and the both groups, as compared to the asthma-
only group.     
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 Table 4: Expenditures as a Percentage of Total Costs for the Entire Study Period 
 Cost Type Overall 
Sample 
$ (% of Total 
Costs) 
Asthma-only 
$ (% of Total 
Costs) 
COPD-only 
$ (% of Total 
Costs) 
Both 
$ (% of Total 
Costs) 
Hospitalization 
Costs 
732,157 
(13.5) 
72,914 
(7.4) 
390,382 
(14.4) 
268,861 
(15.7) 
ED Costs 114,652 (2.1) 13,181 (1.4) 62,781 (2.3) 38,690 (2.3) 
Outpatient 
Costs 
1,829,139 
(33.7) 
349,807 
(35.5) 
976,038 
(38.8) 
503,294 
(29.4) 
Prescription 
Costs 
2,746,471 
(50.7) 
547,975 
(55.7) 
1,295,146 
(47.5) 
903,350 
(52.6) 
Total Costs 5,422,419 
(100.0) 
983,877 
(100.0) 
2,724,347 
(100.0) 
1,714,195 
(100.0) 
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  Mean number of events (hospitalizations, ED visits, outpatient visits, 
prescriptions) and mean cost per event are listed in Table 5.  T-tests and one-way 
ANOVA were used to determine statistically significant differences between the asthma-
only, COPD-only, and the both groups.  The mean number of hospitalizations per 
recipient was highest for the both group (although not statistically significant), however, 
the hospitalization rate (per 10,000 enrollees) was the highest for the COPD-only group.  
Mean cost per hospitalization as determined from Medicare DRG reimbursements, was 
the highest for the COPD-only group, followed by the both group.  The average LOS for 
the entire sample was 3.9 days, and was similar across the three disease groups.  Mean 
number of ED episodes and the mean number of outpatient visits were significantly 
higher for the asthma-only and the both group as compared to the COPD-only group, 
however, mean cost per ED episode and mean cost per outpatient visit was higher for the 
asthma-only and the both group as compared to the COPD-only group.  The mean 
number of prescriptions per recipient was highest for the both group at an average cost of 
$56 per prescription.     
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 Table 5: Average Utilization/Costs and Utilization Rates    
Utilization Type Overall Sample Asthma-only COPD-only Both 
Mean # 
Hospitalizations/ 
Recipient 
1.3 ± 0.1 1.1 ± 0.3 1.3 ± 0.7 1.4 ± 1.1 
Hospitalization 
Rate (Per 10,000) 
15.2 2.2 7.5 5.5 
Average LOS* 
(days) 
3.9 ± 1.9 3.9 ± 2.3 3.9 ± 1.9 4.1 ± 2.0 
Mean Cost per 
Hospitalization / 
Recipient*§ ($) 
3,091 ± 1,069 2,559 ± 706 3,316 ± 1,295 2,993 ± 710 
Mean # ED 
Episodes / 
Recipient 
1.4 ± 1.4 1.3 ± 0.8 1.3 ± 1.1 1.8 ± 2.1 
ED Utilization 
Rate (Per 10,000) 
75.3 8.1 49.2 17.9 
Mean Cost per 
ED Episode / 
Recipient*§ ($) 
87 ± 130 102 ± 132 79 ± 127 101 ± 136 
Mean # 
Outpatient 
Visits/Recipient§ 
2.9 ± 2.1 3.0 ± 3.6 2.3 ± 4.5 7.3 ± 8.2 
Outpatient 
utilization Rate 
(Per 1,000) 
80.0 12.5 59.7 7.9 
Mean Cost per 
Outpatient 
Episode / 
Recipient*§ ($) 
59.4 ± 72.7 76.5 ± 105.3 54.0 ± 64.5 73.1 ± 61.5 
Mean # 
Prescriptions/ 
Recipient§ 
9.3 ± 14.2 10.8 ± 12.1 7.1 ± 12.6 18.7 ± 19.8 
Mean Cost per 
Prescription / 
Recipient*§ ($) 
43.9 ± 61.5 39.8 ± 52.5 39.6 ± 59.7 56.2 ± 69.9 
*Denominator included only enrollees who experienced the event 
§Significantly different (p<=0.05)  
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 Results for Research Question 1 
The overall objective of research question 1 was to examine whether medication 
use was according to NHLBI guidelines for asthma and GOLD guidelines for COPD.   
 
For Asthma-Only Group 
According to the NHLBI guidelines, enrollees with asthma were classified into 4 
groups:  
Group I: Short-acting beta-agonist only; 
Group II: Combination therapy without inhaled anti-inflammatory medications; 
Group III: At least one prescription claim for inhaled anti-inflammatory therapy (ICS, 
inhaled cromolyn, or inhaled nedocromil) 
Group IV: No prescription claims for chronic pulmonary disease-related medications   
Figure 2 describes the pharmacotherapy use among the asthma-only group.  
Tables 6 and 7 describe pharmacotherapy use among asthma-only enrollees by age group 
and gender.   
As shown in Figure 2, only 6.2% of the recipients received short-acting beta-
agonist only.  Almost one-third (29.5%) of asthma-only enrollees received combination 
therapy (such as long-acting beta-agonists) without inhaled anti-inflammatory 
medications.  More than half (52.5%) received at least one prescription of an inhaled anti-
inflammatory medication, and only 12% of the respondents received no prescriptions for 
asthma-related medications.   
Among patients with asthma receiving short-acting beta-agonists only, around 
10% were in the 18 – 30 year age group, and more than half (52%) were between 46 and 
 116
 64 years (Table 6).  Among patients with asthma receiving ICS therapy (Group III) and 
combination therapy (Group II), almost 3/4th were between 46 – 64 years of age.  
Females were responsible for almost 3/4ths of the pharmacotherapy use in Groups I – III 
(Table 7).  Among patients with asthma not receiving any pharmacotherapy too, females 
constituted the majority.     
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 Figure 2.  Pharmacotherapy Use Among Asthma-Only Enrollees 
6.20%
29.50%
52.30%
12.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
SABA Only Combination Tx Any ICS Use No Rx
Pe
rc
en
t
 
 
 118
 Table 6: Drug class by Age Group for Asthma-only Enrollees 
Age Range 
(years) 
Group I 
N (%) 
Group II 
N (%) 
Group III 
N (%) 
Group IV 
N (%) 
18 – 30 9 (9.8) 18 (4.1) 35 (4.5) 7 (3.9) 
31 – 45 35 (38.0) 101 (23.0) 208 (26.6) 33 (18.3) 
46 – 64 48 (52.2) 321 (72.9) 538 (68.9) 140 (77.8) 
Total 92 (100.0) 440 (100.0) 781 (100.0) 180 (100.0) 
Group I: Short-acting beta-agonist only; Group II: Combination therapy without inhaled 
anti-inflammatory medications; Group III: At least one prescription claim for inhaled 
anti-inflammatory therapy (ICS, inhaled cromolyn, or inhaled nedocromil); Group IV: No 
prescription claims for chronic pulmonary disease-related medications   
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 Table 7: Drug Class by Gender for Asthma-only Enrollees 
Gender Group I 
N (%) 
Group II 
N (%) 
Group III 
N (%) 
Group IV 
N (%) 
Male 24 (26.1) 120 (27.2) 220 (28.2) 50 (27.8) 
Female 68 (73.9) 320 (72.8) 561 (71.8) 130 (72.2) 
Total 92 (100.0) 440 (100.0) 781 (100.0) 180 (100.0) 
Group I: Short-acting beta-agonist only; Group II: Combination therapy without inhaled 
anti-inflammatory medications; Group III: At least one prescription claim for inhaled 
anti-inflammatory therapy (ICS, inhaled cromolyn, or inhaled nedocromil); Group IV: No 
prescription claims for chronic pulmonary disease-related medications 
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 For COPD-only group 
 The objective of research question 1 was to examine whether medication use was 
in accordance with GOLD guidelines.  Figure 3 describes the pharmacotherapy use 
among the COPD-only group.  COPD patients are classified as receiving bronchodilators-
only, corticosteroids only, both bronchodilators and corticosteroids, and no COPD-related 
medications.  Tables 8 and 9 describe pharmacotherapy use among COPD-only enrollees 
by age group and gender.  As shown in Figure 3, 13.2% of COPD-only patients received 
any bronchodilator.  Of these, 7.5% received short-acting beta-agonist only.  More than 
one-fifth (20.5%) of the patients received any corticosteroid, of which 15.7% received at 
least one inhaled corticosteroid prescription.  Almost one-third of all COPD-only patients 
received both bronchodilators as well as corticosteroids.  More than one-third (36%) of 
the COPD-only enrollees received no COPD-related medications.  Females and COPD-
only patients between 46 – 64 years of age were responsible for the majority of 
prescription drug use.  
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 Figure 3.  Pharmacotherapy Use Among COPD-Only Enrollees 
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 Table 8. Drug Class by Age Group for COPD-only Enrollees 
Age Range 
(years) 
Bronchodilators 
Only 
N (%) 
Corticosteroids 
Only 
N (%) 
Both 
Bronchodilators 
and 
Corticosteroids 
N (%) 
No COPD-
Related 
Medication 
N (%) 
18 – 30 48 (5.1) 54 (3.7) 71 (3.3) 149 (5.8) 
31 – 45 263 (27.7) 339 (23.1) 611 (28.1) 649 (25.3) 
46 – 64 639 (67.3) 1072 (73.2) 1494 (68.7) 1,771 (68.9) 
Total 950 (100.0) 1,465 (100.0) 2,176 (100.0) 2,570 (100.0) 
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 Table 9.  Drug Class by Gender for COPD-only Enrollees 
Gender Bronchodilators 
Only 
N (%) 
Corticosteroids 
Only 
N (%) 
Both 
Bronchodilators 
and 
Corticosteroids 
N (%) 
No COPD-
Related 
Medication 
N (%) 
Male 378 (39.8) 536 (36.6) 885 (40.7) 1,650 (64.2) 
Female 572 (60.2) 929 (63.4) 1,291 (59.3) 920 (35.8) 
Total 950 (100.0) 1,465 (100.0) 2,176 (100.0) 2,570 (100.0) 
 
 124
 Both Asthma and COPD 
 Since the both group consisted of enrollees having diagnosis codes for both 
asthma as well as COPD, pharmacotherapy use for this group was analyzed based on the 
NHLBI guidelines, since the GOLD guidelines do not have explicit recommendations for 
medication use unlike asthma.  Figure 4 describes the pharmacotherapy use among the 
both group enrollees.  Tables 10 and 11 describe pharmacotherapy use among the both 
group enrollees by age group and gender.   
As shown in Figure 4, only 3.7% of the recipients received short-acting beta-
agonist only.  Almost one-third (30.3%) of both-group enrollees received combination 
therapy without inhaled anti-inflammatory medications.  More than half (59%) received 
at least one prescription of an inhaled anti-inflammatory medication, and only 7.2% of 
the respondents received no prescriptions for asthma-related medications.   
The age and gender distribution for pharmacotherapy use among the both group 
patients was similar to the asthma-only group (Tables 10 and 11).  A majority of patients 
who received either ICS therapy (Group III) or other combination therapy were between 
46 and 64 years of age.  In groups I – III, females were responsible for the majority of 
pharmacotherapy use.  Among patients not receiving any pharmacotherapy, females also 
constituted the majority.   
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 Figure 4. Pharmacotherapy Use Among Both Group Enrollees 
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  Table 10. Drug Class by Age Group for Both-group Enrollees 
Age Range 
(years) 
Group I 
N (%) 
Group II 
N (%) 
Group III 
N (%) 
Group IV 
N (%) 
18 – 30 2 (5.7) 12 (4.1) 17 (3.1) 0 (0.0) 
31 – 45 12 (34.3) 60 (21.0) 103 (18.6) 13 (19.4) 
46 – 64 21 (64.0) 213 (74.9) 433 (78.3) 54 (80.6) 
Total 35 (100.0) 285 (100.0) 553 (100.0) 67 (100.0) 
Group I: Short-acting beta-agonist only; Group II: Combination therapy without inhaled 
anti-inflammatory medications; Group III: At least one prescription claim for inhaled 
anti-inflammatory therapy (ICS, inhaled cromolyn, or inhaled nedocromil); Group IV: No 
prescription claims for chronic pulmonary disease-related medications   
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 Table 11. Drug Class by Gender for Both-Group Enrollees 
Gender Group I 
N (%) 
Group II 
N (%) 
Group III 
N (%) 
Group IV 
N (%) 
Male 11 (31.4) 86 (30.0) 150 (27.1) 14 (20.9) 
Female 24 (68.6) 199 (70.0) 403 (72.9) 53 (79.1) 
Total 35 (100.0) 285 (100.0) 553 (100.0) 67 (100.0) 
Group I: Short-acting beta-agonist only; Group II: Combination therapy without inhaled 
anti-inflammatory medications; Group III: At least one prescription claim for inhaled 
anti-inflammatory therapy (ICS, inhaled cromolyn, or inhaled nedocromil); Group IV: No 
prescription claims for chronic pulmonary disease-related medications   
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 Discussion for Research Question 1 
 More than half of adult patients with asthma in the asthma-only group received a 
prescription for ICS therapy.  Only 6% of patients with asthma in the asthma-only group 
received a prescription for short-acting beta agonists only.   Almost 59% of both group 
enrollees received at least one prescription for asthma or COPD-related medication, and 
only 3.7% of the patients used short-acting beta-agonists only.  These findings suggest 
that a significant proportion of patients in the asthma-only and the both groups were 
receiving medications according to NHLBI guidelines.  It has been shown that 58% of 
patients with asthma in a managed care plan used ICS therapy concomitantly with 
bronchodilators (Nestor et al, 1998).  Physician prescribing for asthma-related 
medications has been shown to vary by physician specialty.  The rate of ICS prescribing 
has been shown to be the lowest among nonspecialists (22%), and highest among 
specialists (39%) (Stempel et al, 1997).  Also, asthma patients are more likely to use 
inhaled corticosteroids after an emergency room visit (Stempel et al, 1997).  Patients in 
the both group experienced a higher number of ED visits than those in the asthma-only or 
the COPD-only groups.   Thus, high ICS use in this group could be attributed to 
increasing disease severity, which may have led to an adverse outcome such as an ED 
visit or a hospitalization.  
It is difficult to assess whether guidelines were followed for COPD-only patients, 
since the guidelines do not explicitly recommend the prophylactic use of any specific 
agent.  It can be assumed that patients in this group who received a prescription for both 
bronchodilators as well as corticosteroids were more severe, than those receiving drugs 
from either class only.  In the COPD-only group, around 36% of the patients with a 
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 medical claim did not have any pharmacy claims.  This seems to suggest that these 
patients had mild COPD, and did not require pharmacotherapy, or that these patients 
were misdiagnosed as having COPD, which could potentially explain the lack of 
pharmacotherapy use in this group. In order to address this issue, a subanalysis was 
carried out to examine the average number of outpatient visits among those who received 
a prescription versus those who did not.  For the entire Phase I sample, patients who 
received at least one prescription for an asthma or COPD-related medication experienced 
a significantly higher number of outpatient visits than those who did not receive any 
prescription (4.6 versus 1.9).  In the asthma-only group, patients who received at least 
one prescription experienced an average of 3.5 ± 4.0 (SD) outpatient visits, as compared 
to 2.4 ± 2.9 (SD) visits for those who did not receive any prescription.  For the COPD-
only group, the differences were slightly higher, with patients receiving at least one 
prescription experiencing an average of 3.7 ± 7.4 (SD) outpatient visits, as compared to 
1.7 ± 2.3 (SD) for those who did not receive any prescription.  In the both group, patients 
with at least one prescription experienced an average of 8.3 ± 9.0 (SD) outpatient visits, 
however, patients without a prescription also experienced an average of 4.2 ± 3.3 (SD) 
outpatient visits.  Based on this subanalysis, the probability of being potentially 
misclassified seems to be the highest for patients in the COPD-only group.       
 
Results for Research Question 2 
 The objective of research question 2 was to examine the overall prevalence of 
asthma and COPD, and to examine prevalence by age group and gender.  On average, 
there were 119,725 PEIA members between the ages of 18 – 64 years from 2001 through 
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 2003 in WV.  Of these, gender data was available for 52,005 (43.4%) males, and 63,817 
(53.3%) females.  Also, based on age group, on average, 20,843 members were between 
18 –  64 years of age, 31,906 were between 31 – 45 years of age, and 62,780 were 
between 45 – 64 years of age.  The following formulae were used to calculate prevalence.   
 
Overall Prevalence of Asthma = (Number of asthma patients/119,725)*10,000   
                            = (1,493/119,725)*10,000 
      = 124.7 /10,000 
Overall Prevalence of COPD = (Number of COPD patients/119,725)*10,000 
    = (7,161/119,725)*10,000 
    = 598.1/10,000 
Overall Prevalence of Patients having Both Asthma and COPD = (Number of Patients 
with Both Asthma and COPD/119,725)*10,000 
        = (940/119,725)*10,000 
    = 78.51/10,000 
 Similarly, the prevalence for the asthma-only, COPD-only, and both group 
patients was measured for each age group and gender.  The denominators used for these 
analyses were the number of PEIA covered members in each age group, or in each gender 
category.  The results of this analysis are presented in Table 12.  The prevalence of 
COPD was significantly higher than asthma for each age group as well as gender.  The 
prevalence of asthma as well as COPD increased with age, and was highest in the 46 – 64 
year age group.  The prevalence of asthma and COPD was significantly higher in females 
than males.     
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 Table 12:  Prevalence of Asthma and COPD in WV PEIA Members 
Prevalence Per 10,000 WV PEIA Members Characteristic 
Asthma-Only COPD-Only Both Asthma and 
COPD 
Age Group    
18 – 30 years 41.3 154.5 13.0 
31 – 45 years 130.7 583.6 61.4 
46 – 64 years 157.7 792.8 114.2 
Gender    
Male 81.1 522.8 47.1 
Female 167.8 854.1 110.7 
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 Discussion for Research Question 2 
 Based on the analyses, the null hypothesis A that there is no difference in 
prevalence by age group and gender is rejected for the asthma-only, COPD-only as well 
as the both groups.   
The prevalence rate for asthma in 2001 was 730 per 10,000 persons (CDC, 2001).  
Thus, the prevalence of asthma in WV PEIA employees was significantly lower than 
national estimates.  Combining the asthma-only and the both group yielded a total asthma 
prevalence of 203 per 10,000 persons, which is slightly higher than the asthma 
prevalence in WV Medicaid for enrollees in the 18 – 64 age group (177 / 10,000 
persons), according to a recent study (Joshi and Smith, 2003).  Asthma prevalence was 
higher in females compared to males, which was consistent with national estimates 
(Stempel et al, 2001 and CDC, 2001).  The overall prevalence of COPD in the WV PEIA 
sample was similar to national estimates.  Findings from the National Health Interview 
Survey (NHIS) suggested that the prevalence of chronic bronchitis and emphysema in the 
United States was 619 per 10,000 persons in 1993 (NHIS, 1993).  Data from the Lung 
Health Study conducted by the NHLBI in 1993 showed that the prevalence of 
emphysema is higher in males (97/10,000 in males vs. 6/10,000 in females), whereas the 
prevalence of chronic bronchitis is higher in females (630/10,000 in females vs. 
445/10,000 in males) (Hurd, 2000).  In WV PEIA members, the prevalence of COPD was 
significantly higher in females as compared to males.    
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 Results for Research Question 3  
This study objective measures the extent of nonadherence to maintenance 
medications using indices such as the MPR and median gap.  The mean MPR for the 
entire sample was 0.17 ± 0.3 and the median gap was 561 ± 435 days.  The MPR and 
median gap for each group are shown in Table 13.  Both MPR and median gap values 
indicate that the COPD-group was the least adherent, and the both group was the most 
adherent.  The use of both indices enabled the validation of trend in nonadherence among 
the three groups.  Spearman’s rank correlation coefficient between MPR and median gap 
was statistically significant for the overall sample as well as each disease subgroup.     
The mean TMS for the overall sample was 18.1 ± 16.7, and the mean CMS for the 
overall sample was 4.6 ± 5.3.  Table 13 shows the TMS and CMS values for the 3 groups.  
Differences in TMS and CMS scores between the asthma-only and the COPD only 
groups were not significant, however, the both group had significantly higher TMS and 
CMS scores than the asthma-only and the COPD-only groups.      
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 Table 13: Distribution of Medication Adherence-Related Variables 
Variable Overall Sample Asthma-only COPD-only Both Group 
Mean MPRa 0.17 0.35 0.10 0.40 
Median Gapb (days) 561 306 653 268 
TMSc 18.1 17.8 17.6 22.3 
CMSd 4.6 4.7 4.4 6.3 
aOne-way ANOVA showed statistically significant differences in Mean MPR among the 
3 groups 
bOne-way ANOVA showed statistically significant differences in Median Gap between 
the Asthma-only group and the COPD-only Group, and the Asthma-only group and the 
Both group   
c,dOne-way ANOVA showed significantly higher values for the Both Group as compared 
with the Asthma-only and the COPD-only groups 
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 Discussion for Research Question 3 
Based on the analyses, the adherence was highest for the both group, and lowest 
for the COPD-only group.  These results are not surprising since NHLBI guidelines 
recommend the use of ICS pharmacotherapy as the primary prophylactic medication for 
asthma, as well as the use of other maintenance drugs as add-on prophylactic 
medications.  Due to a lack of specific recommendations for patients with COPD, the 
MPR was the lowest for the COPD-only group.  The MPR was the highest in patients 
having both asthma and COPD, indicating an increased use of maintenance therapy, 
which was a function of increasing disease severity.    
In another study, patients with asthma have been classified as being poor adherent 
(up to 2), moderate adherent (3 – 6), or good adherent (at least 7), based on the number of 
prescriptions for maintenance medications per year (Luskin et al, 2001).  Based on this 
criteria, for the overall Phase I sample, only 7.8% were classified as adherent, 8.8% were 
classified as moderate adherent, and the majority (83%) were classified as poor adherent.  
Among the three disease groups, the proportion of patients classified as poor adherent 
was the highest for the COPD-only group (almost 90%), followed by the asthma-only 
group (72%).  The proportion of patients classified as poor adherent was lowest for the 
both group (51%).  Overall, the prevalence of medication adherence in WV PEIA 
members in the asthma-only and COPD-only group was lower than national estimates, 
based on refill claims data.  Generally, medication adherence rates for asthma range from 
3 to 46%, with the mean adherence being less than 50% (Kelloway et al, 1994 and Fish 
and Lung, 2001).  For the both group, the prevalence of medication adherence was 
similar to the national average.         
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  Results for Research Question 4  
 The objective of research question 4 was to examine the impact of medication 
adherence on healthcare utilization. The dependent variables were number of adverse 
outcomes (hospitalizations and/or ED visits), number of outpatient visits, and LOS.  
Since the number of adverse outcomes, and the number of outpatient visits represent 
count data, either Poisson or negative binomial regression was used to measure the 
impact of medication adherence – the primary predictor, on utilization.  OLS regression 
was used to measure the impact of medication nonadherence on LOS.  Of the total Phase 
I sample, only 182 patients (from the 3 disease groups combined) experienced at least 
one hospitalization.  Since OLS regression requires at least 15 – 20 subjects per predictor 
variable, there were not enough cases to run separate models for each disease group.  
Hence, a combined model with all 3 disease groups was run with LOS as the dependent 
variable.    
 
Number of Adverse Outcomes 
 The results of the Poisson regression models measuring the impact of medication 
adherence on the number of adverse outcomes are presented in Tables 14 – 21.   For the 
asthma-only group, when MPR was used as the primary predictor, TMS and asthma 
severity were significant predictors of the number of adverse outcomes (Table 14).  Every 
unit increase in TMS was associated with a 1.6% increase in the number of adverse 
outcomes.  Patients with level I asthma severity experienced a 116% lower number of 
adverse outcomes than patients with level V asthma severity, and patients with level III 
asthma severity experienced a 133% lower number of adverse outcomes than level V 
asthma patients.  When MPR was replaced by median gap  (Table 15), the model did not 
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 change significantly.  Median gap was not a significant predictor of the number of 
adverse outcomes.   
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 Table 14:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using MPR Adherence for the Asthma-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- -0.0116 0.0086 1.82 0.1779 
Female Sex -- 0.1803 0.1893 0.91 0.3410 
TMS 1.0163 0.0162 0.0071 5.20 0.0227* 
CMS -- -0.0353 0.0268 1.73 0.1880 
Asthma Severity      
Level I 2.1586 -0.7695 0.3628 4.50 0.0339* 
Level II -- -0.1265 0.7850 0.03 0.8720 
Level III 2.3331 -0.8472 0.3876 4.78 0.0289* 
Level IV -- -0.1791 0.3277 0.30 0.5846 
Level V -- -- -- -- -- 
MPR -- -0.0408 0.2413 0.03 0.8657 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -464.92; Deviance  = 0.58, N = 1,413; Chi-square = 806.9; Sig. = 0.000 
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 Table 15:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using Median Gap Adherence for the Asthma-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- -0.0115 0.0086 1.81 0.1784 
Female Sex -- 0.1837 0.1894 0.94 0.3320 
TMS 1.0165 0.0164 0.0071 5.43 0.0198* 
CMS -- -0.0356 0.0266 1.80 0.1803 
Asthma Severity      
Level I 2.1643 -0.7721 0.3560 4.70 0.0301* 
Level II -- -0.1347 0.7792 0.03 0.8628 
Level III 2.2880 -0.8277 0.3909 4.48 0.0342* 
Level IV -- -0.1710 0.3251 0.28 0.5989 
Level V --     
Median Gap -- 0.0200 0.2744 0.01 0.7966 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -464.86; Deviance  = 0.58, N = 1,413; Chi-square = 2786.4; Sig. = 0.000 
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 For the COPD-only group, being female was associated with a 33% reduction in 
the number of adverse outcomes as compared to males.  A 100% increase in adherence as 
measured by the MPR was associated with 360% increase in the number of adverse 
outcomes (Table 16).  When MPR was replaced by median gap  (Table 17), the model 
did not change significantly.  An increase in median gap by 1 day (reduced medication 
adherence) was associated with a 0.6% decrease in the number of adverse outcomes.    
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 Table 16:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using MPR Adherence for the COPD-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- -0.0022 0.0038 0.33 0.5639 
Female Sex 1.3328 -0.2873 0.0688 17.44 0.0001* 
TMS -- 0.0031 0.0030 1.08 0.2993 
CMS -- 0.0124 0.0096 1.64 0.2001 
MPR 4.60 1.5268 0.1011 227.88 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -2524.0; Deviance  = 0.60, N = 7,161; Chi-square = 12392.67; Sig. = 0.000 
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 Table 17:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using Median Gap Adherence for the COPD-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- 0.0017 0.0038 0.21 0.6459 
Female Sex 1.3627 -0.3095 0.0687 20.27 0.0001* 
TMS 1.0007 0.0007 0.0030 0.05 0.8275 
CMS -- 0.0287 0.0092 9.76 0.1008 
Median Gap 1.0006 -0.0006 0.0001 59.34 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -2591.0; Deviance  = 0.62, N = 7,161; Chi-square = 15168.32; Sig. = 0.000 
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 For the both group, TMS and female sex were significant predictors of the 
number of adverse outcomes.  Every unit increase in TMS was associated with a 5.1% 
increase in the number of adverse outcomes. Being female was associated with a 26% 
lower number of adverse outcomes (Table 18). The model did not change when MPR 
was replaced by median gap (Table 19).   
 144
 Table 18:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using MPR Adherence for the Both Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- 0.0016 0.0054 0.08 0.7729 
Female Sex 1.2569 -0.2287 0.1001 5.22 0.0224* 
TMS 1.0510 0.0149 0.0000 15.01 0.0001* 
CMS -- -0.0091 0.0038 0.57 0.4517 
MPR -- 0.0761 0.0121 0.37 0.5418 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -771.37; Deviance  = 1.70, N = 940; Chi-square = 4217.81; Sig. = 0.000 
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 Table 19:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using Median Gap Adherence for the Both Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- 0.0018 0.0053 0.11 0.7391 
Female Sex 1.2612 -0.2321 0.0998 5.41 0.0200* 
TMS 1.0147 0.0146 0.0039 14.30 0.0002* 
CMS -- -0.0082 0.0120 0.47 0.4940 
Median Gap -- -0.0001 0.0001 0.72 0.3966 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -771.19; Deviance  = 1.79, N = 940; Chi-square = 4175.40; Sig. = 0.000 
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 In order to adjust for confounding by disease severity, combined group models 
was run with dummy codes for the COPD-only and both groups, with asthma-only as the 
reference (Tables 20 and 21). In this model, female sex, TMS, COPD dummy, asthma 
dummy, and MPR were significant predictors of the number of adverse outcomes.  Being 
female was associated with a 26% lower number of adverse outcomes.  As compared to 
COPD-only patients, asthma patients experienced a 40% lower number of adverse 
outcomes.  As compared to patients having both asthma and COPD, patients having 
asthma-only experienced a 339% lower number of adverse outcomes.  A 100% increase 
in medication adherence (as MPR increased from 0 to 1) was associated with a 117% 
increase in the number of adverse outcomes.  When MPR was replaced by median gap as 
primary predictor, the model did not change significantly (Table 21).  An increase in 
median gap by 1 day was associated with a slightly lower number of adverse outcomes.                
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 Table 20:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using MPR Adherence for the Entire Phase I Sample  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- -0.0017 0.0029 0.33 0.567 
Female Sex 1.2664 -0.2362 0.0537 19.33 0.000* 
TMS 1.0092 0.0092 0.0022 17.85 0.000* 
CMS -- 0.0023 0.0072 0.10 0.748 
COPD Dummy 1.4074 -0.3418 0.0912 14.03 0.002* 
Both Dummy 4.3973 -1.4810 0.0934 251.20 0.000* 
MPR 2.1749 0.7770 0.0787 97.46 0.000* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -3852.12; Deviance  = 0.72, N = 9,594; Chi-square = 21213.5; Sig. = 0.000 
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 Table 21:  Poisson Regression Model with Predictors of Number of Adverse 
Outcomes using Median Gap Adherence for the Entire Phase I Sample  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age -- 0.0002 0.0029 0.01 0.9412 
Female Sex 1.2885 -0.2535 0.0537 22.27 0.0001* 
TMS 1.0077 0.0077 0.0022 11.99 0.0005* 
CMS -- 0.0104 0.0070 2.22 0.1359 
COPD Dummy 1.2977 -0.2606 0.0906 8.27 0.0040* 
Both Dummy 4.5145 -1.5073 0.0933 260.95 0.0001* 
Median Gap 1.0004 -0.0004 0.0001 38.47 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = -3878.93; Deviance  = 0.73, N = 9,594; Chi-square = 22775.8; Sig. = 0.000 
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 Number of Outpatient Visits 
 When Poisson regression was used to identify factors that impact the number of 
outpatient visits using medication adherence as the primary predictor, the deviance in the 
models was significantly greater than 1, which indicates that there is overdispersion.  
This means that the true variance is greater than the mean.  In order to account for 
overdispersion, negative binomial regression is recommended.  Thus, for the following 
models predicting the number of outpatient visits, negative binomial regression was used.  
Note that the deviance in each of the following models is close to 1. 
For the asthma only group, age, female sex, asthma severity, and medication 
adherence were significant predictors of the total number of outpatient visits.  In the 
model using MPR as primary predictor (Table 22), every unit increase in age was 
associated with a 0.75% higher number of outpatient visits.  Being female was associated 
with a 30% higher number of outpatient visits.  Every unit increase in TMS increased the 
number of outpatient visits by 0.6%.   The number of outpatient visits were 59% lower in 
level I asthma patients, and almost 41% lower in level III asthma patients, as compared 
with level V asthma patients.  Increase in medication adherence based on MPR was 
associated with an 86% increase in the number of outpatient visits.        
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 Table 22:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using MPR Adherence for the Asthma-Only Group  
Predictor e  x Estimate SE 
 
Chi-Square 
Statistic 
Age 1.0075 0.0075 0.0025 9.27 0.0023* 
Female Sex 1.2978 0.2607 0.0526 24.60 0.0001* 
TMS 1.0063 0.0063 0.0023 7.57 0.0059* 
CMS -- -0.0139 0.0071 3.89 0.0685 
Asthma Severity      
Level I 1.5972 -0.4683 0.1128 17.22 0.0000* 
Level II -- -0.2053 0.2581 0.63 0.4265 
Level III 1.4083 -0.3424 0.1141 9.01 0.0027* 
Level IV -- -0.1803 0.1073 2.82 0.0928 
Level V -- --    
MPR 1.8574 0.6192 0.0656 89.07 0.0001* 
Significance 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 1086.35; Deviance  = 0.87, N = 1,413; Chi-square = 2188.90; Sig. = 0.000 
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 When MPR was replaced by median gap, the results did not change significantly 
(Table 23).  Every unit increase in median gap was associated with a 0.02% decrease in 
the number of outpatient visits. 
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 Table 23:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using Median Gap Adherence for the Asthma-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.0083 0.0083 0.0025 10.99 0.0009* 
Female Sex 1.2730 0.2416 0.0530 20.79 0.0001* 
TMS -- 0.0038 0.0023 2.79 0.0949 
CMS -- -0.0057 0.0071 0.64 0.4239 
Asthma Severity      
Level I 1.8023 -0.5891 0.1126 27.36 0.0001* 
Level II -- -0.3899 0.2607 2.24 0.1349 
Level III 1.5212 -0.4195 0.1159 13.11 0.0003* 
Level IV 1.3211 -0.2785 0.1081 6.64 0.0100* 
Level V -- --    
Median Gap 1.0002 -0.0002 0.0400 3.23 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 1067.1637; Deviance  = 0.88, N = 1,413; Chi-square = 2151.51; Sig. = 
0.000
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  For the COPD-only model, all the independent variables were significant 
predictors of the number of outpatient visits (Table 24).  Every unit increase in age was 
associated with a 1.2% increase in the number of outpatient visits.  Being female was 
associated with a 5.5% increase in the number of outpatient visits.  Every unit increase in 
TMS was associated with a 0.36% decrease and every unit increase in CMS was 
associated with a 2.8% increase in the number of outpatient visits.  Increase in medication 
adherence by 100% (since MPR measures adherence from 0 to 1) was associated with a 
276% increase in the number of outpatient visits.  When MPR was replaced by median 
gap, female sex was no longer a significant predictor of the number of outpatient visits 
(Table 25).  Every unit increase in median gap was associated with a 0.06% decrease in 
the number of outpatient visits.  Thus, the number of outpatient visits decreased with 
increasing adherence.  
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 Table 24:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using MPR Adherence for the COPD-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.0122 0.0122 0.0012 96.40 0.0001* 
Female Sex 1.0547 0.0533 0.0233 5.23 0.0222* 
TMS 1.0036 -0.0036 0.0012 9.23 0.0024* 
CMS 1.0276 0.0273 0.0038 51.84 0.0001* 
MPR 3.7678 1.3265 0.0446 885.71 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 2897.26; Deviance  = 0.77, N = 7,161; Chi-square = 14920.47; Sig. = 
0.000 
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 Table 25:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using Median Gap Adherence for the COPD-Only Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.014 0.0142 0.0013 124.59 0.0001* 
Female Sex -- 0.0321 0.0238 1.82 0.1778 
TMS 1.0069 -0.0069 0.0012 31.06 0.0001* 
CMS 1.049 0.0485 0.0038 161.33 0.0001* 
Median Gap 1.0006 -0.0006 0.0000 413.17 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 2644.94; Deviance  = 0.79, N = 7,161; Chi-square = 17876.02; Sig. = 
0.000 
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 For the both group, age, female sex, TMS, and medication adherence were 
significant predictors of the number of outpatient visits (Tables 26 and 27).  In both 
models, the number of outpatient visits increased with age, and being female was 
associated with an almost 18% increase in the number of outpatient visits.  Increase in 
medication adherence by 100%, as indicated by the MPR, was associated with a 70% 
increase in the number of outpatient visits.  With every unit increase in median gap, the 
number of outpatient visits decreased by 0.05% (Table 27).                   
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 Table 26:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using MPR Adherence for the Both Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.0144 0.0143 0.0028 25.47 0.0001* 
Female Sex 1.1792 0.1649 0.0575 8.24 0.0041* 
TMS 1.0077 0.0077 0.0026 8.72 0.0031* 
CMS -- -0.0011 0.0072 0.02 0.8816 
MPR 1.7023 0.5320 0.0679 61.32 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 8335.6; Deviance  = 0.97, N = 940; Chi-square = 1723.67; Sig. = 0.000 
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 Table 27:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using Median Gap Adherence for the Both Group  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.016 0.0163 0.0028 32.87 0.0001* 
Female Sex 1.165 0.1530 0.0578 7.00 0.0081* 
TMS 1.005 0.0057 0.0026 4.63 0.0315* 
CMS -- 0.0082 0.0071 1.31 0.2515 
Median Gap 1.0005 -0.0005 0.0001 46.55 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 8327.61; Deviance  = 0.98, N = 940; Chi-square = 1520.33; Sig. = 0.000 
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 In order to adjust for confounding by disease severity, the models were rerun with 
dummy codes for COPD-only and both asthma and COPD as compared to patients with 
asthma only.  In the model with MPR as primary predictor (Table 28), asthma-only 
patients experienced 122% fewer outpatient visits than patients with both asthma and 
COPD.  Being female was associated with an 8% increase in the number of outpatient 
visits, as compared to males.  The number of outpatient visits increased with age and 
CMS.  A 100% increase in medication adherence was associated with a 168% increase in 
the number of outpatient visits.  When MPR was replaced by median gap (Table 29), 
every unit increase in median gap was associated with a 0.06% decrease in the number of 
outpatient visits.    
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 Table 28:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using MPR Adherence for the Entire Phase I Sample  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.0125 0.0125 0.0010 145.21 0.0001* 
Female Sex 1.0878 0.0842 0.0201 17.59 0.0001* 
TMS -- 0.0005 0.0010 0.27 0.6018 
CMS 1.0168 0.0167 0.0031 29.87 0.0001* 
COPD Dummy -- 0.0215 0.0273 0.62 0.4316 
Both Dummy 2.2219 -0.7984 0.0347 528.80 0.0001* 
MPR 2.6815 0.9864 0.0320 949.46 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 12268.55; Deviance  = 0.8098, N = 9,594; Chi-square = 20494.5; Sig. = 
0.000 
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 Table 29:  Negative Binomial Regression Model with Predictors of Number of 
Outpatient Visits using Median Gap Adherence for the Entire Phase I Sample  
 
Predictor ex Estimate SE Chi-Square 
Statistic 
Significance 
Age 1.010 0.0139 0.0011 175.15 0.0001* 
Female Sex 1.070 0.0683 0.0204 11.27 0.0008* 
TMS 1.002 -0.0026 0.0010 6.79 0.0092* 
CMS 1.030 0.0330 0.0031 116.21 0.0001* 
COPD Dummy 1.080 0.0794 0.0277 8.20 0.0042* 
Both Dummy 2.230 -0.8027 0.0352 519.38 0.0001* 
Median Gap 1.0006 -0.0006 0.0000 518.64 0.0001* 
*Significant at p<=0.05; SE: Standard Error; ex: Exponential of the estimate; Log 
Likelihood  = 12046.72; Deviance  = 0.82, N = 9,594; Chi-square = 21850.69; Sig. = 
0.000 
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 LOS 
 The results of the OLS regression models measuring the impact of MPR 
adherence and median gap adherence on LOS are presented in Table 30 and Table 31, 
respectively.  Both models were checked to see if the assumptions of OLS regression 
were met.  The VIF was less than 10 for both models, indicating absence of 
multicollinearity.  The Durbin-Watson statistic was around 1.7 for both models, 
indicating absence of autocorrelation.  The plot of predicted versus residual values 
showed a uniform distribution, indicating absence of heteroskedasticity in both models.    
MPR adherence was a significant predictor of LOS.  A 100% increase in 
adherence (since MPR adherence is measured on a scale on 0 to 1) was associated with 
an increase in LOS by 1.4 days.  No other predictor variables were significant predictors 
of LOS.  In the model using median gap as primary predictor, there were no significant 
predictors of LOS.       
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 Table 30: OLS Regression Model with Predictors of LOS using MPR Adherence for 
the Entire Phase I Sample  
Predictor Estimate SE T-statistic Significance 
Age 0.006 0.018 0.306 0.760 
Male Sex -0.314 0.316 -0.994 0.322 
TMS -0.005 0.011 -0.439 0.662 
CMS -0.012 0.037 -0.342 0.733 
COPD Dummy -0.034 0.446 -0.077 0.939 
Both Dummy 0.057 0.457 0.126 0.900 
MPR 1.405 0.383 3.671 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 4.3%, N = 181; F = 2.149; 
Sig. = 0.041 
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 Table 31: OLS Regression Model with Predictors of LOS using Median Gap 
Adherence for the Entire Phase I Sample  
Predictor Estimate SE T-statistic Significance 
Age 0.012 0.019 0.624 0.534 
Male Sex -0.201 0.327 -0.615 0.539 
TMS -0.006 0.012 -0.480 0.632 
CMS 0.012 0.038 0.330 0.741 
COPD Dummy 0.008 0.463 0.017 0.987 
Both Dummy 0.248 0.472 0.525 0.600 
Median Gap -0.001 0.000 -0.392 0.695 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 3.1%, N = 181; F = 0.230; 
Sig. = 0.978 
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 Discussion for Research Question 4 
 There was a significant variation in the number of adverse outcomes 
(hospitalizations or ED visits) by medication adherence for the COPD-only group, 
however, no significant differences were observed for the asthma-only and the both 
groups by medication adherence.  Hence, the null hypothesis B is accepted for the 
asthma-only and the both groups.  For the COPD-only group, null hypothesis B is 
rejected.  Null hypothesis C is rejected for each of the 3 disease groups since the number 
of outpatient visits showed differences by medication adherence for each of the 3 disease 
groups.  Since LOS showed differences by MPR, null hypothesis D is rejected.   
The other variables that were able to explain differences in the number of adverse 
outcomes were sex, TMS, and disease severity (dummy codes).  As expected, the number 
of adverse outcomes as well as the number of outpatient visits increased with disease 
severity.  Patients having both asthma as well as COPD were more severe than those with 
COPD-only, or asthma only, and therefore experienced the highest number of adverse 
outcomes.  Outpatient use too, was highest in the both group, and lowest in the asthma 
only group, which could be attributed to disease severity.  TMS is also a proxy for 
disease severity, hence an increase in TMS was associated with an increase in the number 
of adverse outcomes.   
Surprisingly, for the COPD-only group, the number of adverse outcomes 
increased with MPR.  This can be explained by the fact that MPR indicates increased 
frequency of taking medications, which is related to disease severity.  Similar results 
have been found by Balkrishnan et al (2000), who examined the association between 
medication adherence and number of adverse outcomes in the elderly.   
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  The other interesting finding is the difference in the number of adverse outcomes 
and outpatient use by gender.  Females experienced significantly fewer adverse 
outcomes, but had higher outpatient utilization after adjusting for disease severity as well 
as medication adherence.  Findings from the CDC Asthma Prevalence Survey have 
shown that outpatient utilization rates are significantly higher among females than males 
(CDC, 2001).  The rate of hospitalizations and emergency room visits were also higher in 
females (CDC, 2001).   Females tend to be more aware of their overall health and 
generally exhibit higher outpatient use than males, which could help potentially explain 
the differential use of healthcare services between males and females (Lindamer et al, 
2003).   
For outpatient use, an increase in the MPR was associated with increasing 
outpatient use.  Conceptually, better medication adherence should result in improved 
outcomes and reduced healthcare utilization.  However, the probability of receiving a 
prescription is higher after an outpatient visit (Joshi and Shireman, 2001).  Thus, patients 
who took their medication more regularly visited their physician more often in order to 
obtain their prescription (since a prescription is generally a result of an outpatient visit).   
There was a significant variation in the LOS by MPR in the combined model.  
Although LOS increased with MPR, the model had low predictive power (R-sq = 4.3%).  
Conceptually, the most important predictor of LOS is DRG-based reimbursement.  Since 
PEIA bases its reimbursement on Medicare DRG rates, hospitals would try to reduce 
LOS according to the fixed sum they would receive based on the DRG.  This is further 
reinforced by the fact that more than 90% of the hospitalizations had the LOS within two 
standard deviations of the mean (average LOS = 3.9 ± 1.9 days; Range = 2 – 12 days).  
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 Thus, LOS is more likely a function of DRG-based reimbursement, rather than 
medication adherence, which could help explain the low predictive power of the OLS 
regression models for LOS.          
 
Results for Research Question 5 
 Objective 5 was to examine the impact of medication adherence on total 
healthcare costs (hospital, ED, outpatient, and prescription).  OLS regression analysis 
was used to achieve this objective.  Costs were log-transformed in order to achieve 
normality.  For each of the OLS models using either MPR or median gap as primary 
predictors, each of the regression assumptions were met.  Normality was achieved by log-
transformation of total costs.  The VIF was less than 10, indicating absence of 
multicollinearity.  The Durbin-Watson statistic for each of the variables was around 2, 
indicating absence of autocorrelation.  The graph of predicted versus residual values 
showed an even distribution, indicating absence of heteroskedasticity.     
For the asthma-only group, TMS, asthma severity, and MPR were significant 
predictors of the total healthcare costs (Table 32).  Every unit increase in TMS was 
associated with a 0.6% increase in total healthcare costs.   Every unit increase in the level 
of asthma severity increased total healthcare costs by 11.7%. An increase of 100% in 
medication adherence (as the MPR scores range from 0 to 1) was associated with a 241% 
increase in total healthcare costs.  The variables together were able to explain 50% of the 
total variance in total healthcare costs.  When MPR was replaced by median gap 
adherence as the primary predictor, the predictive power of the model dropped 
significantly to 30% from 50% (Table 33).  As compared to the MPR model, the model 
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 using median gap had CMS, asthma severity, and median gap as significant predictors.  
Total costs increased by 19% with every unit increase in asthma severity, and by 3.7% 
with every unit increase in the number of chronic medications (CMS).  Total costs 
decreased by 0.2% as adherence decreased (as indicated by a unit increase in median gap, 
which is one day). 
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 Table 32:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using MPR Adherence for the Asthma-Only Group 
Predictor Estimate SE T-statistic Significance 
Age -0.004 0.003 -1.549 0.122 
Male Sex -0.09 0.059 -1.498 0.134 
TMS 0.006* 0.003 1.976 0.048* 
CMS 0.005 0.009 0.518 0.604 
Asthma Severity 0.117* 0.075 32.186 0.000* 
MPR 0.002* 0.021 5.606 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 50.1%, N = 1,400; F = 
235.028, Sig. = 0.000 
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 Table 33:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using Median Gap Adherence for the Asthma-Only Group 
Predictor Estimate SE T-statistic Significance 
Age  -0.001 0.003 -0.104 0.917 
Male Sex -0.006 0.070 -0.084 0.933 
TMS -0.004 0.003 -1.145 0.253 
CMS 0.037 0.010 3.687 0.000* 
Asthma Severity 0.186 0.025 7.594 0.000* 
Median Gap -0.002 0.000 -18.297 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 29.8%, N = 1,400; F = 
100.166, Sig. = 0.000   
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 For the COPD-only group, age, TMS, and MPR were significant predictors of 
total healthcare costs (Table 34).  Every unit increase in age was associated with a 0.3% 
increase in total healthcare costs.  Every unit increase in TMS was associated with a 0.9% 
increase in total healthcare costs.  An increase of 100% in medication adherence was 
associated with a 373% increase in total healthcare costs.  The variables together were 
able to explain 48% of the total variance in total healthcare costs.  Replacing MPR 
adherence in the model with median gap adherence reduced the predictive power of the 
model to 36% (Table 35).  In this model, age, CMS and median gap adherence were 
significant predictors of total costs.  Every unit increase in age was associated with a 
0.6% increase in total healthcare costs.  Every unit increase in CMS was associated with 
a 3.7% increase in total healthcare costs. Total costs decreased by 0.2% as adherence 
decreased (as indicated by a unit increase in median gap, which is one day).   
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 Table 34:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using MPR Adherence for the COPD-Only Group 
Predictor Estimate SE T-statistic Significance 
Age 0.003 0.001 2.561 0.010* 
Male Sex 0.010 0.024 0.419 0.675 
TMS 0.009 0.001 7.252 0.000* 
CMS 0.003 0.004 0.559 0.576 
MPR 3.730 0.053 70.624 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 48.2%, N = 7,002; F = 
1301.562, Sig. = 0.000 
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 Table 35:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using Median Gap Adherence for the COPD-Only Group 
Predictor Estimate SE T-statistic Significance 
Age 0.006 0.001 3.936 0.000* 
Male Sex 0.018 0.027 0.659 0.510 
TMS 0.001 0.001 0.104 0.917 
CMS 0.037 0.004 8.320 0.000* 
Median Gap -0.002 0.000 -52.277 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 36.1%, N = 7,002 F = 
793.394, Sig. = 0.000
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  For the both group, TMS and MPR were significant predictors of total healthcare 
costs (Table 36).  Every unit increase in TMS was associated with a 0.6% increase in 
total healthcare costs.  An increase of 100% in medication adherence was associated with 
a 233% increase in total healthcare costs.  The variables together were able to explain 
almost 53% of the total variance in total healthcare costs.  Replacing the MPR adherence 
with median gap adherence reduced the predictive power of the model to 30% (Table 37).  
Age, CMS, and median gap were significant predictors of total costs.  Every unit increase 
in age increased total costs by 1.3%, and every unit increase in CMS increased total costs 
by 3.8%.  Total costs decreased by 0.1% as adherence decreased (as indicated by a unit 
increase in median gap, which is one day).   
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 Table 36:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using MPR Adherence for the Both Group 
Predictor Estimate SE T-statistic Significance 
Age 0.004 0.003 1.154 0.249 
Male Sex -0.100 0.068 -1.468 0.142 
TMS 0.006 0.003 2.099 0.036* 
CMS 0.008 0.009 0.942 0.346 
MPR 2.331 0.081 28.655 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 52.8%, N = 937; F = 
211.05, Sig. = 0.000 
 
 176
 Table 37:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using Median Gap Adherence for the Both Group 
Predictor Estimate SE T-statistic Significance 
Age 0.013 0.004 3.056 0.002* 
Male Sex 0.024 0.083 0.291 0.771 
TMS 0.003 0.004 0.869 0.385 
CMS 0.038 0.010 3.703 0.000* 
Median Gap -0.001 0.000 -15.858 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 30.2%, N = 937; F = 
81.909, Sig. = 0.000
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  In order to adjust for any confounding by disease severity, the regression model 
was rerun for the entire Phase I sample with dummy codes for the COPD-only, and both 
groups, using asthma-only as the reference group (Table 38).  Age, COPD dummy, both 
dummy, TMS, and MPR were significant predictors of log-transformed total healthcare 
costs.  Every unit increase in age was associated with a 0.3% increase in total healthcare 
costs.  As compared to respondents with asthma-only, respondents having COPD only 
experienced a decrease in total healthcare costs by 11.2%, whereas respondents having 
both asthma and COPD experienced an increase in total healthcare costs by 91.5%.  
Every unit increase in the total number of medications (TMS) was associated with a 1.0% 
increase in total healthcare costs.  Total costs increased with increasing MPR; an increase 
of 100% in medication adherence was associated with a 309% increase in total healthcare 
costs. All the variables were able to explain 57% of the variance in total healthcare costs.  
Replacing MPR adherence with median gap adherence reduced the predictive power of 
the model to 46% (Table 39).  Age, CMS, COPD dummy, both dummy and median gap 
were significant predictors of total costs.  Every unit increase in age increased total costs 
by 0.5%, and every unit increase in CMS increased total costs by 3.6%.  As compared to 
respondents with asthma-only, respondents having COPD only experienced a decrease in 
total healthcare costs by 28.7%, whereas respondents having both asthma and COPD 
experienced an increase in total healthcare costs by 100.1%.  Total costs decreased by 
0.2% as adherence decreased (as indicated by a unit increase in median gap, which is one 
day).   
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 Table 38:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using MPR Adherence for the Entire Phase I Sample 
Predictor Estimate SE T-statistic Significance 
Age 0.003 0.001 2.213 0.027* 
Male Sex -0.010 0.021 -0.443 0.658 
TMS 0.010 0.001 9.186 0.000* 
CMS 0.003 0.003 0.781 0.435 
COPD Dummy -0.112 0.030 -3.735 0.000* 
Both Dummy 0.915 0.042 22.035 0.000* 
MPR 3.089 0.039 80.209 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 57.0%, N = 9,418; F = 
1750.097, Sig. = 0.000 
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 Table 39:  OLS Regression Model with Predictors of Log-Transformed Total 
Healthcare Costs Using Median Gap Adherence for the Entire Phase I Sample 
Predictor Estimate SE T-statistic Significance 
Age 0.005 0.001 4.078 0.000* 
Male Sex 0.014 0.024 0.606 0.544 
TMS 0.001 0.001 0.814 0.415 
CMS 0.036 0.004 9.635 0.000* 
COPD Dummy -0.287 0.033 -8.600 0.000* 
Both Dummy 1.001 0.046 21.647 0.000* 
Median Gap -0.002 0.000 -57.948 0.000* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 46.1%, N = 9,418; F = 
1149.427, Sig. = 0.000 
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 Discussion for Research Question 5 
Based on the analysis, total asthma and COPD-related healthcare costs showed 
significant differences by medication adherence.  Thus, the null hypothesis E that there is 
no difference in total costs between patients who are adherent to maintenance 
medications and those who are not is rejected for each of the disease groups.   
 The primary independent variable – medication adherence as indicated by the 
MPR and median gap, was a significant predictor of total healthcare costs in each of the 
models.  However, contrary to theory, total healthcare costs increased as medication 
adherence increased.  Thus, findings from this study do not support the popular notion 
that prophylactic drug therapy decreases total costs.  Similar results have been found in 
other studies (Balkrishnan et al, 1998, and Balkrishnan and Christensen, 2000).  These 
findings can be explained by the fact that disease severity was a potential confounder in 
the models.  Thus, an increase in the number of prescription refills was an indicator of 
increasing disease severity.  When the models were rerun using dummy codes for patients 
with COPD only, and patients with both asthma and COPD, as compared to asthma-only 
as the reference, patients with COPD-only experienced lower total healthcare costs than 
patients with asthma-only, and patients with both asthma and COPD experienced 
significantly higher total costs that patients with asthma-only.  Another likely explanation 
for the statistical association between medication adherence and total costs is the fact that 
more than half of total costs were due to prescription use, and since medication adherence 
was measured using refill frequency, increasing refills were associated with increasing 
total costs.  An increase in TMS or CMS indicates worse overall health status, and 
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 increase in total healthcare costs with increasing TMS/CMS was as expected.  Total costs 
have been shown to increase with TMS and CMS (Balkrishnan and Christensen, 2000).         
 
Results for Research Question 6  
The objective of this research question was to examine the relative risk of adverse 
health outcomes such as a hospitalization or an ED visit as a consequence of medication 
nonadherence.  A case-control study design was used for the analysis.  Recipients who 
experienced an adverse outcome were cases, and those who did not were controls.  Upon 
examining the refill patterns of cases preceding the adverse outcome (for six months), 
and controls for a predefined period (first six months of the study period), a logistic 
regression model was used with a dichotomous dependent variable indicating any versus 
no adverse outcome.  The predictors used were age, gender, TMS, CMS, and asthma 
severity.  Medication adherence as measured by the MPR was the main predictor 
variable.  The results of the logistic regression models for each of the three groups are 
presented in Tables 40 – 43.  
For the asthma-only group (Table 40), TMS significantly impacted the probability 
of experiencing an adverse outcome.  As TMS increased, the probability of experiencing 
an adverse outcome increased.  No other variables including MPR were significant 
predictors.   
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 Table 40:  Adjusted Estimates of Odds Ratios Predicting the Risk of Any Adverse 
Outcome as a Consequence of Adherence Using Logistic Regression Analyses for the 
Asthma-Only Group 
Predictor OR Significance 95% CI 
Age    
18 – 30†    
31 – 45 0.75 0.529 0.306 – 1.836 
46 – 64 0.62 0.272 0.266 – 1.554 
Male Sex 0.73 0.253 0.427 – 1.251 
TMS 1.03 0.008* 1.007 – 1.050 
CMS 0.94 0.111 0.871 – 1.014 
Asthma-Severity    
Level I†    
Level II 3.71 0.100 0.778 – 17.650 
Level III 0.66 0.409 0.316 – 1.602 
Level IV 1.41 0.220 0.813 – 2.461 
Level V 1.32 0.615 0.441 – 3.991 
MPR 1.02 0.957 0.538 – 1.920 
*Significant at p<=0.05; OR: Odds Ratio; 95% CI: 95% Confidence Interval; N = 79 
Cases and 1334 Controls; -2 Log Likelihood Ratio = 590.440; Chi-square = 18.734, Sig. 
= 0.044; R-sq = 3.8%  
†Reference Group 
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  For the COPD-only group (Table 41), age group, sex, TMS, and MPR 
significantly impacted the probability of experiencing an adverse outcome.  As compared 
to recipients in the 18 – 30 age group, recipients between 46 – 64 years were 39% less 
likely to experience an adverse outcome.  Males were 38% more likely to experience an 
adverse outcome.  The probability of experiencing an adverse outcome increased with 
TMS.  As the MPR increased, the probability of experiencing an adverse outcome 
increased significantly.  For the both group (Table 42), there was no significant predictors 
impacting the probability of an adverse outcome.    
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 Table 41:  Adjusted Estimates of Odds Ratios Predicting the Risk of Any Adverse 
Outcome as a Consequence of Adherence Using Logistic Regression Analyses for the 
COPD-Only Group 
Predictor OR Significance 95% CI 
Age    
18 – 30†    
31 – 45 0.67 0.055 0.441 – 1.009 
46 – 64* 0.61 0.013 0.409 – 0.901 
Male Sex 1.38 0.001* 1.147 – 1.662 
TMS 1.01 0.015* 0.998 – 1.016 
CMS 0.99 0.949 0.971 – 1.028 
MPR 1.94 0.000* 1.429 – 2.638 
*Significant at p<=0.05; OR: Odds Ratio; 95% CI: 95% Confidence Interval; N = 490 
Cases and 6,668 Controls; -2 Log Likelihood Ratio = 3528.122; Chi-square = 51.14, Sig. 
= 0.000; R-sq = 1.8%  
†Reference Group 
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 Table 42:  Adjusted Estimates of Odds Ratios Predicting the Risk of Any Adverse 
Outcome as a Consequence of Adherence Using Logistic Regression Analyses for the 
Both Group 
Predictor OR Significance 95% CI 
Age    
18 – 30†    
31 – 45 1.32 0.631 0.429 – 4.041 
46 – 64 1.12 0.833 0.379 – 3.329 
Male Sex 1.09 0.631 0.754 – 1.593 
TMS 1.01 0.098 0.998 – 1.029 
CMS 0.99 0.857 0.952 – 1.042 
MPR 1.04 0.871 0.670 – 1.603 
*Significant at p<=0.05; OR: Odds Ratio; 95% CI: 95% Confidence Interval; N = 172 
Cases and 768 Controls; -2 Log Likelihood Ratio = 887.281; Chi-square = 7.367, Sig. = 
0.288; R-sq = 1.3%  
†Reference Group
 186
  Since confounding by disease severity was a likely possibility, the model was 
rerun for the entire Phase I sample, with dummy variables for disease severity having 
asthma-only as the reference category (Table 43).  Age group, sex, TMS, disease 
severity, and number of refills significantly impacted the probability of experiencing an 
adverse outcome.  Recipients in the 46 –64 age group were 35% less likely to experience 
an adverse outcome as compared to enrollees in the 18 – 30 year age group.  Males were 
25% more likely to experience an adverse outcome than females.  The probability of 
experiencing an adverse outcome increased with TMS.  Recipients with COPD-only were 
1.36 times more likely to experience an adverse outcome than recipients with asthma-
only, and recipients with both asthma and COPD were 3.7 times more likely to 
experience an adverse outcome than recipients with asthma-only. As the MPR increased, 
the probability of experiencing an adverse outcome increased significantly.  
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 Table 43: Adjusted Estimates of Odds Ratios Predicting the Risk of Any Adverse 
Outcome as a Consequence of MPR Adherence Using Logistic Regression Analyses 
for the Entire Phase I Sample 
Predictor OR Significance 95% CI 
Age    
18 – 30†    
31 – 45 0.74 0.101 0.521 – 1.059 
46 – 64* 0.65 0.013 0.459 – 0.910 
Male Sex 1.25 0.005* 1.053 – 1.445 
TMS 1.01 0.002* 1.004 – 1.018 
CMS 0.99 0.534 0.970 – 1.016 
Disease-Severity    
Asthma Only†    
COPD Only 1.36 0.015* 1.061 – 1.754 
Both Asthma and COPD 3.71 0.000* 2.808 – 4.902 
MPR 1.41 0.004* 1.117 – 1.790 
*Significant at p<=0.05; OR: Odds Ratio; 95% CI: 95% Confidence Interval; N = 746 
Cases and 8,846 Controls; -2 Log Likelihood Ratio = 5062.75; Chi-square = 180.499, 
Sig. = 0.000; R-sq = 4.4%  
†Reference Group 
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 Discussion for Research Question 6 
 Based on the analyses, the null hypothesis F that there is no significant difference 
in the risk of adverse outcomes between patients who adherent to maintenance 
medications and those who were not is accepted for the asthma-only, and the both groups.  
For the COPD-only group, the null hypothesis F is rejected.  
 Medication adherence as defined by the MPR prior to an adverse outcome for 
cases, and during a predefined period for controls was unable to significantly predict the 
probability of experiencing an adverse outcome for the asthma-only and the both groups.  
For the COPD-only group, increase in adherence was associated with an increased 
probability of experiencing an ED visit or a hospitalization.  The inability of medication 
adherence to predict the risk of adverse outcomes could be attributed to omitted variable 
bias.  Other factors that affect the risk of an ED visit or a hospitalization such as disease 
severity or exposure to specific risk factors such as smoke could not be included as 
predictors in the models.   In the case of acute conditions such as asthma, acute attacks 
are not necessarily life-threatening and can be managed with use of quick-relief short-
acting beta-agonists.  A subanalysis showed that the mean number of maintenance 
medications used in the six months prior to an adverse outcome was 7 for cases, and 4 for 
controls in the entire Phase I sample.  However, in the asthma-only group, the mean 
number of maintenance medications was 5.1 for cases, and 5.4 for controls.  In the 
COPD-only group, the difference in mean number of prescriptions were significantly 
different in cases (5.0) versus controls (2.1), whereas the in both group, differences were 
not significant (13 in cases vs. 11 in controls).  This probably explains why medication 
adherence was a significant predictor of adverse outcomes in the COPD-only and the 
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 combined group models.  This was also reflected in the results of the combined model, 
where COPD-only patients, and patients with both asthma and COPD being more likely 
to experience adverse outcomes.   
The other surprising finding was the reduced risk of adverse outcomes in the 46 – 
64 year age group, compared to the 18 – 30 year age group, in the COPD-only and the 
both groups.  Theoretically, older patients should be at a higher risk of experiencing 
adverse outcomes.  It is possible that older patients are more knowledgeable about the 
disease, and are better at disease management, compared to younger patients, which 
resulted in fewer adverse outcomes requiring a visit to the hospital or the ER.  The use of 
maintenance medications among 46 – 64 year old patients was three times higher than 18 
– 30 year olds, which could on one hand, indicate greater disease severity, but on the 
other hand, it also indicates more experience in using inhaler medications.  Males were 
significantly more likely to experience an adverse outcome than females.  The mean 
number of maintenance medications used was similar in males and females.  Studies have 
shown that the hospitalization rates as well as ED use rates were higher among asthmatic 
females than asthmatic males (Stempel et al, 1997 and CDC, 2001).      
 Overall, the findings from Phase I study objectives have shown that there was a 
relationship between medication nonadherence and related-healthcare utilization and 
costs.  Instead of showing that medication adherence resulted in reduced healthcare 
utilization and costs, findings from Phase I have shown the opposite, most likely due to 
confounding by disease severity.  This phase also identified the inability of claims data to 
recognize the severity levels of patients’ conditions as a limitation for studying the 
utilization of healthcare services in patients with asthma and COPD.    
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 Phase II Results 
 Phase II of the study was designed to examine the impact of medication 
nonadherence on HRQL and productivity losses.  HRQL was measured cross-sectionally 
using the St. George’s Respiratory Questionnaire, which has been designed to measure 
HRQL in patients with both asthma as well as COPD (domains include symptoms, 
activity, and impact).  The number of work-days lost due to respiratory illness and the 
number of unproductive hours while at work due to the disease were assessed using the 
Work Productivity Short Inventory (WPSI).  Another objective of Phase II was to 
measure the self-reported nonadherence using the Morisky scale, and determine the 
congruence between self-reported adherence and adherence from claims data.  All 
enrollees in the asthma-only and the both groups were mailed the questionnaire; whereas 
a random sample (N=2000) of COPD-only enrollees were mailed the questionnaire.  
Before analyzing the specific research questions, a response analysis was conducted. This 
helped us determine whether the respondents were representative of the general sample.      
 
Survey Response Analysis   
 A total of 918 usable responses were obtained.  This was after excluding 17 
surveys due to incomplete data.  This yielded an overall response rate of 22.6% with one 
mailing.  Response rates for the asthma only group was the highest (25.1%, N=385), 
followed by the both group (24%, N=234), and was the lowest for the COPD-only group  
(15%, N=299).  As shown in Table 44, more than 3/4th of the respondents were in the 45 
– 64 age group for all three disease groups.  Also, as shown in Table 45, a majority of the 
respondents were female in each of the three disease groups.  Chi-square statistics 
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 showed differences in age and gender distribution between the survey respondents and 
the overall Phase I sample for the asthma-only and the COPD-only groups.  Overall, the 
age and gender distribution was similar between survey respondents, non-respondents, 
and the entire Phase I sample.     
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 Table 44:  Number and Percent of Survey Respondents and Non-Respondents by 
Age Group  
Age Range 
(Years) 
Overall Sample 
 
N (%) 
Survey 
Respondents 
N (%) 
Survey Non-
Respondents 
N (%) 
Asthma-only*    
18 – 30 86 (5.8) 16 (4.2) 70 (6.3) 
31 – 45 471 (27.9) 89 (23.1) 329 (29.7) 
45 – 64 990 (66.3) 280 (72.7) 708 (64.0) 
Total 1,493 (100.0) 385 (100.0) 1,106 (100.0) 
COPD-only*    
18 – 30 322 (4.5) 11 (3.7) 77 (4.5) 
31 – 45 1,862 (26.0) 53 (17.7) 465 (27.4) 
45 – 64 4,977 (69.5) 235 (78.6) 1,156 (68.1) 
Total 7,161 (100.0) 299 (100.0) 1,698 (100.0) 
Both Asthma and 
COPD 
   
18 – 30 27 (2.9) 6 (2.6) 21 (3.0) 
31 – 45 196 (20.9) 46 (19.7) 150 (21.2) 
45 – 64 717 (76.3) 182 (77.8) 535 (75.8) 
Total 940 (100.) 234 (100.0) 706 (100.) 
*Significantly different (p<=0.05)  
 193
 Table 45:  Number and Percent of Survey Respondents and Non-Respondents by 
Gender  
Gender Overall Sample  
 
N (%) 
Survey 
Respondents 
N (%) 
Survey Non-
Respondents 
N (%) 
 
Asthma-only*    
Male 422 (28.3) 93 (24.2) 328 (29.7) 
Female 1,071 (71.7) 292 (75.8) 778 (70.3) 
Total 1,493 (100.0) 385 (100.0) 1,106 (100.0) 
COPD-only*    
Male 2,719 (38.0) 99 (33.1) 656 (38.6) 
Female 4,442 (62.0) 200 (66.9) 1,042 (61.4) 
Total 7,161 (100.0) 299 (100.0) 1,698 (100.0) 
Both Asthma and 
COPD 
   
Male 245 (26.1) 50 (21.4) 195 (27.6) 
Female 695 (73.9) 184 (78.6) 511 (72.4) 
Total 940 (100.0) 234 (100.0) 706 (100.0) 
*Significantly different (p<=0.05)      
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 Power Analysis      
 For the asthma-only and the both groups, all patients as identified from Phase I 
were mailed the questionnaire.  For the COPD-only group, 2000 patients were randomly 
selected and were mailed the questionnaire.  In order to determine the representativeness 
of survey respondents as compared to the overall Phase I COPD population, a power 
analysis was carried out based on the proportion of COPD patients who were assumed to 
be adherent.  Based on this power analysis, at least 384 usable responses have to be 
obtained in order to achieve representativeness (Kalton, 1987).  Among the three disease 
groups, the COPD-only sample had the lowest response rate (15%), with only 299 
respondents out of the 2,000 who were mailed the survey sending usable responses.  
Thus, there is a possibility that this lack of power may potentially yield the COPD sample 
unrepresentative of the entire COPD population.  The number of usable responses for the 
asthma-only group were 385, with a response rate of 25.1%, and the both group had 234 
usable responses with a usable response rate of 24%.  In order to adjust for the lack of 
power in the COPD-only sample, the three groups were combined for analyzing each 
research question in Phase II, in addition to conducting specific analyses for each of the 
three groups.
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  The demographic characteristics of the Phase II sample respondents are described 
in Table 46.  The survey respondents were predominantly female with a mean age of 50.9 
± 9 (SD) years.  The average age was similar in the three disease groups.  Overall, around 
3/4th of the total respondents were female.  The gender distribution was similar for the 
asthma-only and the both groups (77%), however, the COPD-only group had a relatively 
lower percentage of females.  The respondents were very highly educated, with almost 
half the respondents having at least 4 years of college education.  Only 25.3% of the 
respondents had less than a high school education, which was expected since PEIA 
enrollees are state employees, and are predominantly employed by state universities, or 
the state government.  
 Only 6.3% (N=58) of the respondents reported excellent health status, almost 
27% reported very good, and 35% reported good health status.  The proportion of 
respondents reporting excellent or very good health status decreased with increasing 
disease severity, with both group enrollees reporting the smallest proportion of enrollees 
with excellent or very good health status, followed by the COPD-only group, and the 
asthma-only group, in that order.     
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 Table 46:  Demographic Characteristics of the Phase II Study Subjects 
Variable Overall Sample
 
Asthma-only 
 
COPD-only 
 
Both 
 
Mean Age ± SD (years) 50.9 ± 9.1 50.1 ± 9.3 51.4 ± 9.0 51.7 ± 8.7 
Gender* (N,%)     
Male 232 (25.1) 87 (22.7) 93 (31.7) 51 (22.2) 
Female 677 (73.3) 296 (77.3) 200 (68.3) 178 (77.4) 
Education* (N,%)     
8th Grade or Less 23 (2.5) 4 (1.0) 16 (5.4) 3 (1.3) 
9th-12th Grade / High 
School Graduate 
210 (22.8) 83 (21.7) 71 (24.1) 56 (23.9) 
College 1-3 years 232 (25.1) 83 (21.7) 86 (29.2) 61 (26.1) 
College >= 4 years 450 (48.8) 212 (55.5) 122 (41.4) 113 (48.3) 
Self-Reported Health 
Status* (N, %) 
    
Excellent 58 (6.3) 30 (8.0) 19 (6.6) 8 (3.5) 
Very Good 248 (26.9) 130 (34.5) 71 (24.5) 46 (20.0) 
Good 325 (35.2) 139 (36.9) 95 (32.8) 89 (38.7) 
Fair 192 (20.8) 67 (17.8) 67 (23.1) 58 (25.2) 
Poor 69 (8.6) 11 (2.9) 38 (13.1) 29 (12.6) 
*Significantly different (p<=0.05) 
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 Results for Research Question 7 
The objective of research question 7 was to examine the overall HRQL among 
respondents with asthma and COPD, and compare differences in HRQL between the 
asthma-only, COPD-only, and both groups.  The SGRQ was used to measure HRQL 
among the respondents, which yields a total HRQL score, as well as domain-specific 
scores for each of the three domains (symptoms, activity, and impacts).  The SGRQ 
measured each score on a scale of 0 to 100, where 0 indicated best HRQL, and 100 
indicated worst HRQL.  A reliability analysis was performed using Cronbach’s alpha.  
The analysis showed that for the activity and impacts domains, Cronbach’s alpha was 
0.85 and 0.83, respectively, indicating good internal consistency.  For the symptoms 
domain, however, Cronbach’s alpha was significantly lower than 0.7, which is the cutoff 
for acceptable internal consistency.  Similar problems with internal consistency for the 
symptoms domain of the SGRQ have been reported by Barr et al (2000), when they 
examined the psychometric stability of the SGRQ in the US population.    
As shown in Table 47, the mean total score for the entire sample was 37.0 units.  
Overall HRQL was the worst for the Symptoms domain (57.0 units), followed by the 
Activity domain (43.6 units), and the Impacts domain (28.1 units).  Mean HRQL scores 
obtained from this study sample were similar to those from other studies (Jones et al, 
1992, Barr et al, 2000), thereby indicating a similar perception of HRQL among patients 
with asthma and COPD in the WV PEIA population.  HRQL scores varied by age group, 
gender, self-reported health status and disease severity.  As expected, HRQL worsened 
with age for each domain as well as the total score.  Males reported statistically as well as 
 198
 clinically worse HRQL than females.  A high correlation between self-reported health 
status and HRQL reinforced the validity of the SGRQ.   
As expected, the total score as well as the domain-specific scores increased with 
increasing disease severity, with respondents in the both group having significantly worse 
HRQL (both statistically as well as clinically) as compared to the asthma-only and the 
COPD-only groups.  Differences in scores between the asthma-only and COPD-only 
groups were neither statistically nor clinically significant (a difference of 4.0 units 
between groups is deemed clinically significant). 
 199
 Table 47:  Health-Related Quality of life Scores for the Phase II Study Sample 
Variable Overall Sample 
 
Asthma-only 
 
COPD-only 
 
Both 
 
HRQL Scores* (Mean 
± SD) 
    
Total Score 37.0 ± 22.0 33.3 36.2 43.8 
Symptoms 53.1 ± 23.1 49.3 52.6 59.9 
Activity 43.6 ± 28.9 39.6 41.7 52.5 
Impacts 28.1 ± 21.3 24.6 28.1 33.9 
*Both group reported significantly worse HRQL scores than Asthma-only or COPD-
only; higher scores indicating worse HRQL (p<=0.05)           
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 Discussion for Research Question 7 
Mean domain-specific as well as total HRQL scores obtained from the WV PEIA 
sample were similar to those obtained in other patients with asthma and COPD (Hajiro et 
al, 1999, Jones et al, 1992, Barr et al, 2000, Spencer et al, 2000).  In a study involving 
COPD patients with varying levels of disease severity, the total score, symptom score, 
activity score and impact score were 48 units, 66 units, 61 units, and 35 units, 
respectively (Spencer et al, 2000).  In another study involving COPD patients in an 
outpatient setting, the mean total score, symptom score, activity score, and impacts score 
were 49 units, 42 units, 27 units, and 36 units, respectively (Hajiro et al, 1999).  Similar 
perceptions of HRQL were observed in COPD patients in an outpatient setting (Domingo 
et al, 2002).  Mean total score was 43.4 units, and the mean symptoms, activity, and 
impacts scores were 49, 34, and 39 units, respectively (Domingo et al, 2002).  Overall, 
the HRQL scores indicate a similar perception of HRQL and a similar impact of asthma 
and COPD on HRQL among WV PEIA members as compared to asthma and COPD 
patients in other parts of the United States.   
As expected, HRQL deteriorated with increase in disease severity.  The total score 
as well as domain-specific scores were significantly higher for PEIA members having 
both asthma and COPD, as compared to those who had COPD-only and asthma-only.  
The both group not only had statistically higher scores than asthma-only or COPD-only 
patients, but the scores were clinically significant as well (>4 units).  This is indicative of 
the validity of the SGRQ in measuring HRQL in patients with asthma and COPD.   
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 Results for Research Question 8 
 The objective of research question 8 was to examine the self-reported prevalence 
of nonadherence based on responses to the Morisky scale.  The Morisky scale yields an 
overall adherence score on a scale of 0 to 4, where 0 indicates most adherent, and 4 
indicates least adherent.  Patients with a score of ‘0’ are classified as ‘high adherent,’ 
patients with scores between 1 and 2 are classified as ‘medium adherent,’ and those 
having scores between 3 and 4 are classified as ‘low adherent.’   
For the overall sample, 39.5% of the respondents were classified as high adherent, 
14.4% of the respondents were medium adherent, and 40.4% were low adherent, based 
on their responses to the Morisky adherence scale (Table 48).  Overall, the prevalence of 
adherence was similar in each of the three disease groups, although the chi-square tests 
showed that differences were statistically significant.  The proportion of high adherent 
respondents was similar in the asthma-only and the COPD-only groups, and was slightly 
higher in the both group.  Conversely, the proportion of medium adherent respondents 
was the lowest in the both group, and highest in the asthma-only group.  The proportion 
of respondents having low adherence was the lowest in the COPD-only group, and were 
similar for the asthma-only and the both group, although the both group was slightly 
higher.   
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 Table 48:  Self-Reported Adherence based on the Morisky Scale for the Phase II 
Study Sample 
Morisky Adherence 
Classification* 
Overall Sample 
N (%) 
Asthma-only 
N (%) 
COPD-only 
N (%) 
Both 
N (%) 
High Adherent*  
 
365 (39.5) 150 (39.0) 116 (38.8) 99 (42.3) 
Medium Adherent*  
 
133 (14.4) 62 (16.1) 39 (13.0) 29 (12.4) 
Low Adherent*  
 
373 (40.4) 162 (42.1) 105 (35.1) 104 (44.4) 
*Distribution of adherence significantly different among the three disease groups 
(p<=0.05); Column-percentages do not total to 100% because responses to the Morisky 
adherence scale were missing for some respondents  
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 Discussion for Research Question 8 
 The prevalence of noandherence among asthma patients has been shown to be 
between 3-46% (Bender, 2002, and Bauman et al 2002).  On average, at least half of the 
patients with asthma are nonadherent to maintenance medications (Fish and Lung, 2001).  
Based on a self-report asthma-specific adherence scale, only 20% of patients with asthma 
were classified as adherent (Erickson et al, 2001).  Therefore, we can say that the 
prevalence of adherence based on self-report, among PEIA members with asthma and 
COPD is similar to the overall prevalence of nonadherence among patients with asthma 
in the United States.    
Conceptually, in the asthma-only group, the rate of medication adherence should 
be higher since guidelines explicitly recommend the use of prophylactic medications.  
Since patients having both asthma and COPD should be prescribed maintenance 
medications (based on asthma guidelines), one would expect the adherence rates to be 
higher in both of these groups as compared to the COPD-only group.  Among PEIA 
enrollees with asthma, the proportion of adherent patients (high plus medium – 55%) was 
slightly higher than those with COPD-only (52%), and was similar to enrollees with both 
asthma and COPD (54%).  Ideally, the proportion of adherent COPD patients should be 
significantly lower than those with asthma, due to the absence of explicit guidelines 
recommending the use of maintenance medications unlike those for asthma.   
It has been shown that patients with asthma tend to over-report adherence with 
self-report measures (Rand et al, 1992).  Thus, adherence rates obtained from the 
Morisky scale could potentially be an overestimation of the true adherence in WV PEIA 
members with asthma and COPD. 
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 Results for Research Question 9  
The objective of this question was to examine the congruence between self-
reported adherence and refill-based adherence (MPR and median gap) for respondents 
having an MPR greater than zero.  Spearman’s correlation coefficient was used to 
measure the correlation.  As shown in Table 49, there was a statistically significant 
correlation between median gap and MPR (as expected), and Morisky adherence was 
significantly correlated with both MPR and median gap, for the entire Phase II sample.  
The correlation between MPR and median gap was expected, since both measures was 
based on refill patterns from claims data.  The negative sign exists because for the MPR, 
the higher the score (closer to 1.00) the higher the adherence, whereas for the median 
gap, the higher the score the lower the adherence (since gaps between refills would be 
larger).  The same holds true for the relationship between Morisky scale adherence and 
MPR, since a higher score on the Morisky scale indicates low adherence.  Although the 
correlation between Morisky scale and refill-based measures (MPR and median gap) is 
significant, the coefficient is relatively small, thus the statistical significance could be a 
function of sample size.        
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 Table 49:  Spearman’s Correlation between Self-Reported and Claims-Data Based 
Adherence for the Entire Phase II Sample 
Adherence 
Measure 
MPR Morisky Median Gap 
MPR 1.000 -0.193* -0.309* 
Morisky -- 1.000 0.134* 
Median Gap -- -- 1.000 
*Significant at p<0.01; N = 622 
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  Table 50 shows the correlations between the adherence measures for the asthma-
only group.  A significant correlation was observed between MPR and median gap, and 
MPR and Morisky adherence.  For the COPD-only group too (Table 51), a statistically 
significant correlation was found between the Morisky scale and MPR, but the magnitude 
of the correlation was small.  No significant correlation was found between Morisky 
adherence and median gap.  For respondents with both asthma and COPD, a significant 
correlation was found between self-reported adherence and each of the refill-based 
measures (Table 52).  Although the correlation between MPR and Morisky scale, and 
median gap and Morisky scale was weak, it was statistically significant.  The correlation 
between MPR and Median Gap was strong, as indicated by the correlation coefficient.   
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 Table 50:  Spearman’s Correlation between Self-Reported and Claims-Data Based 
Adherence for the Asthma-Only Group 
Adherence Measure MPR Morisky Median Gap 
MPR 1.000 -0.155* -0.379* 
Morisky -- 1.000 0.114 
Median Gap -- -- 1.000 
*Significant at p<0.01; N = 294 
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 Table 51:  Spearman’s Correlation between Self-Reported and Claims-Data Based 
Adherence for the COPD-Only Group 
Adherence Measure MPR Morisky Median Gap 
MPR 1.000 -0.287* -0.015 
Morisky -- 1.000 0.064 
Median Gap -- -- 1.000 
*Significant at p<0.01; N = 127 
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 Table 52:  Spearman’s Correlation between Self-Reported and Claims-Data Based 
Adherence for the Both Group 
Adherence Measure MPR Morisky Median Gap 
MPR 1.000 -0.212* -0.444* 
Morisky -- 1.000 0.239* 
Median Gap -- -- 1.000 
*Significant at p<0.01; N = 198 
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 Discussion for Research Question 9 
 The objective of research question 9 was to examine the congruence between self-
reported adherence and adherence obtained from claims data.  Based on the analyses, for 
each of the three disease groups, as well as for the overall sample, there was no clinically 
significant correlation between self-reported adherence (Morisky scale) and adherence 
obtained from claims data (MPR or median gap).  Thus, null hypothesis G is accepted for 
each of the three disease groups.   
 Although the Morisky scale was significantly correlated with MPR and median 
gap adherence, the magnitude of the correlation was not large enough to assume clinical 
significance.  Statistical significance is simply a function of large sample size.   
 Although no significant correlations were found between self-reported and claims 
based measures of adherence in this study, both methods are widely used to measure 
adherence.  Self-reports are the most easy and least equipment-intrusive method to 
measure adherence.  These measures have been found to be valid measures of medication 
adherence (Brooks et al, 1994).  Claims data based indices such as the MPR have also 
been shown to be valid measures of adherence (Steiner and Prochazka, 1997).  It has 
been shown that in self-reports, respondents tend to over-report adherence (Rand et al, 
1995).  Using self-reports to measure adherence is also subject to acquiescence bias 
(Erickson et al, 2001), which suggests that a patient is more likely to respond positively 
to a question, regardless to the question asked.  Either deliberate over-reporting of 
adherence or acquiescence bias could potentially explain the lack of correlation between 
Morisky adherence and MPR.  
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  Another possible explanation for the lack of correlation between the two measures 
in this study is the fact that self-report adherence was measured using a generic scale, as 
opposed to an asthma-specific scale.  Although the Morisky scale has been shown to be a 
valid measure of adherence, an asthma-specific instrument would probably be able to 
better capture the intricacies of adherence to asthma-specific medications, such as being 
able to capture the correct/incorrect use of inhalers.   
 Among four studies that have compared adherence from claims data with self-
report measures, two studies found significant correlations between the two measures, 
while two did not (Steiner et al,1991, Wandless et al, 1979, and Peterson et al, 1982).  
Steiner et al (1991) examined the congruence between refill compliance for 
antihypertensive medications and self-report compliance using the Morisky scale, and 
found that patients reporting as noncompliant based on the Morisky scale correlated well 
with refill scores, however, among those reporting themselves as compliant, very poor 
correlations were found between the two measures (Steiner et al, 1991).  Two other 
studies found significant correlations between refill-based and self-report adherence 
measures (Wandless et al, 1979, and Peterson et al, 1982).  
   
Results for Research Question 10 
The objective of this question was to examine differences in HRQL by medication 
adherence.  Separate OLS regression models were run for each group, with age, gender, 
education, self-reported health status, TMS, CMS, and adherence as predictors.  Separate 
models were run with MPR as primary predictor, and with Morisky adherence as primary 
predictor.  Asthma severity based on medication use was also included as a predictor for 
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 the asthma-only group model.  The regression models were checked to see if the 
regression assumptions were met.  The VIF was less than 10, indicating absence of 
multicollinearity.  The Durbin-Watson statistic for each of the variables was around 2, 
indicating absence of autocorrelation.  The graph of predicted versus residual values 
showed an even distribution, indicating absence of heteroskedasticity.     
  Table 53 shows the results of the OLS regression model identifying factors that 
successfully explained the variance in the total HRQL score for the asthma-only group.  
Results of the OLS models for the COPD-only and the both groups are presented in 
Tables 54 and 55, respectively.   
For the asthma-only group (Table 53), self-reported health status and asthma-
severity, as determined from the index by Grana  et al (1997) were significant predictors 
of the Total HRQL score.  As self-reported health status worsened, the Total HRQL score 
increased, thereby indicating a deteriorating HRQL.  The health status variable was 
included as a continuous variable on a scale of 1 to 5, where 1 indicated excellent health 
status, and 5 indicated poor health status.  With every unit increase in health status score, 
Total HRQL score increased by 13.7 units.  Based on the asthma severity indicator, every 
unit increase in the level of asthma severity was associated with a 1.74 unit increase in 
Total HRQL score.  Thus HRQL worsened with asthma severity.  The variables together 
were able to explain 47.6% of the total variance in Total HRQL score, which indicates a 
high predictive power of the model. 
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 Table 53:  OLS Regression Model with Predictors of Total HRQL Score Using MPR 
Adherence for the Asthma-Only Group 
Predictor Estimate SE T-statistic Significance 
Age -0.049 0.084 -0.553 0.581 
Male Sex -2.966 1.782 -1.664 0.097 
Education -0.773 0.927 -0.843 0.405 
Health Status 13.703 0.858 15.965 0.000* 
TMS 0.008 0.091 0.088 0.930 
CMS 0.157 0.252 0.623 0.534 
Asthma Severity 1.743 0.583 2.988 0.003* 
MPR -2.135 2.092 -1.020 0.308 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 47.6%, N = 359; F = 
41.794; Sig. = 0.000       
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 For the COPD-only group (Table 54), self-reported health status and MPR were 
significant predictors of total HRQL score.  HRQL score worsened with worsening health 
status, and increasing medication adherence.  With every unit increase in health status 
score, total HRQL score increased by 15.4 units.  Total HRQL score increased with 
increasing MPR.  The predictive power of the independent variables was even higher 
than the asthma-only model, since the variables together were able to explain 60.1% of 
the total variance in Total HRQL score.      
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 Table 54:  OLS Regression Model with Predictors of Total HRQL Score Using MPR 
Adherence for the COPD-Only Group  
Predictor Estimate SE T-statistic Significance 
Age 0.107 0.112 0.951 0.342 
Male Sex -0.238 2.056 0.116 0.908 
Education -1.914 1.073 -1.783 0.076 
Health Status 15.369 0.990 15.519 0.000* 
TMS 0.063 0.102 0.623 0.534 
CMS -0.185 0.315 -0.588 0.557 
MPR 10.946 3.403 3.216 0.001* 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 60.1%, N = 286; F = 
62.550; Sig. = 0.000 
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 For the both group (Table 55), education and self-reported health status were 
significant predictors of Total HRQL score.  Education was also included as a continuous 
variable on a scale of 1 to 4, where 1 indicated lowest education (8th grade or less), and 4 
indicated highest education (college >= 4 years).  Every unit increase in the level of 
education was associated with a 4-unit decrease in the Total score.  Thus HRQL 
improved with increasing education.  HRQL score worsened with worsening health 
status.  With every unit increase in the health status score, Total HRQL score increased 
by 10.7 units.  All the predictive variables were able to explain 43.4% of the variance in 
Total HRQL. 
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 Table 55:  OLS Regression Model with Predictors of Total HRQL Score Using MPR 
Adherence for the Both Group  
Predictor Estimate SE T-statistic Significance 
Age 0.017 0.119 0.143 0.886 
Male Sex 1.796 2.479 0.725 0.469 
Education -3.886 1.225 -3.171 0.002* 
Health Status 10.698 1.067 10.022 0.000* 
TMS 0.134 0.102 1.316 0.190 
CMS 0.383 0.294 1.304 0.194 
MPR -1.059 2.710 -0.391 0.696 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 43.4%, N = 229; F = 
26.114; Sig. = 0.000   
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 Since disease severity could be a potential confounder, the model was rerun for 
the entire sample of respondents, with a dummy codes for COPD-only, and both groups, 
with asthma-only as the reference group.  The results of this model are shown in Table 
56.  Education, self-reported health status, and the dummy variable for the both group 
were significant predictors of Total HRQL.  Every unit increase in the level of education 
was associated with a 2.2-unit decrease in the Total score.  Thus HRQL improved with 
increasing education.  HRQL score worsened with worsening health status.  With every 
unit increase in the health status score, Total HRQL score increased by 13.6 units.  As 
compared to the asthma-only group, respondents having both asthma and COPD 
experienced a 2.6-unit increase in Total HRQL score, thus indicating that HRQL 
worsened with disease severity.  All the predictive variables were able to explain almost 
52% of the variance in Total HRQL.   
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 Table 56:  OLS Regression Model with Predictors of Total HRQL Score Using MPR 
Adherence for the Entire Phase II Sample 
Predictor Estimate SE T-statistic Significance 
Age 0.024 0.059 0.400 0.689 
Male Sex -0.437 1.189 -0.367 0.713 
Education -2.216 0.614 -3.606 0.000* 
Health Status 13.625 0.554 24.614 0.000* 
TMS 0.080 0.056 1.437 0.151 
CMS 0.126 0.165 0.759 0.448 
COPD Dummy -2.264 1.290 -1.755 0.080 
Both Dummy 2.605 1.311 1.987 0.047* 
MPR 2.082 1.490 1.397 0.163 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 51.8%, N = 890; F = 
107.182; Sig. = 0.000 
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   MPR was replaced by Morisky adherence as the predictor variable, and the 
models were rerun for each of the three disease groups as well as the combined model for 
the entire Phase II sample.  The results of these models are presented in Tables 57 – 60.  
In these models, dummy codes were used for medium adherence and low adherence, with 
high adherence as the reference group.  The results were almost identical to the models 
using MPR adherence as a predictor, except for the fact that Morisky adherence was not a 
significant predictor in any of the models.  All the other variables showed an identical 
impact as the models using MPR as a predictor.     
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 Table 57:  OLS Regression Model with Predictors of Total HRQL Score Using 
Morisky Adherence for the Asthma-Only Group  
Predictor Estimate SE T-statistic Significance 
Age -0.048 0.085 -0.574 0.567 
Male Sex -3.081 1.782 -1.729 0.085 
Education -0.725 0.930 -0.780 0.436 
Health Status 13.727 0.860 15.957 0.000* 
TMS 0.017 0.091 0.188 0.851 
CMS 0.107 0.249 0.431 0.667 
Asthma Severity 1.604 0.566 0.118 0.005* 
Morisky Scale     
Medium Adherence 1.240 1.653 0.750 0.454 
Low Adherence 2.331 2.237 1.042 0.298 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 47.5%, N = 359; F = 
37.088, Sig. = 0.000 
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 Table 58:  OLS Regression Model with Predictors of Total HRQL Score Using 
Morisky Adherence for the COPD-Only Group  
Predictor Estimate SE T-statistic Significance 
Age 0.169 0.113 1.493 0.137 
Male Sex 0.253 2.083 0.121 0.904 
Education -1.899 1.094 -1.736 0.084 
Health Status 15.986 1.020 15.668 0.000* 
TMS 0.092 0.104 0.891 0.374 
CMS -0.142 0.325 -0.438 0.661 
Morisky Scale     
Medium Adherence -3.196 2.085 -1.533 0.126 
Low Adherence -1.320 2.994 -0.441 0.660 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 58.8%, N = 286; F = 
52.071; Sig. = 0.000 
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 Table 59:  OLS Regression Model with Predictors of Total HRQL Score Using 
Morisky Adherence for the Both Group  
Predictor Estimate SE T-statistic Significance 
Age -0.017 0.121 -0.149 0.882 
Male Sex 2.098 2.499 0.839 0.402 
Education -3.793 1.224 -3.098 0.002* 
Health Status 10.619 1.063 9.991 0.000* 
TMS 0.123 0.102 1.209 0.228 
CMS 0.363 0.290 1.250 0.213 
Morisky Scale     
Medium Adherence -1.526 2.148 -0.710 0.478 
Low Adherence -5.381 3.324 -1.619 0.107 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 43.8%, N = 229; F = 
23.318; Sig. = 0.000 
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 Table 60:  OLS Regression Model with Predictors of Total HRQL Score Using 
Morisky Adherence for the Entire Phase II Sample 
Predictor Estimate SE T-statistic Significance 
Age 0.027 0.059 0.468 0.640 
Male Sex -0.361 1.189 -0.304 0.761 
Education -2.213 0.615 -3.596 0.000* 
Health Status 13.676 0.556 24.584 0.000* 
TMS 0.084 0.056 1.499 0.134 
CMS 0.154 0.164 0.935 0.350 
Disease Severity     
COPD Dummy -2.901 1.230 -0.062 0.019* 
Both Dummy 2.683 1.312 0.053 0.041* 
Morisky Scale     
Medium Adherence -0.723 -0.723 -0.016 0.518 
Low Adherence -0.122 -0.122 -0.002 0.938 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 51.6%, N = 890; F = 
96.038, Sig. = 0.000 
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 Discussion for Research Question 10 
 Based on the analysis, for the asthma-only and the both group, the null hypothesis 
H that there is no difference in HRQL between patients who are adherent to maintenance 
medications and those who are not is accepted.  For the COPD-only group, the null 
hypothesis H is rejected since there was a difference in HRQL score by medication 
adherence.   
 The primary predictor variable of medication adherence, as indicated by the MPR, 
was not a significant predictor for the asthma-only and the both groups.  This is not 
surprising since there is considerable endogeneity between medication adherence and 
HRQL.  On one hand, patients who are adherent to medications should experience better 
outcomes consequently leading to an improved HRQL.  However, disease severity can 
adversely impact HRQL, which in turn could result in reduced adherence to medication 
therapy.  It has been shown that patients who are discouraged or depressed may be more 
likely to be noncompliant, contributing to a downward spiral of symptoms and 
exacerbations (Bosley et al, 1995).  Conversely, it is also possible that patients who are 
worried about their disease may be more likely to be adherent to their medication 
regimen, but still report poor HRQL due to low levels of well-being (Schmeir and Leidy, 
1998).  The assessment of HRQL cross-sectionally in conjunction with medication 
adherence is difficult because of the endogeneity between adherence and HRQL.  For the 
COPD-only model, MPR was associated with HRQL.  As MPR increased, indicating 
better medication adherence, HRQL scores increased, indicating worsening of HRQL.  
The most likely explanation for this finding is that patients who consumed more 
medications were more severe, and had worse perceptions of HRQL.  This hypothesis is 
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 further strengthened by the absence of explicit guidelines recommending the use of 
maintenance medications prophylactically in COPD.  Thus, the MPR was inflated by an 
increased frequency of medication use due to disease severity, adversely impacting 
HRQL.  In order to adjust to confounding by disease severity, a combined sample OLS 
model was run (Table 56).  As shown in the model, patients having both asthma and 
COPD experienced significantly worse HRQL, than those having asthma-only, and 
COPD-only.                
   As expected, self-reported health status was a significant predictor of HRQL.  In 
each of the three OLS models, as shown in Tables 53 – 55, HRQL worsened with 
deteriorating perceived health status.  Similar results have been found in other studies 
(Hajiro et al, 1999, Spencer et al, 2000). Spencer et al (2000) found that in patients with 
COPD, HRQL measured using the SGRQ worsened with deteriorating health status, 
which was also correlated with scores from the SF-36.  The relationship between self-
reported health status and HRQL also validates the measurement of HRQL using the 
SGRQ in WV PEIA recipients with asthma and COPD.   
 Education was a significant predictor among PEIA members with both asthma 
and COPD.  With every unit increase in the level of education, the HRQL score 
decreased by a clinically significant 4 units.  HRQL worsened as education increased for 
the combined sample model as well.  Sociodemographic variables such as education have 
been shown to be significant predictors of HRQL in patients with respiratory illnesses.  
Educated individuals are more likely to be compliant as compared to those with lesser 
education (Tashkin, 1995).  Although age and gender did not significantly impact HRQL 
in any of the above models, it has been shown that women with asthma or COPD are 
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 more likely to be compliant with maintenance medications than men (James et al, 1985).  
It has also been shown that older patients with asthma were more likely to be adherent 
than younger patients with asthma (Bailey et al, 1992) and had lower rates of healthcare 
utilization.  Rand and colleagues (1995) reported that adherence was more likely to be 
higher among females who were married, and older, after adjusting for various covariates 
in a multivariate logistic regression model.  
 The OLS models could potentially suffer from omitted variable bias.  Clinical 
measures, socioeconomic status, and the cost of medications are variables that can predict 
adherence, and subsequently impact HRQL.  Absence of data on these variables could be 
a potential limitation as well.   
              
Results for Research Question 11  
 Differences in productivity-related costs by disease group are shown in Table 61.  
The number of days experienced with the disease were higher for the COPD-only group 
and the both group as compared with the both group.  The number of days missed from 
work increased with disease severity, with asthma-only patients experiencing an average 
of 5 lost workdays per year, and patients with both asthma and COPD experiencing 
almost 12 lost workdays per year.  Although the number of unproductive hours while at 
work were similar among the three groups, this translated into significantly higher 
productivity losses for the COPD-only group, and the both group as compared with the 
asthma-only group.   Total productivity losses increased with increasing disease severity 
as shown in Table 61.   
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 Table 61:  Workplace Productivity Costs for the Phase II Study Sample 
Variable Overall Sample 
 
Asthma-only 
 
COPD-only 
 
Both 
 
Productivity 
(Mean ± SD) 
    
Days Experienced 92.6 ± 120.1 76.0 100.7 112.6 
Days Lost 7.59 ± 20.0 5.3 7.0 11.9 
Work-Hours 
Unproductive 
1.3 ± 2.2 1.1 1.5 1.5 
Abseenteeism Dollars* 852.1 ± 2273.0 596.9 786.2 1338.3 
Presenteeism Dollars* 925.1 ± 2640.9 657.7 1130.3 1187.3 
Total Dollars* 1747.9 ± 3758.1 1232.5 1926.9 2461.7 
*Both group reported significantly higher productivity losses than Asthma-only or 
COPD-only (p<=0.05); higher scores indicating worse HRQL 
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 The objective of this question was to examine the impact of medication adherence 
on total productivity dollars (absenteeism plus presenteeism).  OLS regression analysis 
was used to examine the impact of medication adherence on the dependent variable – 
total productivity dollars.  Log-transformed total productivity dollars were used in the 
OLS regression model in order to yield normality.  The results of the semi-logarithmic 
model for each of the three disease groups are presented in Tables 62, 63 and 64.  For 
each of the OLS models using either MPR or median gap as primary predictors, each of 
the regression assumptions were met.  Normality was achieved by log-transformation of 
total productivity dollars.  The VIF was less than 10, indicating absence of 
multicollinearity.  The Durbin-Watson statistic for each of the variables was around 2, 
indicating absence of autocorrelation.  The graph of predicted versus residual values 
showed an even distribution, indicating absence of heteroskedasticity.     
 For the asthma-only group (Table 62), age, self-reported health status, and TMS 
were significant predictors of the total productivity dollars.  Every unit increase in age 
was associated with a 2.9% decrease in total productivity dollars.  Self-reported health 
status was included as a continuous variable on a scale of 1 to 5, where 1 indicated 
excellent health status, and 5 indicated poor health status.  Every unit increase in self-
reported health status was associated with a 74.5% increase in total productivity dollars 
lost. Thus, as self-reported health status worsened, total productivity dollars lost 
increased.  Every unit increase in TMS was associated with a 2.9% increase in total 
productivity dollars lost.  The variables together were able to explain 30.1% of the total 
variance in total productivity dollars lost.   
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 Table 62:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using MPR Adherence for the Asthma-Only Group  
Predictor Estimate SE T-statistic Significance 
Age -0.029 0.010 -2.765 0.006* 
Male Sex -0.351 0.227 -1.548 0.123 
Education 0.055 0.111 0.494 0.622 
Health Status 0.745 0.106 7.059 0.000* 
TMS 0.029 0.010 2.845 0.005* 
CMS -0.051 0.028 -1.806 0.073 
Asthma Severity 0.064 0.069 0.924 0.357 
MPR -0.141 0.258 -0.546 0.586 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 30.1%, N = 173; F = 
10.303, Sig. = 0.000 
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 For the COPD-only group (Table 63), male sex and self-reported health status 
were significant predictors of total productivity dollars lost.  Males experienced 67.8% 
higher total productivity dollars lost than females, and every unit increase in self-reported 
health status was associated with an almost 40% increase in total productivity dollars lost.   
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 Table 63:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using MPR Adherence for the COPD-Only Group  
Predictor Estimate SE T-statistic Significance 
Age -0.016 0.014 -1.142 0.256 
Male Sex 0.678 0.255 2.654 0.009* 
Education -0.218 0.122 -1.784 0.077 
Health Status 0.397 0.119 3.341 0.001* 
TMS 0.008 0.011 0.660 0.510 
CMS -0.006 0.044 -0.133 0.894 
MPR -0.333 0.438 -0.759 0.449 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 22.2%, N = 121; F = 5.938, 
Sig. = 0.000 
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 For the both group (Table 64), education and self-reported health status were 
significant predictors of total productivity dollars.  Total productivity dollars lost 
decreased with increasing education, and increased with deteriorating health status.  
Every unit increase in the level of education was associated with a 38.4% decrease in 
total productivity dollars lost.  Every unit increase in self-reported health status was 
associated with a 56.8% increase in total productivity dollars lost.  MPR was not a 
significant predictor of total productivity dollars in either of the models.      
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 Table 64:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using MPR Adherence for the Both Group  
Predictor Estimate SE T-statistic Significance 
Age -0.008 0.013 -0.575 0.567 
Male Sex -0.029 0.306 -0.096 0.924 
Education -0.384 0.133 -2.894 0.005* 
Health Status 0.568 0.128 4.431 0.000* 
TMS 0.009 0.011 0.837 0.404 
CMS -0.001 0.035 -0.018 0.985 
MPR 0.165 0.300 0.549 0.584 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 22.6%, N = 115; F = 5.808, 
Sig. = 0.000 
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 In order to adjust for any confounding by disease severity, the regression model 
was rerun for the entire sample of respondents with dummy codes for the COPD-only, 
and both groups, using asthma-only as the reference group.  The results of this model are 
summarized in Table 65.  Age, education, self-reported health status, TMS, and the 
dummy variable for the both group were significant predictors of log-transformed total 
productivity dollars lost.  Contrary to expectation, every unit increase in age was 
associated with a 1.9% decrease in total productivity dollars lost.  Total productivity 
dollars lost decreased with increasing education, and increased with deteriorating health 
status.  Every unit increase in the level of education was associated with a 14.8% 
decrease in total productivity dollars lost.  Every unit increase in self-reported health 
status (which indicates deteriorating health status) was associated with a 62.5% increase 
in total productivity dollars lost.  Every unit increase in the total number of medications 
used (TMS) was associated with a 1.7% increase in total productivity dollars lost.  As 
compared to respondents with asthma-only, respondents having both asthma and COPD 
experienced an increase in total productivity dollars lost by 29.2%.  All the variables 
were able to explain 25% of the variance in total productivity dollars lost.       
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 Table 65:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using MPR Adherence for the Entire Phase II Sample 
Predictor Estimate SE T-statistic Significance 
Age -0.019 0.007 -2.731 0.007* 
Male Sex 0.034 0.144 0.236 0.813 
Education -0.148 0.070 -2.117 0.035* 
Health Status 0.625 0.065 9.554 0.000* 
TMS 0.017 0.006 2.867 0.004* 
CMS -0.025 0.019 -1.286 0.199 
COPD Dummy 0.044 0.173 0.302 0.763 
Both Dummy 0.292 0.147 2.052 0.041* 
MPR -0.038 0.142 -0.221 0.825 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 25.0%, N = 417; F = 
16.408, Sig. = 0.000 
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   MPR was replaced by Morisky adherence as the predictor variable, and the 
models were rerun for each of the three disease groups as well as the combined model for 
the entire Phase II sample with log-transformed total productivity costs as the dependent 
variable.  The results of these models are presented in Tables 66 – 69.  In these models, 
dummy codes were used for medium adherence and low adherence, with high adherence 
as the reference group.  The results were almost identical to the models using MPR 
adherence as a predictor, and Morisky adherence was not a significant predictor in any of 
the models.  All the other variables showed an identical impact as the models using MPR 
as a predictor.     
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 Table 66:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using Morisky Adherence for the Asthma-Only Group  
Predictor Estimate SE T-statistic Significance 
Age -0.028 0.010 -2.706 0.008* 
Male Sex -0.353 0.227 -1.554 0.122 
Education 0.049 0.111 0.439 0.662 
Health Status 0.745 0.106 7.038 0.000* 
TMS 0.029 0.010 2.855 0.005* 
CMS -0.052 0.028 -1.865 0.064 
Asthma Severity 0.057 0.068 0.839 0.403 
Morisky Scale     
Medium Adherence 0.015 0.197 0.075 0.941 
Low Adherence 0.184 0.267 0.688 0.492 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 29.8%, N = 173; F = 9.142, 
Sig. = 0.000 
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 Table 67:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using Morisky Adherence for the COPD-Only Group  
Predictor Estimate SE T-statistic Significance 
Age -0.017 0.014 -1.237 0.219 
Male Sex 0.634 0.255 2.486 0.014* 
Education -0.225 0.122 -1.844 0.068 
Health Status 0.404 0.120 3.361 0.001* 
TMS 0.008 0.012 0.702 0.484 
CMS -0.011 0.045 -0.239 0.812 
Morisky Scale     
Medium Adherence -0.206 0.232 -0.886 0.378 
Low Adherence -0.052 0.320 -0.161 0.873 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 21.7%, N = 121; F = 5.189, 
Sig. = 0.000 
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 Table 68:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using Morisky Adherence for the Both Group  
Predictor Estimate SE T-statistic Significance 
Age -0.009 0.014 -0.723 0.471 
Male Sex 0.049 0.305 0.163 0.871 
Education -0.378 0.133 -2.847 0.005* 
Health Status 0.557 0.130 4.294 0.000* 
TMS 0.009 0.012 0.808 0.421 
CMS 0.001 0.034 0.035 0.972 
Morisky Scale     
Medium Adherence -0.075 0.237 -0.318 0.751 
Low Adherence -0.266 0.375 -0.710 0.479 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 22.1%, N = 115; F = 5.072, 
Sig. = 0.000 
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 Table 69:  OLS Regression Model with Predictors of Log-Transformed Total 
Productivity Dollars Using Morisky Adherence for the Entire Phase II Sample 
Predictor Estimate SE T-statistic Significance 
Age -0.019 0.007 -2.731 0.007* 
Male Sex 0.023 0.142 0.165 0.869 
Education -0.149 0.070 -2.135 0.033* 
Health Status 0.629 0.066 9.591 0.000* 
TMS 0.017 0.006 2.865 0.004* 
CMS -0.025 0.019 -1.331 0.184 
COPD Dummy 0.040 0.140 0.288 0.773 
Both Dummy 0.278 0.142 1.964 0.050* 
Morisky Scale     
Medium Adherence -0.120 0.126 -0.954 0.341 
Low Adherence -0.026 0.174 -0.150 0.881 
*Significant at p<=0.05; SE: Standard Error; Adjusted R-sq = 24.9%, N = 417; F = 
14.855, Sig. = 0.000 
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 Discussion for Research Question 11 
 The impact of asthma and COPD on absenteeism and presenteeism was 
significantly lower in PEIA members as compared to other asthma and COPD patients 
with asthma and COPD in the United States.  Findings from the World Health 
Organization’s Work and Health Productivity Questionnaire have shown that asthma 
patients experienced 11 mean absenteeism days, and patients with COPD experienced 19 
mean absenteeism days per year in the United States (Wang et al, 2003).  Productivity 
dollars in PEIA COPD patients were slightly higher than national estimates.  Halpern et 
al (2003) showed that mean productivity costs in patients with emphysema were $1,527 
per patient per year.  In PEIA asthma patients, costs were slightly lower than other 
studies.  Cisternas et al (2003) found that productivity costs in patients with asthma were 
$1,550 per patient per year.         
OLS regression was used to estimate the impact of medication adherence on total 
productivity.  Based on the analysis, the null hypothesis I that there were no difference in 
workplace productivity dollars between those who were adherent to maintenance 
medications as compared to those who were not, is accepted for each of the three disease 
groups as well as the combined sample.   
To date, no published study has examined the relationship between medication 
adherence and productivity-related outcomes.  For each of the disease-specific models, 
medication adherence as indicated by the MPR was not a significant predictor of total 
productivity costs.  As expected, self-reported health status was a significant predictor in 
each of the three models, and productivity losses increased as health status worsened.  
The inability of MPR to significantly predict productivity losses could be attributed to 
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 potential omitted variable bias.  In this case, the omitted variable could most likely be 
disease severity.  This was confirmed by the results of the combined model, which 
showed that patients with both asthma and COPD experienced significantly higher 
productivity losses than patients with asthma only.  Confounding by disease severity was 
also indicated by the significance of the TMS variable.  Productivity losses increased as 
the number of total medications increased, which is indicative of worse overall health 
status.  Productivity losses in patients with COPD have been shown to increase with 
disease severity (Halpern et al, 2003). In asthmatic patients too, disease severity 
significantly increase productivity dollars.  Patients with mild, moderate, and severe 
asthma experienced total per-person healthcare costs of $2,646, $4,530, and $12,813, 
respectively, 35% of which were related to absenteeism and reduced effectiveness at 
work (Cisternas et al, 2003).  In the COPD-only model, males experienced significantly 
higher productivity losses than females.  These gender differences could be attributed to 
higher incomes among males than females (Jacobson et al, 2000), thus a lost workday or 
an unproductive work-hour translates into higher dollar values for males than females.           
 In the combined model, productivity losses decreased as the level of education 
increased, with productivity losses decreasing by 15% with every increasing level of 
eductation.  It has been shown that COPD patients with more than high school education 
had 30% higher indirect costs as compared to those with less than high school education, 
and a significant proportion of which were attributed to productivity losses (Halpern et al, 
2003).  Thus, it can be assumed that educated patients tend to be more aware about 
disease management, and the deleterious effects of potential risk factors such as smoking, 
which results in worse outcomes.  Indirect costs in COPD patients who smoked were 
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 significantly higher than those who did not (Halpern et al, 2003).  Increase in tobacco use 
was associated with significant increases in lost productive time, and productivity dollars.  
Individuals who smoked greater than 1 pack of cigarettes per day, experienced70% 
higher losses in productivity dollars than those who never smoked (Stewart et al, 2003).  
Thus, the absence of smoking as a predictor could potentially induce omitted variable 
bias.  
The other surprising result was the relationship between age and productivity 
dollars.  As age increased, productivity losses decreased.  Similar results have been found 
in other studies (Stewart et al, 2003).  The study showed that the cost equivalent of lost 
productive time was the highest for 40 – 49 year olds, as compared to 50 – 65 year-olds.   
A subanalysis was carried out examining the bivariate relationship between age, 
absenteeism, and presenteeism dollars.  This subanalysis showed that although 
absenteeism dollars increased with age, presenteeism dollars were highest among 
recipients between 18 and 30 years of age (Figure 5).  This could be explained by the fact 
that disease severity increased with age, which led to a higher number of days missed 
from work.  Younger patients were less severe and were able to attend work, thereby 
explaining the higher productivity losses while at work as opposed to older patients who 
experienced greater absenteeism dollars.     
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 Figure 5: Bivariate Relationship between Productivity Dollars and Age Group      
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 The measurement of HRQL captured the true impact of asthma and COPD in WV 
PEIA members from the patient perspective.  Measurement of workplace productivity 
losses would provide the employer (state of WV) valuable information regarding the 
impact of asthma and COPD in the workplace.  Measurement of these outcomes in Phase 
II has brought this study closer towards capturing a much broader impact of chronic 
respiratory illnesses such as asthma and COPD on patients’ health.    
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 CHAPTER FIVE 
SUMMARY AND CONCLUSIONS 
 
 This chapter presents a review of the study findings, draws conclusions, presents 
research implications, lists limitations for each phase of the study, and provides 
recommendations for future research.   
 
Phase I  
 Asthma and COPD are chronic respiratory conditions impacting both morbidity 
and mortality.  Medications for asthma and COPD are grouped into two main categories: 
long-acting maintenance medications, and short-acting relief medications.  For the 
management of asthma, long-acting medications such as ICS have been recommended as 
the most potent and cost-effective medication, in addition to add-on maintenance agents 
such as long-acting beta-agonists and leukotrine inhibitors, according to NHLBI 
guidelines.  The use of maintenance medications in patients with asthma has been shown 
to result in fewer adverse outcomes, and reduced healthcare utilization and costs.  For 
COPD, no specific medications are recommended by the GOLD guidelines for long-term 
prophylactic use, however, some studies have demonstrated the beneficial effects of ICS 
in COPD in terms of alleviating symptoms, improving HRQL, and reducing mortality.  In 
patients with asthma, adherence to maintenance medications continues to be a major 
concern, with less than half of them being adherent to prophylactic pharmacotherapy.  In 
WV, there have been no studies examining the impact of medication nonadherence on 
healthcare utilization and costs in patients with asthma and COPD.           
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  Thus, the aim of this phase of the study was to examine the prevalence of 
medication adherence in WV state employees, and to examine the impact of medication 
adherence on utilization of healthcare services such as hospitalizations, ED visits, and 
outpatient visits, as well as related-healthcare costs.  Another aim of this phase was to 
examine the overall prevalence of asthma and COPD in WV state employees, and to 
examine whether medication prescribing for asthma and COPD patients was according to 
NHLBI and GOLD guidelines, respectively.   
 
Conclusions for Phase I    
 The conclusions for Phase I are presented based on research questions proposed in 
the study as follows:  
 
Research Question 1: Examine whether medication prescribing was according to 
guidelines in WV PEIA members 
 This was an exploratory question assessing whether the prescribing of 
maintenance medications in WV PEIA employees with asthma and COPD was according 
to published guidelines.  More than half of all asthma-only and both group enrollees were 
prescribed maintenance medications.  These findings suggest that prescribing in this 
population is slightly better than previously reported prescribing in other populations, but 
there is abundant room for improvement.  In the COPD-only group, it is difficult to 
assess whether prescribing was according to guidelines.  Lack of medication use could 
possibly be a result of an absence of specific guidelines recommending maintenance 
medications (unlike NHLBI guidelines in asthma), or a perception among certain patients 
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 that medications are not effective, or misclassification bias, thus patients were incorrectly 
classified as having the disease and did not require maintenance medications.  
 
Research Question 2:  Examine the overall prevalence of asthma and COPD, and 
examine prevalence by demographic characteristics such as age and gender  
 This was another exploratory question examining the overall prevalence of 
asthma and COPD in WV PEIA enrollees.  The null hypothesis A in this research 
question was that there is no difference in prevalence by age group and gender.  The 
prevalence of asthma in WV PEIA enrollees was significantly lower than national 
estimates, but similar to the prevalence in WV Medicaid.  For COPD, the prevalence was 
similar to national estimates.  Overall, the prevalence of asthma and COPD increased 
with age, and was higher among females as compared to males for all disease groups.  
 
Research Questions 3: Examine the extent of adherence to maintenance medications in 
WV PEIA members with asthma and COPD 
 The extent of adherence based on the absolute MPR value was low for each of the 
three disease groups.  Adherence was lowest for the COPD-only group, and was similar 
for the asthma-only group, and the both groups.  Higher adherence in the asthma-only 
and the both groups was expected since NHLBI guidelines do recommend the use of 
maintenance medications on a regular basis.   
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 Research Question 4: Examine the impact of medication adherence on healthcare 
utilization such as the number of adverse outcomes (hospitalizations/ED visits), 
outpatient visits, and LOS  
 The null hypotheses for this research question were that there is no difference in 
the number of adverse outcomes (null hypothesis B), number of outpatient visits (null 
hypothesis C), and LOS (null hypothesis D) between asthma and COPD patients who 
were adherent to maintenance medications versus those who were not.  Medication 
adherence did affect the number of adverse outcomes, but only for the COPD-only group.  
Increase in medication adherence was associated with an increase in the number of 
adverse outcomes.  Increasing medication adherence was associated with an increase in 
the number of outpatient visits for each of the three disease groups.  LOS also increased 
with increasing MPR.  Although utilization increased with increasing adherence, 
confounding by disease severity was the most likely explanation.  Thus, increased 
medication adherence as indicated by an increasing MPR was possibly a reflection of 
increasing disease severity, which could have led to higher prescription drug use.   
 
Research Question 5: Examine the impact of medication adherence on total healthcare 
costs    
 The null hypothesis E for this research question investigated that there is no 
difference in total healthcare costs between asthma and COPD patients who were 
adherent to maintenance medications versus those who were not.  For each of the three 
disease groups, total healthcare costs increased with increasing medication adherence, as 
indicated by the MPR.  Thus, similar to research question 4, increasing medication refills 
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 was an indicator of increasing disease severity, or reliance on prescription drug therapy 
for disease management, which confounded the relationship between medication 
adherence and total healthcare costs.        
 
Research Question 6: Examine the relative risk of adverse health outcomes such as a 
hospitalization or an ED visit as a consequence of medication nonadherence 
 The null hypothesis F investigated that there was no difference in the relative risk 
of experiencing an adverse outcome such as a hospitalization or an ED visit between 
those who were adherent to maintenance medications versus those who were not.  The 
probability of experiencing an adverse outcome increased with medication adherence for 
the COPD-only group.  In the absence of specific guidelines recommending the 
prophylactic use of any specific medications, pharmacotherapy use in COPD was based 
on the need to take a medication due to increasing disease severity.  For the asthma-only 
and the both groups, there was no difference in the risk of adverse outcomes between 
patients who were adherent versus those who were not.   
 
Phase II 
 This phase of the study involved exploring the relationship between medication 
adherence and humanistic outcomes such as HRQL, as well as studying the impact of 
medication adherence on losses in workplace productivity.  The relationship between 
medication adherence and HRQL has not been examined before.  Also, the relationship 
between medication adherence and workplace productivity has been largely unexplored.  
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 This phase also examined the congruence between refill-based adherence and self-
reported adherence.   
  
Conclusions for Phase II    
 The conclusions for Phase II are presented based on research questions proposed 
in the study as follows:  
 
Research Question 7: Examine the overall HRQL among patients with asthma and 
COPD 
The SGRQ was used to measure HRQL in WV state employees with asthma and 
COPD.  The absolute values for total as well as domain-specific (symptoms, activity, and 
impacts) scores for the WV PEIA sample were similar to those obtained from other 
populations with asthma and COPD, thereby indicating a similar perception of HRQL, 
and a similar impact asthma and COPD on HRQL among WV PEIA members as 
compared to asthma and COPD patients in other populations.  HRQL worsened with 
increasing disease severity.  Patients with both asthma as well as COPD experienced 
significantly worse HRQL than patients with asthma-only or COPD-only.   
 
Research Question 8: Examine the prevalence of adherence based on self-report 
This exploratory question assessed the prevalence of medication nonadherence 
based on the responses to the Morisky scale.  Around 40% of asthma and COPD-patients 
were classified as high adherent, around 15% were classified as medium adherent, and 
another 40% were classified as low adherent, in the entire phase II sample.  Overall, the 
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 proportion of adherent patients in each of the three disease groups were similar.  Based 
on self-report, medication adherence among PEIA members with asthma and COPD is 
similar to the overall prevalence of medication adherence among patients with asthma in 
the United States.  However, respondents are more likely to report themselves as 
adherent, therefore, adherence rates obtained from self-report could potentially be an 
overestimation of the true medication adherence in WV PEIA members with asthma and 
COPD.   
 
Research Question 9: Examine the congruence between self-reported and refill-based 
adherence  
 The null hypothesis G stated that there is no significant correlation between self-
reported adherence and adherence measured from refill claims data.  The correlation 
between self-report and refill adherence (MPR and median gap) was not clinically 
significant.  Statistically significant correlations were found between MPR and Morisky 
adherence, and median gap and Morisky adherence, but the magnitude of the correlation 
was too small to assume clinical significance.   
 
Research Question 10: Examine the impact of medication adherence on HRQL     
 The null hypothesis H this research question aimed to investigate was that there 
were no significant differences in HRQL between asthma and COPD patients who were 
adherent to maintenance medications and those who were not.  For the asthma-only and 
the both groups, medication adherence was not a significant predictor of HRQL.  For the 
COPD-only group, HRQL worsened with increasing MPR.  Self-reported health status 
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 was a significant predictor of HRQL for each of the three disease groups, with HRQL 
worsening with deteriorating health status.   
 
Research Question 11: Examine the impact of medication adherence on losses in 
workplace productivity     
 The null hypothesis I stated that there were no significant differences in 
workplace productivity dollars between asthma and COPD patients who were adherent to 
maintenance medications and those who were not.  For each of the three disease groups, 
medication adherence was not a significant predictor of total productivity dollars.  
 
Study Implications    
This study was undertaken to examine medication adherence with prophylactic 
pharmacotherapy in patients with asthma and COPD and its impact on patient outcomes 
in the WV PEIA population.  The findings of this study should be useful to state/private 
health insurance programs to help them improve the prescribing of maintenance 
medications for prophylactic use in asthma and COPD.  This study also has implications 
for patients, prescribers, and decision-makers.  These implications are described in the 
following sections.     
  
Implications to Health Insurance Programs 
 The results of this study have demonstrated that there is indeed inappropriate 
prescribing of maintenance medications such as ICS therapy in patients with asthma and 
COPD.  As compared to other studies, a significant proportion of patients with asthma 
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 received prophylactic pharmacotherapy, but there is a continual need for improvement.  
Although findings from this study have shown that increased adherence was associated 
with worse outcomes, this was most likely due to confounding due to disease severity.  
The importance of prophylactic pharmacotherapy given the published evidence cannot be 
underscored.  Health insurance programs can develop and implement active interventions 
such as one-on-one education and individual outreach visits that will result in fewer 
adverse outcomes, reduced healthcare utilizations and related-costs, and also improve 
patients’ HRQL.  This study has also shown the tremendous impact that asthma and 
COPD have on workplace productivity.  On average, total productivity losses of around 
$2,000 per asthma or COPD patient per year, with around 10,000 patients translates into 
$20 million annually in terms of lost productivity and lost dollars for the state.  Necessary 
steps such as improving patient and physician education about the disease and its risk 
factors, as well as designing interventions that increase the use of maintenance 
medications, must be taken in order to reduce the burden of asthma and COPD.  This 
could possibly result in improved outcomes from the patients’ perspective (such as 
HRQL), and also potentially save considerable dollars due to fewer losses in workdays, 
and improved efficiency while at work.   
 
Implications to the Patients 
 The findings of this study are of utmost relevance to the patients.  Both asthma 
and COPD are conditions that affect the quality of life, workplace productivity, and also 
incur high expenses to the patients due to utilization of healthcare services (for example: 
insurance plans where patients pay an 80:20 deductible).  These diseases also exert a 
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 tremendous burden on the caregivers, impact their quality of life and productivity.  Thus, 
increased awareness regarding the use of prophylactic pharmacotherapy among patients 
could possibly result in patients requesting their physician to prescribe these medications.  
This could potentially result in reduced adverse outcomes such as hospitalizations and 
ED visits, and improved HRQL in patients with asthma and COPD.  
 
Implications to the Prescribers 
 Although this study did not demonstrate the desired impact of prophylactic 
pharmacotherapy on outcomes, it did demonstrate the lack of prescribing according to 
guidelines, and the burden of asthma and COPD in terms of healthcare utilization and 
costs, and losses in workplace productivity.  Prescribers should realize that the adverse 
outcomes associated with adherence were a consequence of disease severity, which could 
be alleviated through the use of appropriate prophylactic pharmacotherapy.  Overall, the 
findings from this study could potentially result in a heightened awareness of the impact 
of asthma and COPD on patient outcomes. 
    
Implications to the Decision-Makers 
 This study does show that prophylactic medications such as ICS are inadequately 
prescribed.  Thus, decision-makers can develop and implement strategies that will 
increase appropriate prescribing of prophylactic pharmacotherapy in asthma and COPD.  
Decision-makers need to realize that specific interventions have to be targeted towards 
physicians as well as patients.  Today’s consumer (patient) is more proactive and has a 
larger influence on physician decisions.  Thus, appropriate resources should be allocated 
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 towards directing interventions that improve patients’ knowledge about the disease, its 
risk factors and treatment.  Improved education and awareness could potentially result in 
better self-management of asthma and COPD, consequently resulting in better medication 
adherence.  
    
Study Limitations 
 This study had two phases: phase I used secondary data, and phase II used 
primary data.  The limitations of both phases are listed below.   
 
Limitations of Phase I 
 The study used claims data, which is collected for administrative purposes and not 
for conducting research. Thus use of this data has inherent limitations, since the data is 
subject to coding errors.  The biggest concern is misclassification of diagnosis, since 
patients are identified based on their primary diagnosis code.  If patients were incorrectly 
classified as having asthma or COPD, their inclusion in this study sample would be 
incorrect, and would dilute the MPR due to a lack of prescription claims.      
 The absence of data on clinically determined disease severity is a major 
limitation.  Disease severity was a major confounder in all the analyses, and the lack of 
clinical data did not allow for adjustment of clinically determined disease severity.    
 Medication adherence in Phase I was measured using proxy indices.  The use of 
these indices have limitations, the biggest assumption being that a prescription dispensed 
is a prescription taken, although these indices have been used and validated previously 
(Farris et al, 1994 and Christensen et al, 1997).  This assumption assumes special 
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 significance in the case of asthma and COPD medications, where incorrect inhaler 
technique can further impact the actual dose that is delivered.  Thus, a patient having a 
regular refill pattern may still be getting a suboptimal dose.  
 Several behavioral risk factors such as smoking impact outcomes in asthma and 
COPD.  Also, data on socioeconomic status and physician-patient interaction, which 
affect medication adherence, as well as outcomes resulting from adherence, were not 
available.  Thus, the study could suffer from potential omitted variable bias.        
 
Limitations of Phase II 
 A potential limitation of phase II was that only one survey mailing was done.  
This yielded a relatively low overall response rate (23%), which was especially low in the 
COPD-only group (15%).  Thus, it is possible that the survey respondents are not 
representative of the entire phase I sample.   
Another limitation of this study is the endogeneity that exists between medication 
nonadherence and HRQL.  Thus, it is difficult to conclude whether poor HRQL is a 
consequence of adherence, or poor HRQL resulting from the disease affected medication 
adherence. 
 The measurement of self-reported adherence as well as workplace productivity in 
phase II is subject to bias since respondents are more likely to report higher adherence, as 
well as underreport the actual number of workdays missed or work-hours lost, for the fear 
of being reprimanded by their employer.  Thus, adherence is likely to be overestimated, 
whereas losses in workplace productivity are likely to be underestimated in this study 
sample.    
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  Other limitations of using a self-administered mail questionnaire apply to this 
study as well.  Although mail questionnaires possess the advantage of being relatively 
inexpensive to administer, provide access to a larger population, provide anonymity and 
elimination of interviewer bias, there are several limitations.  These include measurement 
errors due to respondents not understanding the instructions and the items, item 
nonresponse, insensitivity to substitution, and recall bias (since the recall period for the 
survey was one year).      
 
Directions for Future Research 
 The two phases in this study have given rise to several interesting questions, 
which will provide the impetus for future research purposes.  The first study that arises 
from phase I is a prospective study which uses multiple measures of medication 
adherence, such as claims data, self-reports, patient diaries, plus the use of an electronic 
device that evaluates either inhaler or peak flow meter use, and its relationship to 
outcomes.  The inability of this study to adjust for patient severity or lifestyle 
modifications can be adjusted for by conducting a prospective study where patients with 
asthma or COPD can be identified from a specific health system and followed for a 
specified period of time to determine outcomes.  Also the measurement of outcomes such 
as HRQL, can be conducted at multiple points in time, such as before and after a 
particular intervention designed to improve medication adherence.  Also, the presence of 
a control group which receives either no intervention or a different type of intervention to 
promote adherence should allow for comparison between groups and examine the true 
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 impact of medication adherence after adjusting for various confounders such as disease 
severity.   
Another future study could examine differences in prescribing patterns by 
physician specialty.  Although some studies have examined this issue and found 
considerable differences by specialty, more information regarding prescribing patterns by 
specialty will enable decision-makers to design interventions in a more cost-effective 
manner by allocating resources more efficiently.   
This study measured losses in workdays and inefficiencies while at work due to 
asthma and COPD based on patient self-report.  A future follow up study should examine 
the correlation between patients’ self-report data and data on absenteeism and short-term 
disability from the employer.  This will help validate the measurement of productivity 
losses from self-report.     
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 APPENDIX A: CLAIM FILES 
Demographic File 
1. RECIPIENT NUMBER (DE-IDENTIFIED) 
2. PATIENT LAST NAME 
3. PATIENT FIRST NAME 
4. PATIENT ADDRESS 
5. PATIENT BIRTHDATE 
6. PATIENT GENDER 
7. ELIGIBILITY BEGIN DATE 
8. ELIGIBILITY END DATE 
Medical Claims File  
1. RECIPIENT NUMBER (DE-IDENTIFIED) 
2. FIRST DATE OF SERVICE 
3. LAST DATE OF SERVICE 
4. PROCEDURE CODES 
5. DIAGNOSIS CODES 
6. DIAGNOSIS CODE DESCRIPTION 
7. BILLED AMOUNT 
8. NOT COVERED AMOUNT 
9. PAID AMOUNT 
10. DEDUCTIBLE 
11. DRG CODE 
12. INPATIENT/OUTPATIENT CODE 
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 Pharmacy Claims File 
1. RECIPIENT NUMBER (DE-IDENTIFIED) 
2. DATE PRESCRIPTION FILLED 
3. NDC CODE 
4. DRUG DESCRIPTION 
5. NEW/REFILL CODE 
6. METRIC QUANTITY 
7. DAYS SUPPLY 
8. BILLED AMOUNT 
9. PAID AMOUNT 
10. PAID DATE 
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 APPENDIX B: CODES FOR IDENTIFICATION 
 
ICD-9-CM Codes Used to Identify Medical Claims for Asthma and COPD  
Asthma     493.xx 
Bronchitis/bronchiolitis    466.xx 
Unspecified Bronchitis    490.xx 
Chronic Bronchitis     491.xx  
Emphysema      492.xx  
Chronic Airway Obstruction    496.xx 
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 APPENDIX C: MEDICATIONS 
 
Inhaled Corticosteroids Aerobid, Advair, Azmacort, Beclovent, Flovent, Intal, Pulmicort, 
Tilade, Vanceril 
Leukotrine Modifiers Accolate, Singulair, Zyflo 
Long-Acting 
Bronchodilators 
Foradil (Formoterol), and Serevent (Salmeterol) 
Theophyline 
Bronchodilators 
Theo-Dur, Theolair 
Oral Corticosteroids Delta-Cortef, Deltasone, Medrol 
Short-Acting 
Bronchodilators  
Brethaire, Bricanyl, Maxair, Tornalate, Ventolin, Proventil 
(Albuterol) 
Anticholinergic 
Bronchodilator 
Atrovent (Ipratropium) 
 
 
 281
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COVERLETTER AND SURVEY
 282
 APPENDIX D: COVERLETTER 
 
Dear Sir/Madam: 
 
 Respiratory illnesses such as asthma and chronic obstructive pulmonary disease (chronic 
bronchitis, emphysema, chronic airways obstruction) are major public health problems in West 
Virginia.  They are among the leading causes of mortality and morbidity in West Virginia.  We 
at the West Virginia University School of Pharmacy, with the approval of the Public Employees 
Insurance Agency (PEIA) are trying to understand these important concerns from the 
perspective of healthcare utilization and patient health-related quality of life.  This study is part 
of a doctoral (Ph.D.) research project.  
 
 We were able to identify you as a patient who may have asthma or chronic obstructive 
pulmonary disease from your medical utilization insurance claims, for which we were given 
approval by PEIA.  Please find attached a survey that measures health-related quality of life 
among patients with asthma and / or chronic obstructive pulmonary disease.  We would really 
appreciate it if you will kindly take a few minutes to complete the survey and return it in the 
postage-paid business reply envelope.   
 
 Your participation in this survey is voluntary and will not affect your PEIA services in 
any way.  Your responses will be coded, and your name will not appear in any reports.  Your 
names will be stored in the master codebook by the investigator.  This codebook will be 
destroyed upon completion of the study.  Therefore, data will be kept as confidential as legally 
possible.   
 
 Although we hope that you answer all of the questions, you do not have to answer any 
question that makes you uncomfortable.  However, your response will provide useful 
information that is very important to the results of this study.  Hence, your participation in this 
study will be very much valued.    
 
 If you have any questions or concerns, please do not hesitate to contact us at (304) 293-
6991 or (304) 293-1652 at the West Virginia University School of Pharmacy.  Thank you very 
much for your time and effort.  
 
 
Sincerely, 
 
 
 
 
Ashish V. Joshi, M.S.    S. Suresh Madhavan, M.B.A, Ph.D. 
Doctoral Candidate       Professor and Chairperson 
 
cc: Tom Susman  
       Director 
       PEIA  
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 RESPIRATORY QUESTIONNAIRE 
 
INSTRUCTIONS:  This questionnaire is designed to help us researchers understand how your respiratory 
illness may be troubling you and how it affects your life.  We are using it to find out which aspects of your 
illness cause you most problems.  Please answer each question by checking the box that best describes your 
situation.  If you are not sure how to answer, please give the best answer you can.  Please do not spend a long 
time deciding on your answers.  
 
PART 1 – Demographics 
 
Age: _________ years                                      Gender:   ? Male   ? Female 
 
What is the highest level of education that you have completed? 
? 8   ? College 1 to 3 years (some college/technical school)  
 
Before completing the rest of the questionnaire, please check one box to show how you rate your
th or less than 8th grade
? 9th to 12th grade/high school graduate     ? College 4 years or more (college graduate) 
 present 
health:        ? Excellent    ? Very Good    ? Good    ? Fair    ? Poor     
 
PART 2 – One Year Description 
These are questions about how often your lung/respiratory problems have affected you over the 
last year.  Please check ONE box for each question. 
  
 
 
 
 
1) Over the last year, I have coughed                        
2) Over the last year, I have brought up phlegm 
(sputum)                
3) Over the last year, I have had shortness of breath                        
4) Over the last year, I have had episodes of wheezing                           
 
5) During the last year, how many severe or very unpleasant episodes of lung/respiratory problems have 
you had? 
 ? More than 3 episodes    ? 3 episodes    ? 2 episodes    ? 1 episode    ? No episode                                          
  
6) How long did the worst episode of lung/respiratory problem last? Please go to Question 7 if you didn’t 
have a severe episode. 
? A week or more    ? 3 or more days    ? 1 or 2 days    ? Less than a day  
 
7) Over the last year, in an average week, how many good days (with few lung/respiratory problems) 
have you had? 
 ? None        ? 1 or 2        ? 3 or 4        ? Nearly every day        ? Every day 
 
8) If you wheeze, is it worse in the morning?  If you don’t wheeze, go to Part 3.  
 ? No          ? Yes        
  
 
 
Almost 
every 
day 
Several 
days a 
week 
A few 
days a 
month 
Only with 
lung or 
respiratory 
infections 
Not 
at 
all 
? ? ? ? ? 
? ? ? ? ? 
? ? ? ? ? 
? ? ? ? ?
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 PART 3  
SECTION 1:  
How would you describe your lung/respiratory condition?  Please check ONE box only. 
 ? The most important problem I have                ? Causes me a few problems 
 ? Causes me quite a lot of problems                   ? Causes no problem 
 
How does your respiratory condition affect your job?  Please check ONE box only. 
 ? My lung/respiratory problem made me stop my job 
 ? My lung/respiratory problem interferes with my job or made me change my job 
     ? My lung/respiratory problem does not affect my job 
 ? Do not hold a job  
 
SECTION 2:  These are questions about activities that usually make you feel short of breath.  
Please indicate True or False for each activity that applies to you now. 
                                                                                                   True    False 
 Sitting or lying still………………………………………… ? ? 
  Washing yourself or dressing ………………………………    ? ? 
 Walking in the house………………………………………. ? ?           
  
 Walking outside on level ground…………………………...    ? ? 
 Walking up a flight of stairs………………………………..    ? ? 
 Walking up hills……………………………………………    ? ? 
 Playing sports or active games (baseball, tennis, etc)………    ? ? 
 
SECTION 3:  These are more questions about your cough and shortness of breath. 
Please indicate True or False for each activity that applies to you now. 
                                                                                                         True    False   
 Coughing hurts……………………………………………...   ? ?   
 Coughing makes me tired…………………………………...   ? ? 
 I am short of breath when I talk……………………………..   ? ? 
 I am short of breath when I bend over………………………   ? ? 
 My coughing or breathing disturbs my sleep……………….   ? ? 
  I become exhausted easily…………………………………..   ? ? 
 
SECTION 4:  These are questions about other effects that your lung/respiratory problems may 
have on you.  Please indicate True or False for each activity that applies to you now.  
                                                                                                                                          True    False
  
 My cough or breathing is embarrassing in public…………………………………….. ? ? 
 My lung/respiratory problem is a nuisance to my family, friends or neighbors………   ? ? 
 I panic or get afraid when I cannot catch my breath………………………………….. ?  ? 
 I feel that I am not in control of my lung/respiratory problem……………………….. ? ? 
 I do not expect my lung/respiratory problem to get any better……………………….. ? ? 
 I have become frail or an invalid because of my lung/respiratory problem…………..  ? ? 
 Exercise is not safe for me……………………………………………………………. ? ? 
 Everything seems too much of an effort……………………………………………… ? ? 
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 SECTION 5:  These are questions about your lung/respiratory medications, including oxygen, 
inhalers, and pills.  If you are not receiving medications go to SECTION 6. 
Please indicate True or False for each activity that applies to you                                                                                        now.
                       True    False 
 My lung/respiratory medication does not help me very much……………………….. ? ? 
 I get embarrassed using my lung/respiratory medication in public…………………... ? ? 
 I have unpleasant side effects from my lung/respiratory medication………………… ? ? 
 My lung/respiratory medication interferes with my life a lot…………………………  ? ? 
 
 
SECTION 6:  These are questions about how your activities might be affected by your breathing 
problem.  For each question, answer True if one or more parts apply to you because of your breathing 
problem.  Otherwise answer False. 
                                                                                                                                           True    False
 I take a long time to get washed or dressed…………………………………………... ? ? 
 I walk slower than other people my age, or I stop to rest…………………………….. ? ? 
 Jobs such as household chores take a long time, or I have to stop to rest……………. ? ? 
 If I walk up one flight of stairs, I have to go slowly or stop…………………………. ? ? 
 If I hurry or walk fast, I have to stop or slow down………………………………….. ? ?
  
  
 My breathing makes it difficult to do things such as walking up hills,  
 carrying things upstairs, light gardening such as weeding,  
 dancing, playing golf, or light sports such as horseshoes……………………………. ? ? 
  
 My breathing problem makes it difficult to do things such as carrying  
  heavy loads, digging in the garden or shovelling snow, jogging  
 or walking briskly, playing tennis or swimming……………………………………... ? ? 
   
 My breathing problem makes it difficult to do things such as very heavy 
 manual labor, riding a bike, running, swimming fast,  
 or playing competitive sports………………………………………………………… ? ? 
 
SECTION 7:  We would like to know how your breathing
 I cannot take a bath or shower, or I take a long time to do it………………………… ? ? 
 usually affects your daily life.  
Please indicate True or False for each activity that applies to you now.  
                                                                                                                                                True    False 
 I cannot play sports or active games………………………………………………….    ? ? 
 I cannot go out for entertainment or recreation………………………………………   ? ? 
 I cannot go out of the house to do the grocery shopping……………………………..   ? ? 
 I cannot do household chores…………………………………………………………  ? ? 
 I cannot move far from my bed or chair……………………………………………… ? ? 
 
Here are examples of activities that your lung/respiratory problem may prevent you from doing.   
 
 Going for walks or walking the dog 
 Doing activities or chores at home or in the garden  
 Going to church, or a place of entertainment  
 Going out in bad weather or into smoky rooms 
 Visiting family or friends or playing with children 
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 Please list some important activities (from those listed above or other) that your lung/respiratory problem 
may be currently stopping you from doing:  
____________________________________________________________________________________
____________________________________________________________________________________ 
____________________________________________________________________________________ 
 
The following questions describe how your breathing problems affect you. Please indicate which 
one of the following applies to you (Please check ONE box only).  
                                                                                                                                                    
 ? It does not stop me from doing anything I would like to do 
 ? It stops me from doing one or two things I would like to do 
 ? It stops me from doing most of the things I would like to do  
 ? It stops me from doing everything I would like to do 
 
PART 4  
SECTION 1:  The following questions pertain to your medication-taking behavior.   
Please indicate either Yes or No for each question.  
                    Yes      No    
  
 Are you careless at times about taking your medicine?…………………………………. ?   ?                                      
 When you feel better do you sometimes stop taking your medicine?……………………  ?  ?  
 Sometimes if you feel worse when you take your medicine, do you stop taking it? ……  ? ? 
       
 
SECTION 2:  Finally, we would like to know how your lung/respiratory problem affects you at 
work.  The following questions are about the effect that your lung/respiratory problem has had on 
your work during the past year.  Please respond
 Do you ever forget to take your medicine?………………………………………………  ?  ?                                      
 only if you are currently employed.  
 
1. During the past year, estimate the TOTAL NUMBER of DAYS you EXPERIENCED 
lung/respiratory problems (Maximum  = 365 days): _______________ Days 
 
2. During the past year, estimate the TOTAL NUMBER OF DAYS you MISSED FROM WORK 
because you experienced lung/respiratory problems: _______________ Days 
 
3. During the past year, estimate the TOTAL NUMBER OF DAYS you were ABLE TO ATTEND 
WORK even when you experienced lung/respiratory problems: _____________ Days 
 
4. During a typical 8-hour workday, when you experienced lung/respiratory problems, estimate the 
TOTAL HOURS you were UNPRODUCTIVE because of your lung/respiratory condition 
(Maximum = 8 hours): _____________ Hours 
Please return the survey in the enclosed self-addressed business reply envelope.   
No postage is required. 
THANK YOU FOR YOUR TIME AND EFFORT! 
WE WISH YOU A LONG, HAPPY AND HEALTHY LIFE! 
       
 
 
Adapted  from the St. George’s Respiratory Questionnaire  Copyright reserved Dr. P. W. Jones 
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